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Chapter 1
Introduction and outline of the thesis
Part of this chapter was published in a modified form in Human Molecular 
Genetics. 2010; 19(R1):R90-7.

Chapter 1
INTRODUCTION
DNA mutations in multicellular organisms can cause loss of functional or 
morphogenetic homeostasis in cells and tissues, and hence, a loss of health. 
Molecular and clinical studies have revealed that clear genotype-phenotype 
correlations exist for most human inheritable diseases. The extent of loss or change 
of gene function due to mutations can vary between affected individuals, but a well- 
defined clinical picture emerges for most genetic disorders. A notable exception to 
this rule is myotonic dystrophy (DM), one of the most frequent inheritable disorders 
(1). DM is caused by a unique type of genetic mutation and has an extremely variable 
clinical picture, characterized by multisystemic features affecting skeletal muscle, 
heart and the nervous and endocrine systems (1). The cause of DM is an expansion 
of a repeat motif in the DM gene (or rather genes, see below), which is also found in 
its transcribed RNA (2, 3) and brings about widespread changes in processing of this 
and other RNAs. DM is therewith the first recognized example of an RNA-mediated 
disease, not caused by expression of a mutated protein (4, 5).
Treatment for DM is currently limited to supportive care. This partially 
alleviates signs and symptoms of the disease but does nothing to slow or halt 
disease progression (1). The ultimate goal in development of new therapies is 
reversal of the disease phenotype, primarily caused by the RNA toxicity. In the 
first experimental chapters of this thesis, I will attempt to provide a better basis 
for these efforts by continuing with earlier studies in the group, which focus on 
detailed description of complex alternative splicing of DM protein kinase (DMPK) 
pre-messenger RNAs and the variable expression profile of DMPK protein isoforms. 
I will then switch to a new area in the DM field and describe the development of 
antisense oligonucleotide approaches to silence expanded DMPK transcripts and 
neutralize RNA-mediated toxicity. First, relevant information about DMPK, DM 
disease and potential therapeutic strategies will be discussed in this introductory 
chapter.
MYOTONIC DYSTROPHY
Myotonic dystrophy (DM) - also called dystrophia myotonica or Steinert's disease - 
was described more than 100 years ago (6, 7). DM displays an autosomal dominant 
mode of inheritance and is now recognized as one of the most common forms 
of muscular dystrophy in adults (8). The name myotonic dystrophy refers to two 
main muscle symptoms seen in this disease: myotonia describes a state of delay 
in muscle relaxation, while dystrophy indicates the progressive deterioration of 
muscle. In addition to muscular dystrophy and myotonia, DM includes a consistent 
constellation of seemingly unrelated and rare clinical features, like cardiac 
conduction defects, insulin resistance, ocular cataracts, cognitive abnormalities 
(developmental delays and learning problems), daytime sleepiness and testicular 
atrophy (4, 8, 9). Because of diversity in symptoms, this disease is perhaps best
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classified as a multisystemic neuromuscular disease. It is important to emphasize 
that not all problems described will occur in a single patient. DM is not only highly 
variable in the type of symptoms, but also severity and age of onset differ strongly.
Myotonic dystrophy type 1 (DM1)
Two types of DM have now been classified. DM1 is the most prevalent form with a 
frequency of 1:8,000 individuals worldwide (8) and the most conspicuous variation 
in disease severity and age of onset. In 1992, the genetic mutation underlying DM1 
(MIM 160900) was identified as an expanding (CTG)n repeat within the DM1 locus 
in the 3' untranslated region of the DMPK gene on chromosome 19q13.3 (2, 3, 10). 
In the DM1 locus, the DMPK gene is directly flanked by two other genes. The DMWD 
gene (11, 12) is located upstream and the SIX5 gene (formerly known as DMAHP) 
gene (13, 14) is located immediately downstream of the DMPK gene (Figure 1).
DMWD DMPK
1 2 3 4 5 1 2
(CTG)n
SIX5
14 15 1 2 3
Figure 1. The DM1 locus. The DMPK gene is flanked upstream by the DMWD gene and 
downstream by the SIX5 gene, together representing the DM1 locus. DMWD exons are 
depicted as grey boxes, DMPK exons as white boxes and SIX5 exons as black boxes. Introns 
and intergenic sequences are shown as black lines. The (CTG)n repeat is located in exon 15 
of the DMPK gene and in the promoter region of the SIX5 gene.
Manifestation of disease generally correlates with (CTG)n repeat length 
(15), as determined in blood DNA. Number of repeats in the DMPK gene tends to 
increase from generation to generation, accounting for the genetic anticipation 
(i.e., the earlier onset of disease manifestation in successive generations) in DM1 
families (16, 17). Next to intergenerational CTG-triplet repeat instability, somatic 
instability in tissues is also observed during adulthood and ageing (18-20).
Four categories of clinical manifestation of DM1 can be distinguished based 
on the number of CTG repeats: (i) normal or unaffected individuals carry a CTG 
repeat between 5 and 37 triplets; (ii) mild or late onset of disease is seen in patients 
with 50 to 150 triplets, these patients mostly only have cataracts; (iii) classic disease 
manifestation is associated with repeat lengths of 100 to 1000 CTG triplets. Typical 
features of classic DM1 are the adult onset and symptoms like myotonia, muscle 
weakness, cardiac conduction defects, endocrine malfunctions, testicular failure and 
mental changes; (iv) DM1 patients with congenital or juvenile onset disease carry 
several thousands of CTG triplets in their blood DNA and have general hypotonia, 
jaw weakness, respiratory and feeding difficulties, skeletal muscle immaturity and 
mental retardation (8, 21, 22). Congenital DM1 is almost invariably inherited from
12
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the mother and therefore represents a maternal bias in transmitting DM1 (23, 24).
Just recently, a few DM1 families were described with imperfect expanded 
alleles that contain a complex array of a (CTG)n repeat interspersed with CCG or 
GGC triplets at its 3' end. Presence of such variant repeats very likely contributes to 
the symptomatic variation seen in these families (25, 26). It is estimated that 3-5% 
of DM1 patients carry such a complex repeat.
Myotonic dystrophy type 2 (DM2)
Once the genetic mutation for DM1 was identified, it became clear that there was 
a subset of patients who did not carry a CTG expansion at the DM1 locus, but did 
share significant clinical aspects of DM. The mutation in patients with this form 
of DM, designated proximal myotonic myopathy (PROMM) or DM2 (MIM 602668) 
(27) was characterized in 2001 as an expanding (CCTG)n-repeat within a (TG)n 
(TCTG)n (CCTG)n segment (28) in intron 1 of the zinc finger protein 9 (ZNF9) gene, 
positioned at chromosome 3q21.3 (29) (Figure 2). The range of expanded allele sizes 
is extremely broad - from ~75 to ~11,000 CCTG repeat motifs with a mean of ~5000 
- caused by the high degree of somatic instability (28). Although anticipation has 
been described for DM2 families, no significant correlation between age of onset 
and expansion size was observed (30, 31). Somatic instability of the (CCTG)n repeat 
complicates studies into this and other clinical correlations between repeat length 
and disease (28). The frequency of DM2 is uncertain, but recent research indicates 
that in certain populations (e.g., Finland, Germany, Minnesota) its incidence could 
be as high as DM1 (32).
It appeared that some families with a DM-like disorder had neither DM1 
nor DM2, which suggested the existence of a DM type 3 (33), but this disease was 
later recognized as Paget's disease (32).
ZNF9
1 2 3 4 5
Figure 2. The ZNF9 gene harbors the DM2 mutation. The ZNF9 gene consists of five exons 
(shown as white boxes). Introns are depicted as black lines. The (CCTG)n repeat is located in 
intron 1.
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Comparison of clinical aspects between DM1 and DM2
Although DM1 and DM2 phenotypes are strikingly similar, they are not identical. 
Overall, DM2 is a milder version of disorder compared to DM1 in most aspects of 
their clinical phenotypes. A primary difference between DM1 and DM2 is that DM1 
can manifest as a severe congenital form that has not been described for DM2 (31).
DM2 shares the core features of DM1, including autosomal dominant 
inheritance, myotonia, muscular dystrophy, cataracts, cardiac problems, insulin 
insensitivity with type 2 diabetes, testicular failure and multisystem involvement 
(4, 34). In both DM1 and DM2 patients myotonia is detectable, but individuals with 
DM1 are often more symptomatic than those with DM2 (4). The central nervous 
system defects, developmental abnormalities and mental retardation seen in DM1 
patients are to a lesser extent recognized in DM2 (31). A recent comparative analysis 
of brain structures between DM1 and DM2 patients revealed widespread brain 
abnormalities similar in both patient groups but more pronounced for DM1(35-37). 
The initial pattern of muscle weakness is noticeably different between DM1, whose 
features adopt a more distal manifestation, and DM2, which shows a proximal 
onset (8, 31). Also fiber-type involvement differs between the two diseases, with 
more type 1 involvement in DM1 and more type 2 in DM2 (38, 39).
DMPK TRANSCRIPTS AND PROTEINS 
DMPK splice isoforms
Sequencing revealed that the DMPK gene of humans and mice contains 15 exons 
(Figure 3A). The DMPK pre-mRNA is extensively alternatively spliced, leading to 
the existence of various DMPK mRNA and protein isoforms (40). For example, 
alternative use of a cryptic 5' splice site in exon 8 results in deletion or inclusion of 
a five-amino acid Val-Ser-Gly-Gly-Gly (VSGGG) motif. Skipping of exons 13 and 14 
creates a short C-terminal end (41) (Figure 3B). Overall, alternative splicing gives 
rise to six major types of DMPK, designated DMPK A to F (41).
All DMPK protein isoforms share an N-terminal leucine-rich domain, a serine/ 
threonine kinase domain, a protein kinase C-terminal domain and a coiled-coil 
region. Presence (DMPK A, C and E) or absence (DMPK B, D and F) of the VSGGG 
motif and variation of the C-terminal tail (DMPK A and B: both contain a hydrophobic 
C-terminal tail; DMPK C and D: deletion of the first four nucleotides of exon 14 
results in a less hydrophobic tail; DMPK E and F: skipping of exon 13 and 14 results 
in loss of the C-terminal tail domain (41)) ultimately determine the actual domain 
arrangement in the six DMPK isoforms (Figure 3C).
The DMPK kinase domain determines DMPK as a serine/threonine kinase (42) 
and is described in more detail below. The VSGGG motif, located within the protein 
kinase C-terminal domain, regulates DMPK autophosphorylation and folding (43), 
whereas the coiled-coil domain is involved in multimerization, substrate binding, 
kinase activity and DMPK localization (44). Long C termini allow DMPK protein
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to anchor in membranes of the endoplasmic reticulum (ER) or mitochondrial 
outer membrane (MOM) (43, 45). Short DMPK isoforms E and F adopt a cytosolic 
localization (43).
One human-specific DMPK isoform is created by use of a cryptic 3' splice site in 
exon 15, resulting in the elimination of the (CUG)n repeat from the messenger RNA 
(46). This DMPK protein was designated DMPK G and carries a unique C-terminus 
(43).
DMPK
A
[ }
(CTG)n
2 34 5 6 7 8 10 1 1 1 3  159
B
C
N-term
kinase
C-term
domain
kinase domain
vVSG G G  coiled 
I coil
(CTG)n
I
■ exon 13/14
1 f
- first 4 nt 
exon 14
tail
Figure 3. DMPK gene organization, alternative splice site use and structural domain 
distribution of protein isoforms. (A) Schematic representation of the DMPK gene which 
consists of 15 exons. Exons are depicted as white boxes, or if extensive alternatively spliced, 
as black boxes (see also chapter 3). Black lines represent introns. The dashed box in exon 15 
represents the (CTG)n repeat. (B) The DMPK gene is subject to extensive alternative splicing. 
Three examples are given whereby deletion of 15 nucleotides from exon 8 will result in loss of 
the VSGGG domain and alternative use of exons 13 and 14 is responsible for the occurrence 
of a truncated C-terminal tail. Removal of the first 4 nucleotides of exon 14 introduces a 
shift in reading frame, which leads to a new C-terminus. (C) Alternative splicing gives rise to 
six major DMPK protein isoforms which all share an N-terminal domain, a serine/threonine 
kinase domain, a protein kinase C-terminal domain and a coiled-coil region. They differ in 
the absence or presence of a VSGGG motif and the size and nature of the C-terminus (long C 
termini allow DMPK protein to anchor in membranes, short DMPK isoforms adopt a cytosolic 
localization).
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DMPK protein function
DMPK transcripts and proteins can be detected in a wide range of tissues with 
highest levels of expression in cardiac and skeletal muscle and in organs containing 
smooth muscle cell linings like stomach and bladder (40, 47, 48). In brain, moderate 
levels of DMPK expression are found, which are restricted to certain regions or cell 
groups in the central nervous system (48, 49) Overall, DMPK is expressed in many, 
if not all, tissues involved in DM1 pathogenesis.
DMPK protein controls phosphorylation of various protein substrates 
and belongs to the AGC class of protein kinases (42, 50), to which DMPK family 
members ROCK-I/-II, MRCKa/P/y, and citron kinase also belong (51, 52). Members 
of the DMPK family have a putative role in cell shape determination, stress fiber 
formation and in regulation of actin-myosin contractility (52, 53). Based on this 
analogy, it has been suggested that DMPK may have a role in actin cytoskeleton 
remodeling, but evidence to sustain this assumption is thus far lacking. It has been 
shown that DMPK acts as a modulator of skeletal muscle voltage-gated Na+- and 
Ca2+-channels (54-56), suggesting involvement of DMPK in the regulation of initial 
events of excitation-contraction coupling in skeletal muscle. Myosin phosphatase 
targeting subunit 1 (MYPT1), a protein involved in actomyosin contraction is another 
protein that has been identified as a substrate for DMPK (43, 57). However, the 
precise effects of DMPK-mediated MYPT1 phosphorylation, and as a consequence 
inhibition of myosin phosphatase activity, on actin-myosin dynamics have still not 
been fully clarified. In a yeast-two-hybrid screen DMPK was found to interact with 
the cardiac form of the regulatory light chain of myosin II (MLC2a) (Groenen and 
Wieringa, unpublished). This observation forms an additional indication that DMPK, 
myosin phosphatase (MYPT) and MLC2 act together in a pathway controlling the 
complex network of actin and myosin (21).
MOLECULAR PATHOGENESIS OF DM1
Various hypotheses have been postulated to explain the complex clinical picture 
seen in DM1. Initially, suggested mechanisms included: (i) haploinsufficiency of 
DMPK protein, (ii) altered expression of neighboring genes, and (iii) pathogenic 
effects of the CUG expansion in DMPK RNA. The fact that genes in the DM2 locus 
bear no obvious relationship to those in the DM1 locus indicates that clinical features 
common to DM1 and DM2 are probably not related to disruption of regulation of 
genes in the vicinity of these expansions (28). Currently, the most broadly accepted 
theory therefore implicates a toxic RNA gain-of-function for expanded DMPK 
transcripts. Aberrant expression of DM1 locus proteins - DMPK, SIX5 and DMWD - 
may have an additive, minor role in certain disease aspects.
DMPK haploinsufficiency
The DMPK haploinsufficiency hypothesis was supported by findings that DMPK mRNA 
and protein levels were reduced in DM1 patient muscle biopsies (58). However,
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DMPK knockout mice generated to test this idea did not have typical multisystemic 
features of disease and developed only a very mild, late-onset myopathy (47, 59) 
and typical cardiac conductions defects (60). DMPK overexpression, examined 
in a transgenic DMPK overexpressor mouse model, leads to hypertrophic 
cardiomyopathy, myotonic myopathy, fiber degeneration and myotonic discharges 
(47, 61). When considered together, these results suggest that DMPK may contribute 
to some of the cardiac and skeletal problems seen in DM1, but that multisystemic 
features of DM1 cannot be explained solely by DMPK haploinsufficiency.
Altered expression of neighbouring genes
Support for involvement of neighbouring genes in the DMPK locus came from 
observations that CTG expansions function as strong nucleosome-binding sites. This 
feature could potentially alter the chromatin structure from an open to a closed 
state, making it less accessible to regulating factors (62, 63). DMPK is located in a 
gene-rich region, flanked by the DMWD and SIX5 genes (Figure 1). Studies examining 
a potential relation between the CTG repeat expansion and DMWD expression 
levels gave conflicting results, with lowered (64, 65) or unchanged (66, 67) DMWD 
levels. The CTG expansion overlaps with the promoter region of the SIX5 gene and 
suppression of SIX5 levels were observed in correlation to an increased number 
of CTGs (68, 69). To test if loss of SIX5 expression contributes to DM1 disease 
phenotype, Six5-deficient mice were created. Heterozygous and homozygous mice 
for the Six5 deletion developed premature cataracts (70, 71), cardiac conduction 
defects (72) and showed impaired spermatogenesis (73). Muscle contractile 
properties and histology were normal in Six5-deficient mice (74). These findings 
suggest that silencing of SIX5 is unlikely to be a major factor in DM pathogenesis.
THE RNA TOXICITY MODEL 
RNA-gain-of function
Since there is no functional link between DMPK and ZNF9, the clinical similarity 
between both DM types most likely reflects a parallel toxicity of their respective 
RNAs. The mechanistic model of RNA gain-of-function proposes that mutant RNAs 
transcribed from expanded alleles are sufficient to induce symptoms of the disease. 
This concept was supported by observations that both expanded (CUG)n- and 
(CCUG)n-containing transcripts accumulate in discrete nuclear foci (75-77). Foci of 
(CCUG)n complexes were also observed in the cytoplasm of DM2 myoblasts (78).
Additional support was provided by the HSALR mouse model, expressing 
250 CTG repeats within the 3' UTR of a transgenic human skeletal a-actin gene 
(79). HSALR mice develop ribonuclear inclusions, myotonia, myopathic features and 
histological muscle changes similar to DM1. These results show that expression of 
a (CUG)n repeat in the context of a non-DMPK mRNA is sufficient to reproduce 
DM1 features. Transgenic mice from the DM300-328 line - so-called DM-XL (600­
700 CTGs), -XXL (900-1000 CTGs) or -SXL (>1200 CTGs) mice - which carry CTG
17
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trinucleotide repeats embedded in the human genomic sequence from the DM1 
locus display DM1 abnormalities not only in skeletal muscle but also in brain (80).
Deleterious effects of stable (CUG)n hairpin formation
Expanded CUG repeats form long hairpin loops in which C^G base pairs are 
interrupted by U^U mismatches (81). Stability of the hairpin correlates with CUG 
expansion length, but even a short (CUG)5 repeat has a distinct tendency to form 
a hairpin (82). The best described RNA-binding proteins with affinity for a (CUG) 
n hairpin are CUGBP1 (CUG-binding protein 1) (83) and members of the MBNL 
(muscleblind) family (84) (Figure 4). Heterogeneous nuclear ribonucleoprotein H 
(hnRNP H) is also capable of binding mutant DMPK mRNA and possibly modulating 
its nuclear retention, while elevated steady-state levels of hnRNP H in DM1 
myoblasts play a possible role in the disease phenotype (85, 86). Expanded DMPK 
transcripts were also found to bind and sequester nuclear transcription factors (TFs) 
leading to disrupted gene expression patterns (87). The precise role of (C/CUG) 
n-RNA protein aggregation and RNP foci formation in DM disease pathobiology is 
still under debate (88)
CUGBP1
The first identified (CUG)n RNA-binding protein, CUGBP1, is a member of the CELF 
family of protein factors. Six proteins that regulate several post-transcriptional 
processing steps, including alternative splicing, translational initiation and 
mRNA stability belong to this family (89-91). CUGBP1 is ubiquitously expressed, 
is distributed in both the nucleus and cytoplasm, and can be phosphorylated to 
differential extent (83, 92). CUGBP1 binds to short single-stranded CUG repeats in 
vitro (83), but neither CUGBP1 nor other members of the CELF protein family bind 
to double-stranded (CUG)n or (CCUG)n repeats or localize in nuclear foci (93-95). 
CUGBP1 steady-state levels are increased in DM1 muscle (96) and heart tissue (97) 
due to hyperphosphorylation by protein kinase C (PKC) activity (98). Recently, it was 
reported that also cultured DM2 myoblasts display elevated levels of CUGBP1 (78).
The consequences of elevated CUGBP1 levels has been studied in a series 
of mouse models. Transgenic mice that overexpress CUGBP1 in muscle and heart 
show splicing defects and neonatal lethality, when CUGBP1 expression was 4-6 
fold above endogenous levels (99). Another transgenic CUGBP1 mouse model 
implicated a role for CUGBP1 in muscle development by showing enhanced levels 
of translational targets p21 and myocyte enhancer factor 2A (MEF2A) (100). Also 
in that study neonatal death was observed after CUGBP1 overexpression. The 
relation between (CTG)n repeat expansion, CUGBP1 levels and DM1 phenotype 
was examined in an inducible and heart-specific DM1 mouse model, expressing a 
(CUG)960 construct in the context of a DMPK 3'UTR. In these mice, elevated levels 
of CUGBP1 expression were observed next to severe cardiac conduction defects 
and misregulated splicing (101). Heart specific overexpression of human CUGBP1 
resulted in the cardiac phenotype of DM1 (102). A muscle-specific mouse model
18
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expressing the same (CUG)960 construct showed again increased CUGBP1 levels 
and related DM1 features like muscle wasting (103). Increased CUGBP1 levels were 
also detected in transgenic mice expressing a DMPK 3' UTR with only five CTG 
repeats (104). Why this model displays DM1 features upon expression of a normal­
sized (CTG)n repeat is still unclear and needs further investigation. Remarkably, in 
contrast to these findings, elevated levels of CUGBP1 were not detected in HSALR 
mice (105).
MBNL
The second important group of RNA-binding proteins implicated in DM pathogenesis 
are members of the MBNL family, initially identified as the major expanded (CUG) 
n RNA-binding proteins in the mammalian nucleus (84). MBNL, a mammalian 
homologue of the Drosophila muscleblind protein, was first implicated in terminal 
differentiation of muscle and photoreceptor cells (106, 107). Now, MBNL family 
members are generally known as tissue-specific alternative splicing regulators 
(108). Three mammalian MBNL proteins have been identified, MBNL1 (formerly 
MBNL), MBNL2 (MBLL) and MBNL3 (MBXL) (95). All three bind to expanded (C/CUG) 
n repeats - in a length-dependent manner - leading to depletion of MBNL from the 
nucleoplasm (95, 109). Recently it was found that MBNL1 binds with high affinity to 
YGCY motifs located in pre-mRNAs involved in DM1 (110).
MBNL1 is present in nuclear foci containing expanded (C/CUG)n RNA, 
raising the possibility that DM1-typical splicing abnormalities (see also below) are 
caused by depletion of MBNL1 (84, 105). To test this hypothesis, a Mbnl1 knockout 
mouse (Mbnl1AE3/AE3) was generated (111). Mbnl1AE3/AE3 mice display overt myotonia, 
delayed muscle relaxation, cataracts and abnormal regulation of alternative splicing 
(111). Another link between Mbnl1 depletion and RNA missplicing was provided 
by the observation that adeno-associated virus (AAV)-mediated overexpression 
of mouse Mbnl1 in skeletal muscle of HSALR mice caused correction of alternative 
splicing and initiated reversal of myotonia (112). Furthermore, Drosophila models 
deficient in muscleblind protein or expressing expanded (CUG)480 RNAs showed 
DM1 features like misregulated splicing, muscle wasting and eye degeneration 
(113, 114).
On the other hand, MBNL1 sequestration may not be sufficient to explain 
all features of DM1 pathogenesis. Mbnl1AE3/AE3 mice, for example, do not display 
muscle wasting (111). Also, even though both (CUG)n and (CAG)n RNA repeats form 
foci that contain MBNL1, only (CUG)n-repeat containing transcripts alter splicing 
of the two pre-mRNAs tested (115). In a recent publication, HSALR and Mbnl1AE3/AE3 
mice were compared for global splicing defects. This study revealed that HSALR mice 
display some Mbnl1-independent splicing defects (116).
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RNA TOXICITY MODEL TARGETS & STRATEGIES
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Figure 4. RNA dominance and therapeutic targets in myotonic dystrophy. Sequence of 
events according to the RNA toxicity model for the molecular pathogenesis of DM (left part). 
Two independent, unstable microsatellite repeats located in DMPK and ZNF9 genes give rise 
to expression of toxic, expanded RNAs with detrimental effects to the cell (black arrows). 
(C/CUG)n transcripts form thermodynamically stable hairpin structures that attract and 
sequester RNA-binding proteins, in particular members of the MBNL family and CUGBP1. 
Imbalance of these, and potentially other, proteins results in disturbance of particular 
cellular mechanisms and pathways, of which aberrant splicing of a DM-typical subset of 
transcripts is the best studied example. Spliceopathy results in abnormal protein expression 
of for example chloride channel 1 (ClCN-1) and insulin receptor (IR). Aberrant expression 
of DM locus proteins and certain transcription factors may be caused by other, still not 
fully resolved mechanisms and may have an additive role in DM's molecular pathogenesis 
(gray dashed arrows). Potential therapeutic targets and strategies at the level of DNA, RNA 
and protein are indicated in boxes on the right. See text for further details. Adapted with 
permission from Human Molecular Genetics (202).
Spliceopathy in DM
CUGBP1 promotes inclusion of specific fetal exons during development in 
embryonic and neonatal tissues (89), whereas postnatal activation of MBNL leads 
to fetal exon skipping and expression of adult protein isoforms (108). During normal 
development, nuclear levels of CUGBP1 decrease (117) while nuclear levels of 
MBNL1 increase (105).
A wide variety of splicing events are mis-regulated in DM1 and some of 
them correlate directly with DM1 symptoms (116) (Figure 4). Recent data indicate 
that certain alternative splicing events are only responsive to CUGBP1 up-regulation 
whereas others are related to MBNL1 depletion (103). Myotonia in DM1 is due 
to abnormal splicing of the skeletal muscle-specific chloride channel 1 (ClCN-1). 
Inclusion of exons containing premature stop codons (i.e., the embryonic splicing 
pattern) initiates nonsense-mediate decay and down-regulation of ClCN-1 mRNA 
and protein, resulting in the onset of myotonia (118, 119). Some individuals with DM 
display insulin resistance caused by aberrant alternative splicing of insulin receptor 
(IR) pre-mRNA, resulting in predominant expression of the insulin insensitive splice 
form lacking exon 11 (120). Increased inclusion of cardiac troponin T (cTNT) exon 
5, which is a splice form produced during early development of heart and skeletal 
muscle but not present in adult heart, may contribute to cardiac conduction 
defects seen in DM1 patients (96). In summary, aberrant expression of CUGBP1 and 
members of the MBNL family induces transcript switches from adult isoforms to 
insufficient embryonic forms.
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OTHER RNA-MEDIATED EXPANSION DISORDERS
In the last two decades, researchers have identified a growing number of 
microsatellite expansion disorders (121, 122), including DM1 and DM2. Typically, 
microsatellite expansion disorders are diseases in which a tandem nucleotide 
repeat within a specific gene, containing a variable number of repeats within the 
population, expands to a pathogenic range. Therefore, the mutations in these 
repeats were initially termed "dynamic mutations". Various pathogenic pathways 
can underlie repeat induced disorders. Both loss-of-function and gain-of-function 
mechanisms are found associated with expanded repeats.
When an expanded repeat is located in a non-coding region it will be 
transcribed, but not translated, and often proteins do not play a central role in the 
disease development. However, the transcribed RNA function might be altered, 
initiating a gain-of-function mechanism (121). Examples of disorders caused by 
expanding repeats located in non-coding gene regions include, besides DM1 and 
DM2, fragile X tremor ataxia syndrome (FXTAS), spinocerebellar ataxia types 8, 10 
and 12 (SCA8, SCA10, and SCA12), and Huntington's disease-like 2 (HDL2) (Table 1).
Table 1. Repeat diseases associated w ith an RNA-gain-of-function mechanism.
Disease Repeat sequence Gene Position within the gene Normal range Disease range
DM1 (CTG)n DMPK 3' UTR 5-37 50-3000
DM2 (CCTG)n ZNF9 Intron 1 <27 75-11000
FXTAS (CGG)n FMR1 5' UTR 5-55 55-200
SCA8 (CTG)n and (CAG)n SCA8 3' UTR or coding region 16-34 100-1300
SCA10 (ATTCT)n ATXN10 Intron 9 <29 800-4500
SCA12 (CAG)n PPP2R2B 5' UTR or coding region <32 51-78
HDL2 (CTG)n JPH3 3' UTR, in tron ic  or coding region 6-28 40-58
Table 1. Repeat disease associated with an RNA-gain-of-function mechanism. DM1: 
Myotonic dystrophy type 1, DM2: Myotonic dystrophy type 2, FXTAS: Fragile X associated 
tremor ataxia syndrome, SCA8: Spinocerebellar ataxia type 8, SCA10: Spinocerebellar ataxia 
type 10, SCA12: Spinocerebellar ataxia type 12 and HDL2: Huntington's disease-like 2.
Fragile X tremor ataxia syndrome (FXTAS)
Fragile X syndrome is the most common congenital mental retardation disorder and 
caused by (CGG)>200 expansions in the 5' UTR of the FMR1 gene (123). Affected 
individuals with expansions over 200 CGG repeats, are referred to as having a full 
mutation, while those individuals who carry CGG repeat expansions between 55 
and 200 triplets are referred to as premutation carriers (Table 1). Premutation 
carriers are found to be at increased risk of developing an age-dependent 
progressive intention tremor and ataxia syndrome, which is uncoupled from fragile 
X syndrome and known as fragile X-associated tremor/ataxia syndrome (FXTAS) 
(124, 125). FXTAS is caused through an RNA gain-of-function mechanism, whereby 
(CGG)n-containing transcripts aggregate in nuclear inclusions (126, 127). MBNL,
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among many other proteins, has been identified in these nuclear inclusions (128), 
suggesting a pathogenic mechanism related to that of DM (129).
Spinocerebellar ataxia (SCA)
Spinocerebellar ataxias (SCAs) are a complex, progressive group of often fatal 
neurodegenerative diseases that lead to generalized incoordination of gait, speech 
and limb movements (130). Altogether, nine SCA types have been described to 
date, of which three - SCA8, SCA10 and SCA12 - are caused by repeats in non-coding 
regions of different genes (Table 1).
SCA8 is the result of a (CTG)74-1300 expansion in the 3' UTR of the 
SCA8 gene (also referred to as ATXN8OS) (131). The SCA8 locus is bidirectionally 
transcribed and produces RNAs with either (CUG)n or (CAG)n expansions. (CAG)n 
expansion transcripts produce a nearly pure polyglutamine protein forming nuclear 
inclusions in neurons. On the contrary, (CUG)n RNA foci remained undetected (132). 
It was proposed that both expanded (CUG)n RNAs and polyglutamine proteins are 
involved in SCA8 pathogenesis (132).
The dominant, noncoding mutation that causes SCA10 is a pentanucleotide 
(ATTCT)n expansion covering 800 to 4500 repeats (133). Similar to DM2, the 
SCA10 mutation is located in an intron whereby the (ATTCT)n repeat is situated 
within intron nine of the ATXN10 gene (formerly known as E46L) (121, 133). Since 
overexpression of a pure (ATTCT)n tract in cell culture can cause accumulation of 
(AUUCU)n-containing RNA and foci formation, an RNA gain-of-function mechanism 
has been proposed to be involved in SCA10 pathogenesis (133, 134).
SCA12 is caused by a (CAG)n expansion mutation (55-78 triplets) initially 
reported to be located in the 5' UTR of the PPP2R2B gene (135). Recent studies of 
additional splice variants now indicate that, depending on the splice variant, the 
repeat can be located at the 5' UTR, in an intron and potentially within an open 
reading frame (134, 136). Hence, also for this disorder a model involving an RNA 
gain-of-function mechanism was proposed. Further research is needed to resolve 
the pathogenic mechanisms of the various SCA types.
Huntington's disease-like 2 (HDL2)
HDL2 is a dominantly inherited disease similar to Huntington's disease and causes 
movement abnormalities, dementia and psychiatric problems (137). HDL2 is 
caused by a (CTG)40-59 expansion in the JPH3 gene (138) (Table 1). Depending 
on alternative splicing, the expanded (CUG)n repeat is present in an intron, in the 
3' UTR, or it encodes a polyleucine or polyalanine tract. Both protein tracts were 
found, next to (CUG)n repeats that include MBNL1, in nuclear inclusions (137, 139).
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THERAPEUTIC STRATEGIES FOR DM
At the moment no treatment is available to slow or halt disease progression or 
really attack DM's molecular cause. Different approaches for a molecular therapy 
for DM1 have been suggested (Figure 4). At the DNA level, possibilities for induction 
of (CTG^CAG)n repeat contraction (140, 141) or prevention of somatic expansion 
(142, 143) to delay disease onset are under debate. At the RNA-protein factor level, 
both overexpression of Mbnl1 protein (112) and suppression of CUGBP1 protein 
expression (144) may have therapeutic potential. In general, most therapeutic 
strategies described target the expanded (CUG)n RNA itself bases on the findings 
that reversal of disease features could be achieved by down-regulation of aberrant 
RNA expression or after complementation of the Mbnl1 protein (104, 112, 145). 
These observations provide the foundation for two possible therapeutic strategies 
for DM, aimed at (i) degradation of the expanded (C/CUG)n RNA and (ii) prevention 
of aberrant protein binding.
Degradation of (CUG)n expanded transcripts
Existing approaches to eliminate toxic DM transcripts are based on nucleic-acid(-like) 
compounds - i.e., ribozymes, antisense RNAs, siRNAs, DNA or modified antisense 
oligonucleotides (AONs) - that hybridize to target sequences in DMPK RNA (no 
reports on silencing of ZNF9 (CCUG)n RNA have been published yet). Two outcome 
options should be distinguished: (i) removal of all DMPK transcripts, irrespective 
of repeat length, or (ii) selective elimination of expanded DMPK RNAs only. With 
regard to option (i), KO mice lacking DMPK protein show a relatively mild phenotype 
(47, 59) and the few patients with homozygous DMPK expansions do not display 
abnormally severe symptoms (146). Regarding the latter possibility, apart from the 
length of the (CUG)n segment, there is no general polymorphism known that allows 
discrimination between mRNAs from normal-sized DMPK alleles and expanded 
transcripts from mutated alleles in each DM patient. An unknown issue is what 
minimum efficacy of DMPK RNA knockdown is needed for a beneficial effect. Partial 
silencing of toxic (CUG)n RNA may already be of clinical relevance to patients.
Ribozymes and conventional antisense strategies
One of the first approaches described to modify the expanded repeat segment 
made use of ribozymes. A Tetrahymena trans-splicing group I intron ribozyme 
was able to swap part of the 3' end of a DMPK transcript for a similar fragment 
contained within the ribozyme, thereby reducing the number of CUG triplets from 
twelve to five (147). A comparable approach was recently published that employed 
so-called artificial trans-splicing molecules (148), which induced a trans-splicing 
event involving 3' exon replacement during DMPK pre-mRNA splicing in the nucleus 
(149). The fate of the excised segment should be studied, as any toxic effect out of 
the context of the DMPK transcript should be avoided.
A hammerhead-type of ribozyme to induce endonucleolytic cleavage of
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DMPK transcripts was designed by Puymirat et al. (150). This group achieved a 60% 
reduction of expanded transcripts, a drop in the number and intensity of nuclear 
DMPK RNA foci and partial restoration of insulin receptor missplicing. However, 
cytoplasmic DMPK transcripts were also 50% reduced. The poor specificity and 
relatively low efficiency implies the need for optimization.
Conventional antisense strategies to evoke degradation of expanded DMPK 
transcripts have also been tested (Figure 4). A retroviral vector expressing a 149- 
bp antisense RNA complementary to part of the 3' UTR of DMPK mRNA including 
a (CUG)13 repeat was introduced in patient myoblasts and resulted in correction 
of CUGBP1 expression and restoration of myoblast functions (151). Expanded 
transcripts were reduced by 80% but also normal DMPK transcripts were 50% lower. 
A second antisense approach (150) tested DNA AONs complementary to different 
sequences in DMPK's 3' UTR in patient cell extracts for their ability to recruit RNase 
H, which degrades the RNA component of an RNA-DNA hybrid (152). Only some 
oligos were able to induce degradation, confirming that accessibility of the target 
sequence is a crucial factor for success in antisense approaches (153).
RNA interference
(CUG)n repeats form stable hairpin structures (81) despite the U^U mismatches 
(154) and any such RNA structure may be a target of the RNA interference (RNAi) 
pathway (154, 155). Krol et al. indeed provided evidence that expanded (CUG) 
n RNAs - and other tandem (CNG)n sequences - are recognized by Dicer (156), 
which cuts double-stranded RNA precursors into ~21-nt duplexes (157). Treatment 
of patient fibroblasts with a synthetic 5' monophosphorylated (AGC)7 RNA oligo 
resulted in selective reduction of mutant DMPK transcripts (156). In a second RNAi 
study, both cytoplasmic and nuclear-retained DMPK transcripts were reduced after 
treatment of DM1 cells with lentiviral vectors that delivered short hairpin RNA 
targeting sequences in the 5' end of the RNA (158). SiRNA approaches targeting 
(CUG)n repeats specifically have not been published to date.
Antisense oligo PS58
Our own lab designed AONs with the aim to degrade expanded DMPK transcripts 
directly by recruiting RNase H, or induce exon skipping or abortive splicing followed 
by conventional RNA breakdown (159). The most effective oligo identified, PS58, 
is directed against the (CUG)n repeat and its identification is described in Chapter 
5. PS58 efficacy in a systemic delivery approach was explored in Chapter 6. 
Subsequently, PS58 was used as a lead compound in a broad screen to identify 
novel effective triplet repeat AONs, based on variation in length, chemistry and 
sequence (Chapter 7).
Inhibition of protein binding to (CUG)n repeat hairpin
A different approach to reduce RNA dominance involves prevention of abnormal 
protein factor binding to stable (CUG)n hairpin structures (Figure 4). Preclusion of
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binding might restore the level of the free protein factor, such that it would become 
available for normal biological function.
Morpholino CAG25
Wheeler et al. described use of a 25-nt (AGC)8A morpholino-type AON (named 
CAG25) complementary to the (CUG)n repeat (160). Morpholinos are a type 
of AONs acting primarily via an occupancy-only mechanism by hybridizing to a 
complementary RNA sequence without activating cleavage of their target (161). 
Treatment of skeletal muscle in HSALR mice resulted in reduction of nuclear foci, 
redistribution of Mbnl1 protein, near-normalization of aberrant splicing and 
restoration of ClCN-1 protein expression and reversal of skeletal muscle myotonia. 
Contrary to expectation, CAG25 administration resulted also in a 50% reduction 
of expanded (CUG)n RNA, while endogenous transcripts bearing a short (CUG)n 
repeat remained unharmed. CAG25 relocated expanded (CUG)n transcripts to the 
cytoplasm and Wheeler et al. propose that elevated cytoplasmic decay may be 
responsible for (CUG)n RNA reduction. To what extent the reduction of expanded 
(CUG)n RNA contributed to the therapeutic effect remains to be investigated.
Small molecules that bind structured nucleic acids
Important progress was also made in the identification of small molecules that 
liberate MBNL1 by binding to (CUG)n repeats (162-164). Studies were based 
on molecules known to bind structured nucleic acids and yielded a number of 
promising lead compounds. The most comprehensive analysis was published on 
pentamidine, a drug to treat P. carinii infections in AIDS patients (162). Pentamidine 
reduced MBNL1-(CUG)n aggregates in the nucleus and rescued missplicing in a 
HeLa cell model expressing (CUG)960 RNA and minigene splicing reporters (165). 
Intraperitoneal injections in HSALR mice resulted in mild reversal of missplicing of 
pre-mRNAs in skeletal muscle. Unfortunately, use of pentamidine is strongly limited 
by its high toxicity (162). Future work should therefore concentrate on strategic 
chemical modification to increase the affinity and specificity and minimize the off­
target effects.
Multivalent modular compounds that bind internal RNA loops
Disney et al. constructed multivalent, modularly assembled, flexible (non-nucleic- 
acid type) ligands for high-affinity binding to (C/CUG)n repeats, based on compounds 
that bind discrete RNA loops (166-169). Ligands were screened for their ability to 
inhibit (C/CUG)n-MBNL1 binding in vitro. The highest affinity binder to a (CCUG)n 
repeat consisted of three kanamycin A modules on a peptoid backbone (166). By 
reducing the distance between the kanamycin modules and increasing the number 
of modules to four, an equally strong ligand for (CUG)n repeats was created (167). 
In a study performed by the same group, a pentameric (CUG)n repeat ligand (which 
also binds (CAG)n repeats) was designed based on Hoechst 33258 modules (168). 
Advantage of these multivalent compounds is that they show high binding affinity
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and are generally cell permeable. Whether these ligands will be able to enter the 
nucleus and subsequently help expanded transcripts to move to the cytoplasm 
requires further investigation.
Relocation of expanded (CUG)n transcripts to the cytoplasm
Any treatment that prevents nuclear retention of mutant (CUG)n RNAs or stimulates 
export of expanded (CUG)n transcripts to the cytoplasm may be beneficial to DM 
cells (Figure 4). This idea was studied via inclusion of a so-called woodchuck post- 
transcriptional regulatory element (WPRE) in an artificial transcript bearing an 
expanded (CUG)200 repeat (170, 171). Presence of the WPRE promoted nuclear 
release of the transcript and improved differentiation of myoblasts in which the 
RNA was expressed. This work and findings in a mouse model that expresses Mbnl1- 
(CUG)400 RNA foci exclusively in the cytoplasm without displaying DM1-typical 
features (172) confirm that stimulation of nuclear export of mutant DMPK RNA or 
induction of a shift in nuclear-cytosolic distribution may become therapeutically 
beneficial. Thus far, no drugs with the specific aim of inducing nuclear export of 
expanded (CUG)n transcripts have been described, but their application may have 
additional advantage in that cytoplasmic relocation of the mutant transcript could 
normalize DMPK protein levels.
Correction of aberrant splicing
Other therapeutic developments aim at correction of events that occur downstream 
in the pathogenesis cascade triggered by mutant (CUG)n RNA (Figure 4). For example, 
skeletal muscle myotonia is a typical DM feature linked to aberrant inclusion of 
exon 7a of ClCN-1 pre-mRNA. Presence of this exon sequence disrupts the open 
reading frame by a premature stop codon and subsequently leads to degradation 
of the ClCN-1 transcript via nonsense mediated decay (119, 173). HSALR and 
Mbnl1AE3/AE3 mice recapitulate this aberrant splice mode and served as models to 
study use of morpholinos for blocking exon 7a inclusion (174). When administered 
to tibialis anterior muscle by injection-electroporation, these AONs suppressed 
exon 7a inclusion to such extent that full-length ClCN-1 protein reappeared at the 
sarcolemma and myotonia became markedly reduced. Importantly, this proof of 
concept was reported for both mouse models, irrespective of the cause of Mbnl 
depletion. An obvious limitation of this approach is that one type of AON can 
only help to restore one aberrant splice event, while dozens of other misspliced 
transcripts - each implicated in single or multiple core features - remain untreated 
(105, 116). One possible solution would be the use of a cocktail of oligos to correct 
multiple splice events simultaneously, but it is unclear whether such an approach is 
realistic and feasible.
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ANTISENSE OLIGONUCLEOTIDE CHEMISTRY
A series of promising strategies for selective elimination or neutralization of expanded 
(C/CUG)n transcripts is now emerging. Effective antisense oligonucleotides are in the 
pipeline of development, but much work needs to be done. The biggest hurdle to 
overcome is efficient delivery of active compounds in vivo (175-177). Full potential 
of antisense oligonucleotides as therapeutic agents will not be attained until better 
methodologies for targeted delivery to cells and tissues are developed. A broad 
variety of delivery strategies have been achieved, including coupling of AONs to cell- 
penetrating peptides (178, 179), nanocarriers (180), receptor-mediated conjugates 
such as cholesterol or transferrin (181) and the use of so-called vivo-porters (182).
AONs composed of naturally occurring nucleic acid are unsuitable for a 
number of applications because of poor stability, as unmodified AONs are rapidly 
degraded in biological fluids by nucleases, and low affinity toward complementary 
sequences. To overcome these problems, modifications at the base, phosphate 
backbone or sugar moiety to improve the biological, biochemical and biophysical 
characteristics of AONs were developed (152) (Figure 5). Introduction of chemical 
modifications can change mechanistic properties of AONs. 2'-O-modifications 
facilitate a change in AON flexibility and stronger base-pairing with the target but are 
incompatible with RNase H recruitment (183). A selection of chemical modifications 
will be shortly discussed below.
Phosphorothioate
In phosphorothioate-modified oligos, one of the non-bridging oxygen atoms in the 
phosphodiester bond is replaced by sulfur creating a phosphorothioate (PT) group 
(Figure 5) (184). The introduction of the phosphorothioate modification into AONs 
enhances their nuclease resistance (185) and is responsible for stronger plasma 
protein binding causing an increased serum half-life (186). But these nonspecific 
interactions may cause cellular toxicity. Phosphorothioate DNAs have a slightly 
reduced affinity towards complementary RNA molecules in comparison to their 
corresponding phosphodiester oligodeoxynucleotide (187).
2'-O-methyl
Problems associated with PT AONs are to some degree solved by use of AONs 
with alkyl modifications at the 2'-OH position of the ribose. Within this class of 
modifications the 2'-hydroxyl (OH) of the ribose is substituted by a 2'-O-methyl 
(OCH3) group (152) (Figure 5). AONs made of these building blocks are less toxic 
than PT DNAs and have an enhanced affinity towards their complementary RNAs
(188).
Locked nucleic acid (LNA)
Locked nucleic acid (LNA)-modified nucleotides contain a methylene bridge that 
connects the 2'-oxygen of ribose with the 4'-carbon (Figure 5) (189, 190). As a
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consequence, LNAs are inflexible and have improved affinities for complementary 
DNA and RNA sequences (189, 190). Furthermore, LNAs are nuclease resistant
(189).
2'-O,4'-C-ethylene-bridged nucleic acid (ENA)
Modified oligonucleotides containing an ethylene bridge between the 2'-O and 
4'-C of the ribose resemble LNAs (Figure 5) (191). These 2'-O,4'-C-ethylene-bridged 
nucleic acid (ENA) modifications introduce a high binding affinity for complementary 
RNA and DNA, and a high resistance against nucleases (192).
Phosphorodiamidate morpholino oligomers (PMO)
Morpholinos are nonionic nucleotide analogs in which the ribose is replaced by
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a 6-membered morpholino moiety and phosphorodiamidate intersubunit linkages 
are used instead of phosphodiester bonds (Figure 5) (193). PMOs can be designed as 
steric-blocking antisense molecules to inhibit translation or prevent proper splicing 
of RNA (161). The non-ionic character of PMOs avoids potential non-specific drug 
interactions with cellular components observed with PT AONs (194). In addition, the 
modified chemistry of PMOs provides excellent resistant to nucleases and protease 
activity (195). PMOs are now used in a wide variety of applications (196, 197).
Peptide nucleic acid (PNA)
Peptide nucleic acid (PNA) is a DNA mimic that is only remotely chemically related 
to DNA (198). In PNA, the sugar backbone of DNA is replaced by an uncharged and 
relatively flexible backbone composed of 2-aminoethyl glycine units to which the 
nucleobases are attached by methylenecarbonyl linkers (Figure 5) (198). PNAs are 
resistant to biological degradation (199), bind complementary RNA or DNA and can 
even invade duplex DNA with extraordinary high affinity and specificity (200, 201).
OUTLINE OF THIS THESIS
Its complex, multisystemic character renders DM type 1 a unique disorder, 
typified by features that become manifest at variable intensity and in different 
combinations in a wide range of tissues and cell types. Ever since it has become 
clear that production of toxic (CUG)n-containing transcripts from the mutant DMPK 
gene with an expanded (CTG)n tract is the main determinant of disease problems 
and their progression, international research is strongly focused on an RNA gain-of- 
function mechanism. The question whether all disease aspects are well explained 
by this RNA toxicity model or whether there could also be a pathophysiological role 
for aberrant DMPK protein expression, has still not been adequately answered. This 
thesis therefore focuses on both protein and RNA-related aspects of normal and 
aberrant DMPK gene expression. The first three chapters deal with the fate and 
consequences of expression of RNA and protein products in normal and transgenic 
tissues. The final three chapters are dedicated to a therapeutic strategy to neutralize 
expanded (CUG)n RNA toxicity.
The finding that an imbalance in DMPK gene products (47, 61) in transgenic 
mouse models causes problems similar to those seen in DM1 manifestation 
prompted us to investigate the significance of the normal DMPK gene products in 
more detail. To gain a detailed picture of the tissue- and cell-type distribution of 
DMPK gene products, we studied DMPK protein expression and distribution profiles 
in different cell types of muscle and brain, as described in Chapter 2. Previous 
work in our group has demonstrated that the DMPK gene is subjected to extensive 
alternative splicing (40, 41). In Chapter 3, we report on an extension of this work 
by profiling of alternative splicing of mDMPK and hDMPK transcripts during the 
process of myogenesis in a DM1 myoblast/myotube cell model. In Chapter 4, we 
study the role of one of the six known major protein splice isoforms, DMPK E, in
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actin cytoskeleton remodelling in myogenic cells to better appreciate its individual 
role in health and disease. study the role of one of the six known major protein 
splice isoforms, DMPK E, in actin cytoskeleton remodelling in myogenic cells to 
better appreciate its individual role in health and disease.
In a first attempt to develop a therapeutic strategy for DM1 based on 
elimination of expanded DMPK transcripts, we investigated the feasibility of 
antisense oligonucleotide-mediated technology. In Chapter 5, we present the 
identification of (CAG)7 AON (antisense oligonucleotide) PS58, which specifically 
eliminates expanded DMPK transcripts with (CUG)n repeats from human and mouse 
DM1 model cells in which these transcripts are expressed. Ideally, for therapeutic 
application in DM1 patients, oligo-mediated elimination of toxic (CUG)n transcripts 
should be effective in all relevant tissues and cell types of the human body. A pilot 
study exploring the potential value of systemic delivery of lead AON PS58 in a DM1 
mouse model is described in Chapter 6. We also analyzed the importance of AON 
length, chemistry and sequence content by testing of (CUG)n knockdown efficacy 
in mouse and human DM1 cell models. These results are important for future AON 
design and are reported in Chapter 7.
Finally, Chapter 8 summarizes the content of this thesis by providing a brief 
discussion of findings and a future outlook.
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ABSTRACT
Myotonic dystrophy type 1 (DM1) is a neuromuscular disorder caused by an 
unstable (CTG^CAG)n segment in the 3' untranslated region of the DM protein 
kinase (DMPK) gene. It is commonly accepted that DMPK mRNA-based toxicity is 
the main contributor to DM1 manifestations, however not much is known about 
the significance of the DMPK protein. To appreciate its normal and possible 
pathobiological role, we analyzed the patterns of DMPK splice isoform expression 
in mouse tissues. Long membrane-anchored DMPK dominated in heart, diaphragm 
and skeletal muscle, whereas short cytosolic isoforms were highly expressed in 
bladder and stomach. Both isoform types were present in diverse brain regions. 
DMPK protein was also detectable in cultured myoblasts, myotubes, cortical 
astrocytes and related cell lines of neural or muscle origin, but not in hippocampal 
neurons. This work identifies DMPK as a kinase with pronounced expression in 
diverse muscle and neural tissues that are affected in DM1.
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INTRODUCTION
Myotonic dystrophy type 1 (DM1) is a complex, multisystemic disorder which affects 
many tissues including skeletal muscle, heart, gastrointestinal tract and brain (1). 
The disease is caused by cell type-specific expression of an abnormal (CTG^CAG) 
n segment located in the 3' untranslated region of the DM protein kinase (DMPK) 
gene (2). The (CTG^CAG)n segment expands over generations in DM1 families and 
in somatic tissues during aging. In tissues like muscle and brain, (CUG)n-expanded 
transcripts become trapped in cell nuclei, forming abnormal RNA protein aggregates 
(3). The aggregation process -  or early steps therein -  is considered to be the main 
contributor to disease problems, because it compromises transcription or processing 
of specific mRNAs or exerts global cell stress (3, 4). Nevertheless, it remains to be 
seen whether all disease aspects, including the selective muscle wasting and loss 
of endocrine function, can be explained by the RNA toxicity model. There may also 
be a causative role for an imbalance in DMPK protein level or isoform distribution 
as well.
There is considerable controversy about the fate and role of DMPK protein 
in tissues of patients with DM1 (summarized by Wansink et al. (5, 6)). Moreover, 
circumstantial evidence from animal and cell model studies connects DMPK to 
problems similar to those in DM1 manifestation. Lack of DMPK in knockout (KO) 
mouse models affects heart physiology (7, 8), viability and calcium regulation in 
skeletal muscle cells (9, 10) and intermediate memory potentiation in brain (11). 
In addition, our group demonstrated that overexpression of hDMPK gene products 
results in hypertrophic cardiomyopathy, cardiac dysrhythmia, myotonia and 
hypotensic stress (7, 12).
DMPK protein occurs as six major splice isoforms, named A-F, in man and 
mouse (13). Mouse DMPK A and C, the prototype long C-tailed isoforms, localize 
to the endoplasmic reticulum (ER) or mitochondrial outer membrane (MOM), 
respectively (14). Strikingly, the human DMPK orthologues of these isoforms both 
localize to the MOM (15). Forced expression of the human DMPK A isoform in 
different animal and human cell types alters mitochondrial morphology, leading 
to perinuclear aggregation of mitochondria with possible consequences for cell 
dynamics or viability regulation (Oude Ophuis et al., manuscript in preparation) 
(15).
DMPK has been classified as a member of a subfamily of the large group of 
AGC protein kinases, to which also ROCK-I/-II, MRCKa/P/y and citron kinase belong 
(6, 16, 17). These kinases have been implicated in smooth muscle contraction, stress 
fiber formation, neurite retraction and cytokinesis (16, 18). DMPK has a presumed 
role in modulating actomyosin dynamics through phosphorylation of the regulatory 
subunit of myosin phosphatase (MYPT) (14, 19). Alterations to the cytoskeleton 
induced by DMPK are implicated in trafficking of the insulin receptor to the cell 
membrane, indicating increased susceptibility of DM1 patients to type II diabetes 
(20). In addition, DMPK is engaged in ion homeostasis, regulating Ca2+, Na+ and Cl-
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currents. Through direct interactions with phospholamban and phosphorylation of 
the P-subunit of the dihydropyrimidine receptor, DMPK is involved in the regulation 
of Ca2+ transients in heart and skeletal muscle (17, 21, 22).
To fully understand DM1 disease etiology at both the RNA and protein level 
it is important to have a detailed picture of tissue and cell-type distribution of all 
DMPK gene products. In an in situ hybridization study on mouse tissues by Reddy 
and co-workers, it was shown that DMPK mRNA is expressed in many, but not all 
tissues where DM1 becomes manifest. The focus was mainly on finding correlations 
between tissue-specific pathogenic effects and the dose of expanded (CUG)n 
segments, present in all DMPK splice variants from the mutant allele. Here, using a 
complementary approach at the protein level, we report on expression profiling of 
DMPK isoforms in tissues known to be prominently involved in disease pathology.
MATERIALS AND METHODS 
Mice and tissues
Tissues were isolated from wild type (WT; 129Ola/C57BL6 background), DMPK 
knockout (KO; 129Ola/C57BL6 background) and Tg26-hDMPK (TG; Fvb background) 
mice generated in our laboratory (7). Directly after killing the animals by cervical 
dislocation, the following muscle-cell containing organ and tissue samples were 
individually excised and snap frozen in liquid nitrogen: ventricle and atrium from 
heart, bladder, stomach, diaphragm and tongue, and soleus, gastrocnemius, tibialis 
anterior from the hind limb. Likewise, from the brains of each of three mice, the 
cortex, brain stem, cerebellum, hippocampus, striatum, hypothalamus and olfactory 
bulb regions were collected, snap-frozen and pooled. Also the brain-connected 
pituitary gland was isolated. All procedures involving animals were approved by the 
Animal Care Committee of the Radboud University Nijmegen Medical Centre and 
conformed to the Dutch Council for Animal Care.
Primary myoblasts and myotubes
Conditionally immortalized myogenic cell lines were derived from the calf muscle 
complex from WT and KO mice harboring the H-2Kb-tsA58 allele as described (23). 
WT and KO myoblasts were ring cloned, and selected for myotube formation ability. 
Myoblasts were propagated at 33°C on gelatin-coated dishes in DMEM (GibcoBRL, 
Gaithersburg, MD) supplemented with 20% (v/v) FCS, 50 ^g/ml gentamycin and 20 
units IFN-y/ml. Myotube formation was induced by placing a confluent myoblast 
culture grown on Matrigel (BD Biosciences, the Netherlands) at 37°C in DMEM 
supplemented with 5% horse serum (HS) and 50 ng/ml gentamycin and maintaining 
these conditions for up to nine days.
Primary hippocampal neurons and cortical astrocytes
Primary cultures of cortical astrocytes and hippocampal neurons were established 
essentially as described (24, 25). Both cell populations (>95% pure) displayed
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expected characteristic morphologies. Astrocyte identity was verified by GFAP 
immunostaining (data not shown). Primary neurons were cultured without an 
astrocyte feeder layer and were maintained for up to ten days in culture.
Established cell lines
Mouse neuro-2A (N2A) neuroblastoma cells, human SK-N-SH neuroblastoma 
cells and mouse C2C12 myoblasts were grown as described elsewhere (15, 26). Rat 
PC12 pheochromocytoma cells were grown on collagen-coated dishes in DMEM 
supplemented with 10% FCS and 5% HS at 37°C and harvested at ~75% confluence. 
Mouse CCL-131 neuroblastoma cells were grown for 2 days until subconfluent in MEM 
supplemented with 10% FCS at 37°C and 5% CO2. CCL-131 cells were differentiated 
for 48 hours in MEM supplemented with 2% FCS and 20 ^M retinoic acid (Sigma, 
the Netherlands) at 37°C and 5% CO2. Human U373 glioblastoma cells were cultured 
in DMEM supplemented with 10% FCS at 37°C and 5% CO2 and harvested at ~75% 
confluence. Mouse HL-1 beating and non-beating cardiomyocytes were cultured for 
2 days until near confluence (27, 28).
Analysis of DMPK distribution by western blotting
Frozen muscle tissues were homogenized on ice in NP40 lysis buffer (1% NP40, 50 
mM Tris-HCl, pH 7.5, 150 mM NaCl, 25 mM NaF, 1 mM sodium pyrophosphate, 0.1 
mM vanadate, 2 ^M microcystin, 1 mM PMSF, 1x protease inhibitor cocktail (Roche, 
Germany), 1 mM EDTA) including 1% SDS using a glass-glass dounce homogenizer. 
Brain tissues were homogenized on ice in NP40 lysis buffer. Lysates were cleared by 
centrifugation for 10 min at 14,000 g at 4°C, and the resulting supernatant fractions 
were mixed with SDS-PAGE sample buffer. Myoblast and myotube or neuron and 
astrocyte cells in culture were lysed in SDS sample buffer directly or NP40 lysis 
buffer, respectively. Lysates were cleared and mixed with sample buffer as described 
above.
Protein lysates were separated on 8% SDS-PAGE gels and transferred by 
western blotting to PVDF membrane (Millipore, USA). For immunodetection the 
following antibodies were used: DMPK-specific antibody B79 (13), monoclonal 
DMPK antibody MANDM1 (29, 30), P-tubulin antibody E7 (Developmental Studies 
Hybridoma Bank, University of Iowa, USA), pyruvate kinase antibody (Rockland, 
Gilbertsville, USA), GFP antibody (31). To decrease the background on blots 
using the B79 antibody, BSA (3% (w/v)) and lysate of DMPK KO myoblasts were 
added to the blocking buffer. As secondary antibody, HRP-conjugated IgG (Jackson 
ImmunoResearch Laboratories, UK) was used, and signals were generated by ECL, 
followed by exposure to film (Kodak X-OMAT AR).
Immunoprecipitation
Whole brains from WT, KO and TG mice were homogenized on ice in NP40 lysis buffer. 
Lysates were cleared by centrifugation for 10 min at 14,000 g. DMPK protein in a 
sample equal to half the cleared homogenate of one brain of postnatal day 0 (~1.5
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mg protein, determined as described (32)) was immunoprecipitated using DMPK 
antibody B79 (13), coupled to protein A-Sepharose beads. Immunoprecipitates 
were washed in NP40 lysis buffer, and bound proteins were solubilized in SDS-PAGE 
sample buffer and analyzed by SDS-PAGE and western blotting.
Transduction
For transient expression of YFP-mDMPK A, C and E, adenoviral-vector mediated 
gene transfer of primary neurons, primary astrocytes, myoblasts and myotubes was 
performed in DMEM for 3 hours at 33°C for myoblasts and at 37°C for other cell 
cultures. Details of the transduction procedure have been given in van Herpen et 
al. (15). Three hours after addition of recombinant virus, fresh new medium with 
composition as indicated was added, and cultures were maintained for 20-48 hours.
Immunofluorescence microscopy
Cells were grown on glass coverslips, coated with gelatin (myoblasts), Matrigel 
(myotubes) or poly-L-lysine (Sigma; neurons and astrocytes). Myoblasts, neurons 
and astrocytes were washed once with phosphate-buffered saline (PBS) and fixed 
in PBS containing 2% (w/v) formaldehyde 20-48 hours after transduction and 
permeabilized in PBS containing 0.5% (w/v) NP40. Samples were processed for 
immunofluorescence microscopy using standard procedures. Mitochondria were 
visualized either by an anti-cytochrome c oxidase antibody (33) or Mitotracker Red, 
CMXROS (Invitrogen, the Netherlands). The ER was stained by an anti-calreticulin 
antibody (Sigma, the Netherlands). Images were obtained with a Bio-Rad MRC1024 
confocal laser-scanning microscope equipped with an argon/krypton laser, using a 
60X 1.4 NA oil objective and LaserSharp2000 acquisition software.
Myotubes were not fixed but stained with Mitotracker Red, CMXH2ROS 
(Invitrogen, the Netherlands), and while they were placed at 37°C on a temperature- 
controlled stage of a Zeiss LSM510-Meta confocal microscope (running software 
release 3.2), images were acquired using the appropriate argon laser lines and a 
63X 1.4 NA oil objective.
RNA isolation and RT-PCR
RNA was isolated using the Aurum Total RNA Mini Kit (Bio-Rad, Hercules, CA, USA), 
according to the manufacturer's protocol. Semi-quantitative RT-PCR analysis was 
performed. Approximately 0.5 ^g RNA served as template for cDNA synthesis with 
random hexamers using the SuperScript first-strand synthesis system (Invitrogen) 
in a total volume of 20 ^l. One ^l of the cDNA reaction mixture was used in PCR 
analysis according to standard procedures. In RT control experiments, reverse 
transcriptase was omitted. Cycle number was 24 for P-actin and 26 for DMPK. 
The following primer pairs were used: human/mouse/rat P-actin forward primer 
5'-GCTAYGAGCTGCCTGACGG-3' and reverse primer 5'-GAGGCCAGGATRGAGCC-3'; 
human DMPK exon 7 forward primer 5'-ACGGCGGAGACCTATGGCAA -3' and 
exon 9 reverse primer 5'-TCCCGAATGTCCGACAGTGT-3'; Mouse/rat DMPK
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exon 7 forward primer 5'-AAGAATTCGCCGAGACATATGCCAAGATT-3', exon 9 
reverse primer 5'-AATCTCGAGTCCTGCATGTCTGACAGCGT-3', exon 12 forward 
primer 5'-AAAGAATTCGAGACCTGGAGGCGCATGT-3' and exon 15 reverse primer 
5'-AAACTCGAGCGAACAGGAGCAGGCAAC-3'. PCR products were analyzed on 1.5­
2.5% agarose gels and stained by ethidium bromide. Signals were imaged on the 
Epi Chemi II Darkroom (UVP BioImaging systems, Cambridge, United Kingdom), and 
images were collected using the Labworks 4.0 software (UVP BioImaging systems, 
Cambridge, United Kingdom).
RESULTS 
DMPK protein in muscle tissues
Earlier work established that mRNAs encoding long DMPK isoforms (isoforms A-D) 
are mainly expressed in heart and skeletal muscle, and transcripts encoding short 
isoforms (E and F) occur predominantly in smooth muscle (12, 13). To verify whether 
the protein products are distributed correspondingly, we analyzed different mouse 
muscle types for presence of DMPK protein. For comparative purposes and to obtain 
reliable signals for DMPK, a low-abundance protein, we examined expression of 
the hDMPK transgene in our Tg26-hDMPK (TG) mouse lineage next to that of the 
endogenous mDMPK gene in wild type (WT) mice. Production of hDMPK protein 
in TG mice is driven by its own hDMPK promoter from multiple gene copies and is 
two to eight-fold higher compared to endogenous mDMPK, depending on the tissue 
type (7, 12).
Using our own DMPK-specific antibody B79 (13), we were able to distinguish 
long and short DMPK isoforms on immunoblot based on the clear difference in 
their molecular weight. The human DMPK transgene product and the endogenous 
mouse DMPK protein could not be separated, so signals obtained in TG samples are 
composed of both products. Tissue samples from the DMPK knockout (KO) mouse 
served as negative controls (7). When compared on the basis of total protein loaded, 
the DMPK signal was clearly strongest in bladder and stomach, of intermediary 
strength in heart, diaphragm and tongue, and - unanticipated - relatively weak in 
skeletal muscle (Figure 1).
In WT and TG ventricle and atrial segments of heart, long and short DMPK 
isoforms were expressed in almost equal amounts (Figure 1A and B). Total DMPK 
protein expression, i.e. transgenic and endogenous level combined, in TG heart was 
considerably higher than in WT heart.
In skeletal muscles, in gastrocnemius, fast twitch tibialis anterior, and 
also in slow twitch soleus muscle of both WT and TG mice, long DMPK isoforms 
predominated. Weak expression of short DMPK isoforms of about 10-40% of total 
signal intensity was observed as well, at variable long:short signal ratios for different 
muscle types in WT and TG (compare e.g., tibialis and soleus). When compared to 
the tubulin control also total DMPK signal levels varied, with the highest expression 
in WT found in soleus and in tibialis anterior in TG.
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Figure 1. DMPK protein expression in skeletal, cardiac and smooth muscle types. Proteins 
in tissue lysates of WT (A) or TG mice (B) were resolved by SDS-PAGE and analyzed on 
western blot using a DMPK antibody. Samples from a KO mouse were included as negative 
controls. GPS = Gastrocnemius Plantaris Soleus muscle complex; L = long DMPK isoforms A-D 
(apparent molecular weight of ~74 kDa), S = short DMPK isoforms E-F (~67 kDa) (13, 14); T 
= tubulin staining used to monitor protein loading.
In diaphragm of WT mice, a mixed fiber type muscle, expression of long 
DMPK isoforms predominated. In diaphragm of TG mice, absolute DMPK expression 
was considerably increased, and the signal level of long and short isoforms appeared 
about equal (Figure 1A and B). In tongue, also a mixed fiber muscle, short and long 
isoforms were present at equal levels in both TG and WT mice (Figure 1A and B). 
In tongue of WT mice, also a faster migrating protein immunoreactive to our anti- 
DMPK B79 antibody was noted (Figure 1A).
By far the highest expression of DMPK, almost exclusively of the short 
isoform, was found in bladder and stomach of WT and TG mice, both tissues with a 
high content of smooth muscle cells (Figure 1A and B).
DMPK protein in brain and distinct brain regions
Northern blot, RT-PCR and ISH studies demonstrated that RNA products from 
the DMPK gene are expressed at low level in the central nervous system (13, 34). 
Since the endogenous DMPK protein level in total WT brain lysate was also very 
low and difficult to detect on western blot (12, 13, and data not shown), we first 
concentrated on the analysis of DMPK protein distribution by examining total 
lysates from regional brain samples in TG overexpressor mice. In all areas examined
- most prominent in olfactory bulb and pituitary gland - a predominant expression 
of long isoforms was observed (Figure 2A). Analysis of WT mice confirmed that the 
pituitary gland contained almost only long DMPK isoforms (data not shown).
To invoke a more sensitive assay for monitoring isoform shifts during brain 
development, we followed DMPK profiles by subjecting equal amounts of protein 
originating from whole brains of KO, WT and TG mice of postnatal days 0, 21 and 42 
to immunoprecipitation by DMPK antibody B79, followed by detection on western 
blot with a second DMPK-specific antibody MANDM1 (29, 30). In agreement with 
previous findings, expression of DMPK was still barely detectable in WT brain, 
but rather strong signals were obtained for TG brain. Long DMPK isoforms were
49
Chapter 2
predominant, and there was a clear increase in signal strength during the first six 
weeks of development (Figure 2B).
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Figure 2. DMPK protein expression in brain and individual brain regions. Lysates of brain 
regions and the pituitary gland from one-year-old TG mice (A) were analyzed by western 
blotting using a DMPK antibody (B79). Protein loading was verified by pyruvate kinase (PK) 
immunoreactivity. Whole brain extracts from one-year-old KO mice (BKO) and TG mice (BTG) 
served as controls. (B) Immunoprecipitated DMPK from whole brains of Ko, WTand TG mice 
isolated at postnatal days 0, 21 and 42 detected by the MANDM1 DMPK antibody. To better 
appreciate signal intensities, a long and a short exposure are shown. L = long DMPk isoforms 
and S = short DMPK isoforms (13,14).
DMPK protein in cultured primary myoblasts and myotubes
Primary myoblasts were isolated from the calf muscle complexes of WT and KO 
mice (7) harboring the H-2Kb-tsA58 allele (23) and allowed to differentiate in vitro. 
In proliferating myoblasts as well as differentiated myotubes (Figure 3A) mainly long 
DMPK isoforms were expressed. Strikingly, no apparent difference in expression 
level was observed between cycling and resting myoblasts and myotubes. We did 
observe, however, that the phosphorylation status of the long DMPK isoforms 
appeared slightly increased in myotubes at later time points of differentiation (7-9 
days), as illustrated by the more intense upper band of the doublet signal (14).
Expression of short DMPK isoforms was low in differentiating myotubes and 
became almost undetectable after nine days of differentiation (Figure 3A). Presence 
of short isoforms in myoblasts could not be determined due to a strong cross-reacting 
signal also observed in KO cells (probably bovine serum albumin since myotubes 
cultured in the presence of horse serum did not show a signal; Figure 3A). To shed 
more light on the repertoire of DMPK isoforms in myoblasts, we also performed 
an RT-PCR analysis of the alternatively spliced exon 12-15 region (Figure 3B). This 
analysis confirmed that transcripts encoding the short isoforms were present in 
myoblasts and that expression was only just detectable in myotubes (Figure 3B). 
Extrapolating this to the protein level, our data indicate that short isoforms are 
present at low level in myoblasts, but they disappear during terminal differentiation 
of myofibers, leaving expression of only long DMPK isoforms.
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Figure 3. DMPK protein expression in primary myogenic cells. Conditionally immortalized 
myoblasts from Wt  and KO mice were cultured and allowed to differentiate into myotubes. 
(A) DMPK protein expression in proliferating myoblasts (P), a confluent myoblast culture (C) 
and myotubes after 1, 3, 5, 7 and 9 days of differentiation was assessed by western blotting. 
Protein loading was related to tubulin expression (T). Note that DMPK isoforms comigrated 
with cross-reacting proteins (see KO samples), the faster migrating one probably being BSA, 
abundantly present in proliferation, but not differentiation medium. L = long DMPK isoforms 
and S = short DMPK isoforms (13,14). (B) Semi-quantitative RT-PCR analysis was performed 
on RNA derived from proliferating myoblasts, a confluent myoblast culture and myotubes 
after 1 and 7 days of differentiation. The main alternative splice products encoding long (L) 
or short (S) DMPK isoforms are indicated on the right. The asterisks indicate a rare DMPK 
isoform containing a premature stop codon as a result of incorporation of part of intron 13, 
potentially encoding a protein isoform with a predicted molecular weight of 63 kDa.
DMPK protein in cultured primary neurons and astrocytes
DMPK expression was also analyzed in primary astrocytes from brain cortex and 
neurons from the hippocampus isolated from E16.5 WT and KO mice and cultured 
in vitro. DMPK protein was clearly detectable in cortical astrocytes but not in 
hippocampal neurons (Figure 4A). Long isoforms were predominant, but short 
isoforms also occurred at low signal strength.
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Figure 4. DMPK expression in primary neurons and astrocytes. (A) Protein lysates of 
primary neurons and astrocytes were analyzed on western blot using antibody B79 against 
DMPK (13) and an anti-pyruvate kinase antibody (PK) as a loading control. DMPK protein 
could be detected in WT astrocytes, but not neurons. L = long DMPK isoforms (~74 kDa) and 
S = short DMPK isoforms (~67 kDa) (13,14). (B) RT-PCR using RNA from primary neurons and 
astrocytes demonstrated presence of DMPK transcripts in WT astrocytes and also neurons. 
The doublet signal represents alternative splicing of 15 nucleotides encoding the VSGGG 
sequence (13). Beta-actin served as control for RNA input.
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We wondered whether the absence of a DMPK signal in neurons was due 
to the limited sensitivity of our western blotting procedure or to complete absence 
of transcription of the DMPK gene in this cell type. We therefore determined mRNA 
levels in the primary neurons and astrocytes using RT-PCR. This revealed DMPK 
mRNA at low signal intensity in neurons and much higher intensity in primary 
astrocytes (Figure 4B), corroborating the western blot findings. Taken combined, 
these results suggest that DMPK mRNA and protein is present in primary neurons 
but at low levels compared to astrocytes.
DMPK protein in established cell lines of myogenic or neural origin
To confirm findings and provide further background for DMPK studies in a cell 
biological setting, we also analyzed DMPK protein expression in a number of 
established cell lines of myogenic or neural origin. HL-1 cardiomyocytes, both 
beating and non-beating variants (27, 28) and C2C12 myoblasts expressed long 
as well as short DMPK isoforms (Figure 5A). In contrast, none of the neural cell 
lines tested (PC12, SK-N-SH, U373, CCL-131, N2A) showed clear DMPK expression, 
although interpretation here was hampered by a cross-reacting signal (compare 
background signal observed in KO myotubes). In PC12 cells an additional 
strong signal was found just below the cross-reacting protein (Figure 5A).
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Figure 5. DMPK expression in established cell lines of skeletal muscle, cardiac or brain 
origin. (A) Lysates of cardiac (HL-1 B (beating), HL-1 NB (non-beating)), skeletal muscle 
( C f )  or brain origin (PC12, SK-N-SH, U373, CCL131 Pro (proliferating), CCL131 Dif 48h 
(differentiated for 48 hours), N2A) were analyzed on western blot for DMPK expression. 
L = long DMPK isoforms and S = short DMPK isoforms (13, 14). Authentic DMPK signals 
are marked by asterisks. Note that a cross-reacting protein detected in KO myotubes is 
also present in many of the cell lines, especially U373 and N2A (arrow, CRP). (B) A semi­
quantitative RT-PCR spanning exon 7 to 9 was performed on RNA derived from PC12, U373, 
N2A and C2C12 (positive control) cells. DMPK transcripts were detected in U373 glioblastoma 
but not in Pc12 and N2A neuroblastomas. The doublet signal represents alternative splicing 
of 15 nucleotides encoding the VSGGG sequence (13). Product size differences between 
U373 and C2C12 samples reflect differences between primers for the human (U373) and 
mouse (C2C122) D12MPK amplicons.
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To solve this confusion, DMPK mRNA expression was again also assessed by RT-PCR. 
No PCR products were found for PC12 and N2A cells (Figure 5B), strongly suggesting 
that the DMPK western blot signals did not represent genuine DMPK protein. To our 
surprise, U373 cells showed a strong signal in RT-PCR, indicating that the DMPK gene 
is transcribed in this cell line. Although we assume that the strong signal on western 
blot, based on its migration behavior, corresponds to a cross-reacting protein, closer 
examination revealed a second, very weak signal that migrated slightly more slowly, 
which may represent DMPK (Figure 5A).
Subcellular localization of DMPK isoforms in primary cells
Finally, we investigated if individual DMPK isoforms transiently expressed in the 
different host cells now identified were targeted to their expected locations (15). 
To this end, primary skeletal muscle cells and neural cells from DMPK KO mice were 
transduced with adenoviral vectors encoding YFP-tagged versions of mDMPK A 
(known to anchor in the ER), mDMPK C (known to anchor in the MOM) or mDMPK 
E (cytosolic) (14, 15).
A B
myoblasts------------------------------------------------------ myotubes
DMPK YFP
Figure 6. Subcellular localization of individual DMPK splice isoforms in myoblasts and 
myotubes. Splice isoforms mDMPK A, C or E fused to YFP were expressed in KO myoblasts (A) 
and myotubes (B) using adenoviral expression vectors. Confocal images were taken 20 hours 
(myoblasts) or 48 hours (myotubes) after transduction. To identify subcellular structures, 
cells were counterstained for ER marker calreticulin or mitochondrial marker MitoTracker 
Red. In myoblasts, YFP-mDMPK A, C and E were found at the ER, mitochondria and in the 
cytosol respectively (A). In myotubes YFP-mDMPK C, but not YFP-mDMPK A and E, localized at 
mitochondria (B). Bars in A: 10 ^ m. Bars in B: 25 ^ m. (C) Western blotting was used to verify 
integrity of expressed fusion proteins. Recombinant proteins were visualized using a DMPK 
and a YFP antibody. Molecular weights of marker proteins are indicated. Asterisks indicate 
C-terminally truncated mDMPK products as a result of non-enzymatic breakdown(15).
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Expression in myoblasts showed localization of DMPK A, C and E at the 
predicted locations (Figure 6A) (15). In myotubes, mDMPK A distribution showed a 
typical reticular ER pattern, clearly different from the mitochondrial distribution of 
DMPK C and cytosolic distribution of mDMPK E (since none of the ER markers tested 
resulted in a well-defined ER staining in myotubes, a mitochondrial counterstain was 
used instead; Figure 6B). YFP-mDMPK C localization overlapped with mitochondria, 
but some cytosolic and nuclear staining was also seen. We attribute this to clipping 
of the fusion protein. This results in release of the relatively resistant YFP moiety, 
which remains as a free-floating, cytosolic and nuclear protein (Figure 6C).
In primary neurons, YFP-mDMPK A colocalized with ER marker calreticulin 
and YFP-mDMPK C with mitochondrial marker Mitotracker Red (Figure 7A).
A B
ne u ron s ------------------------------------------------------- astrocytes
Figure 7. Subcellular localization of individual DMPK splice isoforms in brain-derived 
primary cell types. Splice isoforms mDMPK A, C or E fused to YFP were expressed in KO 
neurons (A) and astrocytes (B) using adenoviral vectors. Confocal images were taken 20 hours 
after transduction. To identify subcellular structures, cells were counterstained for ER marker 
calreticulin or mitochondrial marker cytochrome c oxidase. YFP-mDMPK A, C and E localized 
to the ER, mitochondria and in the cytosol, respectively. For YFP-mDMPK C, many neurons 
and astrocytes also showed nuclear and cytosolic staining. Bars: 10 ^ m. (C) Western blotting 
was used to verify integrity of expressed fusion proteins. Recombinant proteins expressed in 
astrocytes were visualized using a DMPK and a YFP antibody. Molecular weights of marker 
proteins are indicated. An arrow head indicates a cross-reacting protein detected with the 
DMPK and YFP antibody, also in mock-treated astrocytes. In the case of YFP-mDMPK A and C 
some protein clipping occurred, illustrated by YFP signals at 30-40 kDa.
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Some cytosolic and nuclear staining, probably again caused by clipping of YFP- 
mDMPK C, was also seen here (Figure 7A). YFP-mDMPK E adapted a cytosolic 
distribution (Figure 7A). In primary astrocytes, DMPK isoforms exhibited a largely 
similar distribution as seen in neurons, with DMPK A, C and E localized to the ER, 
MOM and cytosol, respectively, against some cytosolic and nuclear background 
staining for YFP-mDMPK C (Figure 7B). Also here, some clipping of the YFP part has 
occurred (Figure 7C).
Overall, these transient expression studies demonstrate authentic 
localization of mDMPK isoforms in all distinct cell types tested.
DISCUSSION
Muscle and brain are prominently implicated in DM1. FISH analyses have 
demonstrated presence of DMPK transcripts in these and other tissues, however 
the occurrence of splice products was not addressed (7, 34). Here, we analyzed 
the distribution of long and short DMPK protein isoforms (13, 14) in muscles of 
different fiber type and in discrete regions and cell types of the brains of mice. Since 
isoform-specific antibodies are not available for DMPK, we have used classification 
of signals in different molecular weight categories to profile expression. Human 
DMPK-overexpressing transgenic (TG) mice aided in the detection of DMPK in tissues 
with low expression, nonetheless we realize that cautious interpretation is needed. 
Effects of transgene integration site, species differences in promoter specificity and 
post-translational control may affect expression level of different human and mouse 
DMPK gene products.
DMPK protein in muscle tissues and cultured muscle cells
All muscle types investigated expressed long and short DMPK isoforms, albeit at 
different levels for different muscle types from WT and TG origin.
Cardiac involvement in DM1 concerns conduction defects leading to 
arrhythmia and heart block and has been correlated with (CTG^CAG)n expansion or 
DMPK gene product dosage (1, 8, 12). Studies in transgenic mice demonstrated that 
DMPK is involved in ion homeostasis in heart, influencing Ca2+, Na+ and Cl" currents 
(8, 12, 21). Combined with our current findings that long and short DMPK isoforms 
are highly expressed in both ventricle and atrium, this leaves open the possibility 
that both toxicity of (CUG)n-expanded mRNAs and mutational effects on DMPK 
protein level or distribution contribute to DM pathology. As we find long and short 
DMPK faithfully expressed in HL-1 cardiomyocytes, we consider these cells a reliable 
experimental model for further studies into the pathophysiological significance of 
DMPK mRNA and protein.
Smooth muscle involvement in DM1 is typically noted by malfunctioning of 
the gastrointestinal tract and vacuolization in the bladder of patients (1). Smooth 
muscle abnormalities have not been reported in KO mice, but overexpression of 
hDMPK affects arterial smooth muscle tone (12). As we report high expression of
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virtually only short DMPK isoforms in both stomach and bladder here, we propose 
that further studies should now be focused primarily on how these particular 
isoforms control cell integrity globally throughout all smooth muscle cell-containing 
tissues in DM1 patients and normal controls.
Weakness and wasting of distal skeletal muscles and myotonia are hallmarks 
of DM1 (1), with type 1 (slow twitch) fibers being most strongly affected (35, 36). 
We show here that long and short DMPK isoforms coexist, but long isoforms 
dominate mostly in skeletal muscles of all fiber types, including soleus, tibialis, and 
gastrocnemius muscle, typical slow, fast and mixed muscles, respectively (37, 38). A 
mixture of long and short DMPK isoforms was also strongly expressed in diaphragm 
and tongue. These tissues are of mixed fiber-type and are implicated in respiratory 
distress or speech and swallowing problems in DM1 patients (1).
In contrast to the persistence of a significant percentage of short DMPK 
isoforms in mature muscles in vivo, short DMPK isoforms occurred at very low 
abundance in myotubes differentiated in vitro. Myoblasts cultured in vitro usually 
lose their commitment imprint and adopt a fast-twitch precursor phenotype 
(39), but neither this fate nor the process of fusion and maturation to myotubes 
affected expression of long DMPK isoforms significantly. As DMPK gene products 
were reported before to exist already in the myotome region of somites (7), we 
now think that long DMPK isoforms remain expressed at all stages in the entire 
trajectory of muscle development and aging. Our findings thus demonstrate that 
our immortalized WT myoblasts-myotubes or the C2C12 cell line represent faithful 
and attractive models for study of the biological significance of DMPK, in particular 
the long isoforms, during skeletal muscle development. Currently, we are using 
complementation transfection experiments with individual DMPK isoforms A-D (14, 
15) in KO myotubes to study their role in isolation.
DMPK expression in brain and brain-derived cells
In congenital and adult-onset DM1, involvement of the CNS includes mental 
retardation, cognitive and emotional disturbances and hypersomnia (1, 40). Our 
results from TG brain suggest that both long and short DMPK isoforms are expressed 
across all regions, including brain stem, olfactory bulb and striatum. In the pituitary 
gland of both WT and TG mice, long DMPK isoforms dominated. A possible 
explanation for this fact is that pituitary tissue (e.g., the anterior lobe) differs from 
other brain regions, in that it does not originate from the neural tube (41).
An important finding is the identification of DMPK protein in astrocytes 
from the primary cortex. Also U373 glioblastoma cells, tumor cells originating from 
the astrocytic progenitor lineage, expressed DMPK at low level. It is of note here 
that we did not observe DMPK protein in whole brain until animals were 3 weeks 
of age. This observation underscores that an increase in DMPK expression during 
terminal brain development is relevant, and it is tempting to speculate that the 
development of DMPK-expressing astrocytes, a process that mainly takes place 
between postnatal weeks 1-6, contributes mostly to the overall tissue-level increase.
56
Chapter 2
At this point we cannot, however, make firm statements about absence or presence 
of DMPK expression in adult neurons. DMPK could either be not yet expressed in 
our primary hippocampal neurons derived from E16.5 embryos, and/or the different 
neuronal cell lines analyzed may all have reverted to an non-expressing embryonic 
phenotype. There is presently no other work to which our results can be compared, 
and more elaborate studies are therefore necessary.
Currently, most work on brain involvement in DM1 is based on the idea 
that repeat-induced missplicing of certain transcripts in neurons is the dominant 
event and is the basis of the neuropsychiatric problems in DM1 (42, 43). DMPK 
transcripts aggregated in RNP foci were revealed in neurons in post-mortem DM1 
tissue (43), but cell-type differences in accumulation and aggregation behavior of 
RNAs may contribute to differential visibility in neurons and astrocytes. Given our 
results, we suggest that study of the fate and effects of normal and mutant DMPK 
gene products in astrocytes now also merits serious attention.
As a prelude to such studies, we compared the distribution fate of mDMPK 
isoforms in transiently transduced primary brain cells to that in muscle cells and 
to already known behavior in other cell types (15). In all cell types analyzed, 
cytosolic or membrane localization was exactly as anticipated for DMPK E or DMPK 
A/C isoforms, respectively (15). Hence, our observations indicate that location of 
DMPK isoforms does not rely on cell-type dependent rearrangements in membrane 
composition (44) or cytoarchitecture. Based on our findings regarding the inter- and 
intracellular distribution patterning of DMPK isoforms, more detailed studies into 
the normal and pathobiological role of DMPK should now become feasible.
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ABSTRACT
Myotonic dystrophy type 1 (DM1) is characterized by a toxic RNA gain-of-function 
of DMPK transcripts with an expanded (CUG)n repeat. Abnormal interaction of 
mutant, long DMPK transcripts with RNA-binding proteins affects the production of 
transcripts of multiple genes via trans-splicing effects. Here, the fate of alternative 
splicing of endogenous mouse DMPK (mDMPK) transcripts and transgenic, 
expanded human DMPK (hDMPK) transcripts was studied in myoblast-myotube 
cell models derived from wild type mice and a DM1 mouse model. Splice site use 
in endogenous mouse transcripts differed subtly between the two cell models. 
Next to seven splice modes already known to be involved in mouse DMPK mRNA 
processing, we identified two novel alternative splice events in the exon 1-7 and 
exon 12-15 regions. During myoblast differentiation, the frequency of skipping of 
exons 13 and 14 from mDMPK pre-mRNA decreased. Exclusively for transgenic 
hDMPK (CUG)500 transcripts, a 15-nucleotide segment of exon 8, which encodes a 
Val-Ser-Gly-Gly-Gly motif involved in DMPK autophosphorylation, was preferentially 
included after onset of myogenesis. Our data demonstrate that our myoblast cell 
lines represent useful model systems to study alternative DMPK splicing during 
myogenic differentiation.
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INTRODUCTION
Myotonic dystrophy type 1 (DM) is the most prevalent inherited neuromuscular 
disorder in adults (1). The mutation causing the disease is an expansion of a CTG 
triplet repeat in the 3' untranslated region in the final exon of the DM protein kinase 
(DMPK) gene (2). The currently favored explanation for the complex DM1 phenotype 
is an RNA gain-of-function at the DMPK transcript level, involving protein factor 
binding to the long (CUG)n segment as the cause of global perturbation of nuclear 
RNA processing (3).
A critical step in the processing of pre-mRNA involves intron removal, i.e. pre- 
mRNA splicing, to yield structurally mature mRNA that can be exported from the 
nucleus and translated to functional protein (4). One aspect of RNA splicing which 
adds to the complexity of the entire process is the constitutive or regulated alternate 
use of exonic and intronic segments in one particular pre-mRNA, a mechanism 
called alternative splicing. Use of alternative splicing gives cells or organisms the 
opportunity to produce multiple protein isoforms from one gene (5).
Recent global genome approaches have shown that alternative splicing is the 
norm rather than the exception within the human genome, with about 94% of genes 
being alternatively spliced (6). One of these alternatively spliced genes is the DMPK 
gene itself. Most DMPK alternative splice modes are conserved between humans 
and mice and result in the formation of six major DMPK isoforms (7). Alternative 
splicing thus determines presence or absence of a Val-Ser-Gly-Gly-Gly (VSGGG) 
amino-acid motif and the identity of the C-terminus (Figure 2A) (8). A minor human- 
specific splice mode uses a cryptic splice site in exon 15 and results in excision of the 
(CUG)n repeat containing mRNA segment (9).
Here, we analyze alternative splicing of transcripts from a mutant hDMPK gene 
derived from human DM patients with a (CTG)500 segment and make comparison 
to splicing of endogenous mDMPK mRNA in normal or transgenic mouse myoblasts 
during myogenic differentiation.
MATERIALS AND METHODS 
Cell Culture
Immortalized mouse myoblasts expressing endogenous mDMPK transcripts alone 
(WT) or in addition to transgenic hDMPK (CUG)500 transcripts (DM500) were 
derived from gastrocnemius-plantaris-soleus tissue isolated from DM500 or WT 
mice carrying one copy of the H-2Kb-tsA58 allele (10). Myoblasts were cultured and 
allowed to differentiate as described (11).
RNA isolation
RNA was isolated using the Aurum Total RNA mini kit (Bio-Rad) according to the 
manufacturer's protocol.
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RT-PCR
Approximately 0.5 ^g RNA was subjected to cDNA synthesis with random hexamers 
using the SuperScript first-strand synthesis system (Invitrogen) in a total volume 
of 20 ^l. One ^l of cDNA preparation was subsequently used in PCR analysis 
according to standard procedures. In RT control experiments, reverse transcriptase 
was omitted. PCR primers were designed on the basis of NCBI database sequence 
information (see list below). Cycle number was on average 30 for each primer set. 
PCR products were analyzed on 1-2.5% agarose gels, stained by ethidium bromide 
and signal was recorded on a high performance ultraviolet transilluminator (VWR 
international). Identity was verified by DNA sequencing. Radioactive PCR was 
performed as described above in the presence of [a-32P]-dCTP and products were 
analyzed on 8% polyacrylamide gels. Gels were exposed to X-ray film (X-Omat AR, 
Kodak).
The following primers were used: 
mDMPK exon 1-F: 5'-T CACCTAGCCCAGGACAAGTA-3' 
mDMPK exon 7-R: 5'-AACACGCCCAGT GCCCACCA-3' 
mDMPK exon 7-F: 5'-AAAGAATTCGCCGAGACATATGCCAAGATT-3' 
mDMPK exon 9-R: 5'-AATCTCGAGTCCTGCATGTCTGACAGCGT-3' 
mDMPK exon 9-F: 5'-AAAGAATTCAGGAAGACATGCCCCTTG-3' 
mDMPK exon 11-R: 5'-AAT CT CGAGT CT CT GCCT CAGCCACAGG-3' 
mDMPK exon 12-F: 5'-AAAGAATTCGAGACCTGGAGGCGCATGT-3' 
mDMPK exon 15-R: 5'-AAACT CGAGCGAACAGGAGCAGGCAAC-3'
Human DMPK primers were described (11) except for: hDMPK exon 9-F: 
5'-TCGGACATTCGGGAAGGTG-3';hDMPKexon11-R:5'-AGGGACAGCCGCTGGAACT-3'.
RESULTS AND DISCUSSION 
DM500 and WT myogenic cell models
The DM500 myoblast model was isolated from skeletal muscle of the transgenic 
DM300-328 mouse lineage (11). Cells derived from this model carry the entire 
genomic DM1 locus of a patient - comprising the DMWD gene, a DMPK gene 
with a (CTG)500 segment and the SIX5 gene (12) on one transgenic insert - next 
to the full complement of endogenous mouse genes. DM500 myoblasts-myotubes 
express hDMPK (CUG)500 transcripts at levels comparable to that of endogenous 
mDMPK transcripts (11). As a control, we established a myoblast-myotube cell 
line from wild type (WT) mice with the same genetic background as the DM300 
lineage. Intercomparison of splice behavior of endogenous mDMPK transcripts in 
both models enabled us to study any trans effects of expanded hDMPK transcripts 
during myogenic differentiation.
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Mouse DMPK splice modes during myogenesis in WT and DM500 cells
We first focused on alternative splicing of mDMPK transcripts in WT cells across 
four distinct segments in the pre-mRNA. Use of RT-PCR analysis revealed three 
splice modes in the exon 12-15 region that were described before (7): V (inclusion 
of the 3' end of intron 13), AVII (removal of four nucleotides from exon 14) and AVI 
(skipping of exon 13 and 14) (Figure 1A and 2). PCR products with or without the 
VII region appeared difficult to separate on gel (Figure 1A), but sequence analysis 
revealed equal presence of both products (data not shown). Use of splice mode AVI, 
i.e. complete removal of exons 13/14 as present in short DMPK isoforms E and F, 
was prominent in myoblasts but barely detectable during myotube differentiation 
(Figure 1A). A novel splice mode, designated AVIII, involved skipping of exon 13 
and the first four nucleotides of exon 14, resulting in an in frame deletion of 51 
nucleotides (Table 1). This novel DMPK isoform occurred at very low frequency at 
every stage during in vitro differentiation.
Across the exon 9-11 region only one alternative splice event, termed splice 
mode AIII (skipping of exon 10) (Figure 1A and 2), occurred at low frequency but 
appeared somewhat more prominent late in myogenesis. This splice mode was also 
observed in mature skeletal muscle tissue (7).
Across the exon 7-9 region, alternative exclusion of 87 nucleotides within 
exon 8 (splice mode AI) occurred at low frequency. Alternative use of 15 nucleotides 
encoding the VSGGG motif (splice mode AII) occurred at high frequency (Figure 1A 
and 2) (7). PCR fragments with or without region II could not be separated on gel, 
but sequence analysis of this mix of products showed that both forms were present 
in equal amounts in myoblasts (data not shown).
Figure 1. Alternative splice modes of mouse and human DMPK (CUG)500 transcripts in 
proliferating and differentiating WT and DM500 myogenic cells. (A) WT and (B-C) DM500 
myoblasts were cultured and myogenesis was induced by serum withdrawal and temperature 
shift. Radioactive RT-PCR assays using primer sets covering different segments of the 
DMPK genes were performed on RNA derived from proliferating myoblasts (P), a confluent 
myoblast culture (C) and differentiating myotubes after 1, 2, 4 or 7 days. PCR products were 
separated on polyacrylamide gels. Locations of forward and reverse primers are indicated 
in each panel and identity of products is indicated at the right. Roman numerals indicate 
specific alternative splice modes summarized in Figure 2. Asterisks indicate products that 
could not be identified by DNA sequencing. (D) Products covering the exon 7-9 hDMPK region 
were also analyzed on agarose gel. The doublet signal represents alternative splicing of the 
15 nucleotides encoding the VSGGG sequence. >>
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Across the exon 1-7 region a novel splice mode involving skipping of exon 5, 
which we named AX, was observed at low frequency, but appeared at somewhat 
higher level in myotubes. This splice event creates a frameshift and produces a 
premature termination codon (PTC; Figure 1A and 2).
Comparative RT-PCR analysis in DM500 cells revealed virtually identical splice 
products of mDMPK transcripts. We did observe some variation in the relative 
levels of DMPK isoform V versus isoform AVII, and occurrence of splice mode AX 
versus the regular exon 1-7 isoform (compare Figures 1A and B). Probably these 
quantitative changes can be attributed to intrinsic global differences in RNA 
transcription-processing efficiency as may occur between separately derived cell 
lineages. To us, the lack of major shifts in splice site use suggests that expression 
of expanded transgenic hDMPK RNA products has no main effects in trans on 
alternative production of strongly related endogenous mDMPK pre-mRNAs. 
However, we realize that experiments on myoblasts carrying a normal-sized DM1 
locus (12) are required before really valid conclusions can be drawn. Unfortunately, 
these cells are currently not yet available.
Human DMPK splice isoforms during myogenesis in DM500 cells
Homologous human-specific primers were designed to follow splicing of hDMPK 
(CUG)500 transcripts in DM500 cells. Splice events in the exon 12-15 area created 
alternative modes AVI, AVII and AIX. Products with or without the VII region could not 
be separated on gel, but DNA sequencing revealed that both products were equally 
expressed, identical to the situation for mDMPK RNA (data not shown). Splice mode 
AIX, which includes skipping of exon 14 only, resulting in an in frame deletion of 90 
nucleotides (13) (Figure 1C and 2), appeared unique for the human DMPK transcript 
and was not observed for mDMPK transcripts. Another dissimilarity with splicing of 
mDMPK RNA is that production of the hDMPK AVI RNA isoform continues into the 
first phase of myotube differentiation.
No alternative splice products were found for the exon 9-11 region (Figure 
1C), suggesting that the low frequent skipping of exon 10 is truly a mouse-specific 
event.
Figure 2. DMPK gene organization and alternative splicing. (A) Schematic representation of 
the intron-exon organization of the DMPK gene and the corresponding domain organization 
of DMPK protein. Exons are depicted as open boxes or, if alternatively spliced, as black boxes. 
Horizontal lines represent introns. Alternatively spliced introns are shown as grey boxes. 
The alternatively spliced four nucleotides in exon 14 are indicated as a dashed box, and the 
cryptic splice sites in exon 15 are depicted as dashed vertical lines. The shadowed grey box in 
exon 15 represents the (CTG)n repeat. Alternative splice modes are symbolized with Roman 
numerals. Dashed lines relate exons to the corresponding domains in DMPK protein (7, 8). 
(B) Summary of alternative splice modes identified in this paper or described in literature (7, 
9, 13) and (Wang et al. Abstract P6, IDMC-6 meeting, Milan, 2007) for the mouse (m) and 
human (h) DMPK gene. >>
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Analysis of splice products in the exon 7-9 region revealed only removal of 
region II (encoding the VSGGG motif) as an alternative processing step (Figure 1C 
and 2) (7). Interestingly, we noticed a shift in the ratio of region II isoform products of 
the hDMPK gene during myogenic differentiation, which became better noticeable 
during follow-up analyses, when RT-PCR products were loaded on an agarose gel 
(compare Figure 1C, third panel, with Figure. 1D). Clearly, RNA without the VSGGG- 
encoding sequence motif dominated in myoblasts, whereas RNA with VSGGG- 
encoding capacity was more prevalent in developing myotubes. Because the two 
corresponding products of the mDMPK gene could not be separated on an agarose 
gel, such a splice shift remained undetectable for mDMPK transcripts (data not 
shown). This shift in alternative splicing is the second example of differentiation- 
dependent DMPK splice switching, next to expression of the AVI isoform (see 
above).
The novel splice mode AX identified for mDMPK pre-mRNA, was also observed 
for hDMPK pre-mRNAs (Figure 1C and 2). As for mDMPK, the AX level appeared 
higher after myotube differentiation was initiated.
Prediction of protein expression
Alternative splicing of DMPK transcripts contributes to the production of a diverse 
population of DMPK proteins, with different sizes, properties and functions (14). 
Study of the actual composition and fate of this population is difficult due to the lack 
of proper isoform-specific antibodies. Also, overall low abundance of DMPK in many 
cell types - except muscle cells - and lack of knowledge on effects of translational 
or post-translational control mechanisms for this protein impedes experimental 
strategies. We remain therefore concentrated on theoretical predictions here.
An inventory of putative DMPK protein products encoded by - or rather open 
reading frames in - RNA splice variants that were identified here is given in Table 1. 
DMPK splice variants described before are also included (7, 8). Earlier experimental 
analyses showed that the six protein isoforms, designated DMPK A-F, whose 
structural and functional study was described in detail (7, 8, 15-17) prevail.
Minor RNA isoforms probably also produce relatively low levels of protein, 
although this will depend on translational efficiency, overall protein stability and 
turnover. New experimental approaches are needed to reveal whether these 
predicted minor isoforms represent aberrant splicing noise or have true biological 
significance.
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Table 1. Prediction of alternative splice isoforms for DMPK genes in man and mouse
Mode Description
Predicted protein product
Isoform
mouse (kDa) human (kDa)
— Basic DMPK isoform 69.6 69.4 DMPK A
AI In frame deletion of 29 amino acids 66.4 n.d.
AII In frame deletion of 5 amino acids 69.3 69.0 ± VSGGG
AIII Introduction PTC 46.9 n.d.
IV Introduction PTC 62.3 n.d.
V Introduction PTC 62.7 n.d.
AVI Introduction PTC 60.2 59.8 DMPK E
AVII Second ORF 70.3 69.9 DMPK C
AVIII In frame deletion of 17 amino acids 67.9 n.d.
AIX In frame deletion of 30 amino acids n.d. 66.3
AX Introduction PTC 17.3 23.9
AXI Other ORF n.d. 68.7 DMPK G
AXII Deletion in 3' UTR (including (CUG)n) n.d. 69.4
Table 1. Prediction of DMPK protein forms that result from alternative splicing. Protein 
predictions are based on the assumption that the particular splice mode is the only alternative 
splice event in the DMPK mRNA. Roman numerals refer to alternative splice modes of DMPK 
pre-mRNA transcripts illustrated in Figure 2. Light grey rows describe splice modes that were 
not described before. Dark grey rows illustrate isoforms that were not detected in this study, 
but have been described before (7, 9) and (Wang et al. Abstract P6, IDMC-6 meeting, Milan, 
2007). N. d., not determined, because this form was not detected for this species. oRf, open 
reading frame. UTR, untranslated region.
Concluding remarks
Here, we present an inventory of alternative splice modes of DMPK genes in mouse 
myoblasts. In our experimental strategy, we chose for the analysis of four non­
overlapping regions, including fifteen known DMPK exons. Due to this experimental 
setup, it remains unclear whether individual splice events are truly independent 
events or whether they are interdependent and occur only in fixed combinations.
Previous work of our group has demonstrated that six major DMPK isoforms 
result from independent use of the AII, AVI and AVII splice events (7). Here, we 
extend this observation, by showing that for the hDMPK transcript the AII event - 
i.e., the loss of the VSGGG-encoding region from exon 8 - occurs more frequently in 
myoblasts than in myotubes. Likewise, the differential loss of exons 13 and 14 is also 
promoted more strongly in myoblasts than in myotubes, which corroborates earlier 
protein studies (14). Taken together, these observations indicate that expression 
of DMPK splice variants with or without the VSGGG-motif and carrying variable 
C-termini is subject to developmental control and not simply a stochastic process.
Work of other groups identified hDMPK splice modes that involved skipping 
of the (CUG)n repeat segment, designated as modes AXI (9) or AXII (Wang et al. 
Abstract P6, IDMC-6 meeting, Milan, 2007) (Figure 2B and Table 1). We were not
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successful to find these splice modes here in the DM500 cells. Our findings thus 
suggest that these splice modes may indeed be very rare (8) or be blocked by 
presence of the rather long (CUG)n segment in the hDMPK pre-mRNA. Whether 
skipping of a segment where the (CUG)n repeat is localized does occur at 
appreciable frequency or perhaps is limited to certain tissues in DM patients or 
healthy individuals requires further research. Also the previously reported mDMPK 
isoform IV (7) was not detected in this study (Figure 2). Also here, further work is 
necessary to see if the unidentified product located above mDMPK isoform V (see 
asterisk in Figure 1A and B) may represent this isoform.
Only minor differences in relative expression of endogenous mDMPK splice 
variants between WT and DM500 cells were found. This implies that co-presence of 
expanded hDMPK transcripts has no major effect in trans on alternative splicing of 
primary mDMPK transcripts. Whether there are also no trans influences between 
expanded and normal DMPK transcripts in DM1 patient cells is subject to further 
study.
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ABSTRACT
DMPK, the product of the mutated gene in myotonic dystrophy type 1, belongs to 
the subfamily of Rho-associated serine-threonine protein kinases, whose members 
play a role in actin-based cell morphodynamics. Not much is known about the 
physiological role of differentially localized individual DMPK splice isoforms. We 
report here that prominent stellar-shaped stress fibers are formed during early 
and late steps of differentiation in DMPK-deficient myoblast-myotubes upon 
complementation with the short cytosolic DMPK E isoform. Expression of DMPK 
E led to an increased phosphorylation status of MLC2. We found no such effects 
with vectors that encode a mutant DMPK E which was rendered enzymatically 
inactive or any of the long C-terminally anchored DMPK isoforms. Presence of 
stellar structures appears associated with changes in cell shape and motility and 
a delay in myogenesis. Our data strongly suggest that cytosolic DMPK participates 
in remodeling of the actomyosin cytoskeleton in developing skeletal muscle cells.
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INTRODUCTION
Myotonic dystrophy protein kinases (DMPKs) were discovered almost two decades 
ago as different alternative products of the gene altered by a non-coding (CTG) 
n-repeat expansion in patients with myotonic dystrophy type 1 (1). Expanded DMPK 
transcripts carrying long (CUG)n repeats are thought to cause the disease via a so- 
called RNA dominance mechanism (2). Although DMPK isoforms belong to the 
important AGC group of serine-threonine protein kinases, to which also MRCKa/ 
P/y, ROCK-I/-II and citron kinase belong (3, 4), the biological significance of these 
proteins has received little attention until now, as protein products of the affected 
gene seem to have no direct role in disease pathogenesis.
Six major DMPK isoforms arise by alternative splicing, the most important 
distinction being the nature of the C-terminus (5). DMPK isoforms with long C 
termini (DMPK A to D) anchor into membranes of the endoplasmic reticulum or 
mitochondria, whereas isoforms without a C-terminal extension (DMPK E or F) 
adopt a cytosolic localization (6, 7) (Figure 1A). DMPK splice forms show a tissue- 
specific expression in brain and all types of smooth, cardiac and skeletal muscle (8).
DMPK's closest relatives ROCK, MRCK and citron kinase control behavior 
of the actin-myosin based cytoskeleton (9-11). Actomyosin rearrangement plays 
a pivotal role in cell morphodynamic behavior, including motility, cytokinesis, 
phagocytosis and probably intracellular transport processes (12). Reorganization 
of the cytoskeleton is also required during skeletal muscle myogenesis, when 
myoblasts go through sequential steps of recognition, adhesion and finally fusion 
to myotubes. Formation of multinucleated myotubes begins with fusion between 
individual mononucleated myoblasts and is followed by myotube-myotube and 
myoblast-myotube fusion to form the muscle fibers that make up the skeletal muscle 
(13). Different types of myosins play an important role in this development (14), 
whereby non-muscle myosin (NM) IIA and IIB are essential for myoblast alignment 
and fusion (15). Other structural changes that occur later during myogenesis reflect 
the transition from the non-muscle phenotype in the myoblast to the sarcomeric 
phenotype of the myotubes. The entire transition process is dependent on the 
location and plane-of-division orientation of subsarcolemmal satellite cells, the 
ordered temporal expression of specific proteins (16), and interactions between 
these proteins to form the distinct cytoarchitectural arrangement of the skeletal 
muscle cell.
Earlier studies by our group and others have revealed that DMPK gene 
products collectively are not essential for muscle development in vivo (17, 18). 
Here, we focused on individual DMPK isoforms and analyzed a potential role for 
DMPK in actomyosin remodeling during early and late steps of myogenesis using 
an in vitro myoblast-myotube cell model derived from DMPK knockout (KO) mice. 
We found that expression of the cytosolic DMPK E isoform in DMPK-/- myoblasts 
resulted in the initiation of stress fibers with a dense structure and multiradial, 
stellar-like appearance. Presence of these conspicuous actomyosin structures
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was associated with a significant change in myoblast polarity and migration and a 
delay in the progression of myogenesis, not seen after expression of membrane- 
bound DMPK isoforms or an enzymatically inactive DMPK E variant. Our findings 
underscore the need for tight regulation of cytosolic DMPK variants during different 
phases of muscle development.
MATERIALS AND METHODS 
Cell culture
Conditionally immortalized myoblasts were derived from the calf muscle complex of 
wild type (WT) and DMPK KO mice (17) harboring the H-2Kb-tsA58 allele as described 
(19). Myoblasts were cultured in 0.1% (w/v) gelatin-coated dishes in proliferation 
medium containing DMEM (Gibco, Gaithersburg, MD) supplemented with 20% (v/v) 
fetal calf serum, 50 ^g/ml gentamycin, 20 units of y-interferon/ml (BD Biosciences, 
San Jose, CA) and 2% (v/v) chicken embryo extract (Sera Laboratories International, 
Bolney, UK) at 5% CO2 and 33°C. Differentiation to myotubes was induced by placing 
myoblasts, grown to confluency on Matrigel (BD Biosciences), in differentiation 
medium containing DMEM supplemented with 5% (v/v) heat-inactivated horse 
serum and 50 ^g/ml gentamycin at 5% CO2 and 37°C. These conditions were 
maintained for a maximum of seven days. Spontaneous contraction of myotubes, 
indicative of proper development of the excitation-contraction apparatus, appeared 
after two days of differentiation.
Adenoviral vectors and transduction
Adenoviral vectors expressing YFP-mouse DMPK isoforms A, C and E were described 
previously (7). Recombinant adenoviral constructs expressing YFP-mouse DMPK 
E kinase dead (kd), bearing a YFP-DMPK E cDNA insert encoding DMPK E with a 
Lys100Ala mutation which renders the enzyme inactive, were generated as described 
(6). Comparison between effects of catalytically active DMPK E and inactive E kd as 
control enabled us to discriminate between a structural and catalytic function of 
the protein. Viral vector particles were generated in N52.E6 packaging cells (20), 
purified using CsCl gradient purification and stored at -80oC. Viral titer and plaque 
forming units were determined (21).
Adenoviral transduction was performed in serum-free DMEM without 
glucose (Gibco) for 3-4 hours at 5% CO2 and 33 °C, using a multiplicity of infection 
of 100. Transduction was done in proliferating myoblasts at 40% confluency or, for 
differentiation experiments, in confluent myoblast cultures on Matrigel-coated 
dishes. Transduction medium was changed after four hours to proliferation medium 
or, in fusion experiments, to differentiation medium.
Antibodies
Antibodies against the following proteins were used: a-actinin (Sigma-Aldrich, 
Zwijndrecht, NL; A2543), cofilin (rabbit 1439) and P-cofilin (rabbit 4317) (kindly
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provided by Dr. James R. Bamburg, Colorado State University, Fort Collins, CO) 
(22), CK (23), DMPK (antibody B79 (5)), MyoD (Santa Cruz Biotechnology, Santa 
Cruz, CA; clone M-318), NM-MHC IIA (BTI, Stoughton, MA; BT-567), NM-MHC IIB 
(Sigma-Aldrich; M7939), pyruvate kinase (Rockland, Gilbertsville, PA), a-tubulin 
(Sigma-Aldrich; clone B-5-1-2), P-tubulin (Developmental studies Hybridoma Bank, 
University of Iowa; mAb E7), vinculin (Sigma-Aldrich; V-9131).
Two MLC2 antibodies were generated as follows: cDNAs of mouse myosin 
regulatory light chain 2 (NCBI Reference Sequence NM_023402) and myosin 
regulatory light chain 2a (NCBI Reference Sequence NM_022879) were obtained 
by RT-PCR using RNA isolated from mouse brain and heart tissue, respectively. 
Sequence identity of both clones was verified by sequencing and ORFs were 
subcloned in pGEX-2T-3. GST-MLC2 and GST-MLC2a fusion proteins were expressed 
in E. coli BL21(DE3)pLysS, purified using glutathione agarose beads and used to 
immunize New-Zealand White rabbits using standard procedures. MLC2 antiserum 
(antibody K19) diluted 1:5,000 was used in Western blotting to analyze MLC2 
phosphorylation status. MLC2a antiserum (antibody K2) diluted 1:10,000 was used 
in Western blotting to detect a myotube-specific MLC2 isoform during myoblast 
differentiation.
Cell lysis
For conventional Western blotting, cells were lysed directly in 2xSDS sample buffer 
(200 mM Tris-HCl, pH 6.8, 400 mM DTT, 8% (w/v) SDS, 4% (w/v) bromophenol blue 
and 40% (v/v) glycerol). For urea-glycerol PAGE, cells were lysed and scraped in 
10% (w/v) TCA/10 mM DTT/acetone at -80°C (24). Extracts were centrifuged for 20 
minutes, 13,000 rpm at 4°C and subsequently brought to room temperature. Pellets 
were washed once with excess acetone containing 10 mM DTT at room temperature 
to remove TCA. Pellets were air dried and solubilized in urea sample buffer (125 mM 
Tris-HCl, pH 6.8, 5% (v/v) P-mercaptoethanol, 8 M urea, 4% (w/v) bromophenol 
blue) using a glass-glass dounce homogenizer. To analyze TCA/acetone samples 
on SDS-PAGE gels, urea lysates were mixed with 5xSDS sample buffer to a final 
concentration of 2xSDS sample buffer and left at room temperature for 2 hours 
before loading.
SDS or urea-glycerol polyacrylamide gelelectrophoresis and Western blotting
Proteins in cell lysates were resolved on 8-15% (w/v) SDS-PAGE gels and 
electrotransferred to PVDF membrane (Amersham GE Healthcare, Diegem, 
Belgium). Blots were blocked for 2 hours or overnight for MLC2 detection in TBST 
(10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% (w/v) Tween 20) containing 5% (w/v) 
milk powder and then incubated overnight with primary antibody in the same 
buffer. After washing in TBST, blots were incubated with peroxidase-conjugated 
secondary antibody (Pierce), washed in TBST and TBS and developed using a 
chemoluminescence reagent and exposed to X-ray film (Kodak, X-OMAT AR).
Separation of MHC isoforms was performed as described (25). In short, cell
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lysates prepared in 2x SDS sample buffer were analyzed on a stacking gel composed 
of 4% (w/v) acrylamide/bisacrylamide (B7.5:1), BQ% (v/v) glycerol, 7Q mM Tris pH 
6.7 and 0.4% (w/v) SDS. The separating gel was composed of 8% (w/v) acrylamide/ 
bisacrylamide (B7.5:1), BQ% (v/v) glycerol, Q.l M glycine, Q.2 M Tris pH 8.8 and 0.4% 
(w/v) SDS. The upper running buffer consisted of Q.l M Tris base, 15Q mM glycine 
and 0.1% (w/v) SDS. The lower running buffer consisted of 5Q mM Tris base, 75 mM 
glycine and 0.05% (w/v) SDS. Running buffers were precooled and electrophoresis 
was performed at 7Q V for 24 hours at 4°C. The gel was stained with Coomassie 
Brilliant Blue (CBB).
Urea-glycerol PAGE was performed essentially as described (24). Briefly, 
cell lysates isolated via the TCA-acetone method (see above) were loaded on a 
urea-glycerol PAGE gel composed of a separating gel of 16% (w/v) acrylamide/ 
bisacrylamide (B7.5:1), 40% (v/v) glycerol and B8Q mM Tris-HCl, pH 8.8, and a 
stacking gel composed of 5.5% (w/v) acrylamide/bisacrylamide (B7.5:1), 40% (v/v) 
glycerol and 125 mM Tris-HCl pH 6.8. Electrophoresis was performed in running 
buffer (25 mM Tris, 192 mM glycine, 1 mM DTT) for 15 hours at 5 mA at room 
temperature. Gels were blotted to PVDF membrane during B-4 hours at BQQ mA 
in ice-cold blotting buffer (48 mM Tris base, B9 mM glycine, Q.QB7% (w/v) SDS and 
20% (v/v) methanol). Blots were washed and blocked as described above. Detection 
was performed with antibody K19 against MLC2 and with a fluorescent conjugated 
secondary antibody, enabling quantifiable data acquisition on the Odyssey Infrared 
Imaging System (LI-COR Biosciences, Lincoln, NE). For each lane, the sum of the 
three MLC2 signals was set to 100%, after which the relative contribution of each 
form (non-, mono-, or diphosphorylated) was calculated.
Immunofluorescence microscopy and image analysis
Twenty-four hours after adenoviral transduction, DMPK KO myoblasts were 
fixed in 2% (w/v) formaldehyde in PBS for BQ minutes and then processed for 
immunofluorescence according to standard methods. Samples were incubated 
with antibodies listed above or, to stain F-actin, for BQ minutes in PBS containing 
0.05% (w/v) Tween 2Q and Texas Red-conjugated phalloidin (Molecular Probes, 
Invitrogen). DAPI (Q.6 ^g/ml) was included in the mounting medium to stain nuclei. 
Images were collected by confocal laser scanning microscopy (MRC 1Q24, Bio-Rad 
or Olympus FV1QQQ). To quantify occurrence of stellar actin stress fibers, images 
were made under identical exposure settings and analyzed using uniform threshold 
settings.
Confluent DMPK KO myoblast cultures were transduced with adenoviruses 
expressing DMPK C or E and differentiation was induced under low serum conditions. 
After one, two and three days of differentiation cells were fixed in 2% (w/v) 
formaldehyde in PBS and stained for NM-MHC-IIA, F-actin and DNA (DAPI). Fusion 
index was quantified by confocal laser scanning microscopy (Olympus FV1QQQ). 
The number of nuclei per cell was scored for around 5Q cells per treatment by an 
examiner blinded to sample identity. Myosacs were excluded from this analysis.
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Myosacs - with or without F-actin aggregates - were counted by visual inspection of 
a total area of one 14-mm coverslip.
Imaging myogenic differentiation
Confluent DMPK KO myoblast cultures that were transduced with adenoviruses 
expressing DMPK C, E or E kd were cultured for seven days in low serum medium 
at 37oC. Every twelve hours, images were taken of marked positions within the 
culture to follow the process of myogenic differentiation. Images were collected by 
light microscopy using an inverse microscope (DM-IL, Leica, Heidelberg, Germany) 
coupled to a CCD camera (STC-405, Sentech, Texas, USA). Images were taken from 
three independent dishes, at two marked positions per treatment.
Time-lapse microscopy
Four hours after transduction with adenovirus, time-lapse imaging of myoblasts was 
performed for 24 hours in a Microscope Stage Incubator (Okolab, Ottaviano, Italy) 
on a Nikon DiaPhot microscope equipped with a Hamamatsu C8484-05G digital 
camera (26). Images were taken every 10 minutes using TimeLapse Software (version 
2.7; Okolab) with a 10x objective. Movies were made from image sequences using 
Adobe Premiere Software (version Pro 2.0). Cell shape and motility were analyzed 
using Metamorph 6.2 software (Universal Imaging Corporation, Downington, PA). 
Morphodynamic change was defined as the major/minor cell diameter ratio at the 
end (T=24) divided by the major/minor cell diameter ratio at the beginning of the 
measurement (T=0). Single cell motility was measured as the total track distance 
per cell taken the nucleus as reference (26). For each DMPK isoform, ten to thirty 
individual myoblasts of two to four independent experiments were analyzed.
Electron microscopy
EM samples were taken of adenovirus-transduced proliferating or confluent DMPK 
KO myoblasts after 24 hours or seven days under low serum conditions, respectively. 
Samples were briefly rinsed in PBS and fixed by immersion in 2% (v/v) glutaraldehyde 
in 0.1 M sodium cacodylate buffer, pH 7.4, for one hour. After fixation, samples 
were rinsed twice in cacodylate buffer. Post-fixation was carried out in the same 
buffer supplemented with 1% (w/v) osmium tetroxide at room temperature for 1-2 
hours. After extensive rinsing, dehydration was performed in an ascending series 
of aqueous ethanol solutions and samples were embedded in Epon 812. Sections 
were cut (60-80 nm), double contrasted with uranyl acetate and lead citrate and 
examined in a JEOL TEM 1010.
Statistics
Data are expressed as mean ± s.e.m. Between-group comparison was performed by 
a two-tailed unpaired Student's t-test, except for Figure 5C, for which a Chi-Square 
test was used. To compare the average number of nuclei per myotube a Mann­
Whitney test was used (Figure 5). Differences between groups were considered
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significant when P<0.05. *, P<0.05; **, P<0.01; ***, P<0.001. Statistical analyses 
were performed with GraphPad Prism 4 software. The number of replicates and the 
number of cells counted per experiment are given in the figure legends.
RESULTS 
Myoblasts form prominent stellar stress fibers upon cytosolic DMPK expression
DMPK proteins are endogenously expressed in skeletal muscle and cultured 
myoblasts and myotubes, where they occur as a heterogeneous population of splice 
isoforms (Figure S1 and (8)). To analyze the role of individual splice isoforms during 
early myogenesis, we used an in vitro transduction-complementation approach 
with single DMPKs in immortalized myoblasts with a DMPK-deficient background, 
originating from the gastrocnemius-plantaris-soleus complex of DMPK KO mice (17). 
By switching to low-serum conditions, these myoblasts can be induced to enter the 
myogenic program (8) and associated morphodynamic changes can be recorded by 
microscopic monitoring.
DMPK KO myoblasts were transduced with adenoviruses encoding single 
mouse DMPK isoforms as YFP fusion proteins (see a schematic representation of 
DMPK isoforms used in this study in Figure 1A). The intracellular distribution for 
each individual DMPK isoform was as anticipated based on earlier studies (Figure 1B, 
summarized in Figure 1A: DMPK A, endoplasmic reticulum; DMPK C, mitochondria; 
DMPK E, cytosol; note that isoforms originating from the mouse DMPK gene were 
used, as human DMPK A anchors to mitochondria) (6, 7). Phalloidin staining of 
F-actin revealed that myoblasts expressing isoforms DMPK A or C displayed a regular 
pattern of parallel actin stress fibers, both in the centre and periphery of the cell 
(Figure 1B). In contrast, DMPK E-expressing myoblasts exhibited prominent, stellar­
shaped stress fibers (27) along with normal parallel stress fibers. Stellar-like F-actin 
structures were absent or only rarely seen in DMPK A or C-expressing cells (Figure 
1C). Formation of stellar-shaped stress fibers was critically dependent on enzymatic 
activity of DMPK E, since myoblasts transduced with adenoviruses expressing an 
inactive kinase dead mutant (DMPK E kd; Figure 1A) did not express such structures 
(Figure 1B-C). The DMPK E kd control vector was generated by mutating the codon 
for the invariant lysine involved in ATP binding into an alanine codon (6).
Light microscopy analysis revealed that stellar fibers are star-like structures 
with an intensely-stained core and both short and long actin-rich protrusions. The 
number and appearance of these structures varied highly between cells and they 
were present in the cell centre as well as in the periphery (Figure 1D, see also Figure 
3). Ultrastructural analysis using electron microscopy confirmed that stellar fibers 
are large structures with a protein-dense core from which thick bundles of fibers 
radiate (Figure 1E).
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Figure 1. Cytosolic DMPK expression induces formation of stellar actin stress fibers. (A)
Overview of the structural organization of DMPK isoforms - fused to YFP - used in this study 
((5-7); drawn to scale). Alternative splicing defines the C-terminal tail, the nature of which 
determines the intracellular localization of the proteins. An enzymatically inactive DMPK E 
mutant was generated by mutating the codon for a crucial lysine in the active site into an 
alanine codon. (B) DMPK KO myoblasts were transduced with adenoviruses that express 
single DMPK isoforms as YFP fusion proteins. YFP signal shows localization of YFP-DMPK 
isoforms. Staining with phalloidin-Texas Red allowed visualization of the actin cytoskeleton. 
Cytosolic DMPK E was responsible for the introduction of prominent stellar actin stress 
fibers (red), which were virtually never seen after expression of DMPK A or C, or a E kinase 
dead version (E kd). Bar, 10 ^m. (C) Quantification of the occurrence of stellar stress fibers 
upon expression of DMPK isoforms (n=2, 50 cells counted per isoform). (D) Size, number and 
appearance of stellar fibers varied strongly between cells. Typical examples of one single
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stellar fiber (left), a series of semi-interconnected stellar fibers (middle) and a horseshoe-like 
arrangement (right panel) are shown (see also Figure 3). Bar, 10 ^ m. (E) Fiber ultrastructure 
was analyzed by electron microscopy. DMPK E-induced stellar actin fibers displayed as 
large structures with a very dense core from which bundles of fibers radiate. Top panel: a 
stellar actin stress fiber is shown located next to the nucleus; bar, 5 ^m. Bottom panel: high 
magnification of part of a stellar actin stress fiber; bar, 1 ^m. S=stellar stress fiber core, 
N=nucleus
DMPK E expression alters myosin II localization and phosphorylation
Myosin II is an important component of stress fibers (28, 29). We wondered 
whether myosin II was also present in the stellar fibers induced by DMPK E and 
whether the fate of cellular myosin II was altered in presence of these structures. 
Immunofluorescence microscopy revealed that non-muscle myosin heavy chains 
(NM-MHCs) IIA and IIB were located in the core and in the radiating bundles of 
DMPK-E-induced stellar stress fibers (Figure 2A).
A DM PK E F-actin NM -MHC merge
B  DM PK
G FP E kd E C
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Figure 2. Myosin II localization and phosphorylation upon DMPK E expression. (A) DMPK KO 
myoblasts were transduced with adenoviruses that express YFP-DMPKE. Immunofluorescence 
microscopy revealed that NM-MHC IIA and IIB (orange) colocalized with stellar stress fibers, 
including the dense core (red) in YFP-DMPK E (green)-expressing cells. Bar, 10 ^ m. (B) Urea- 
glycerol PAGE analysis was done to examine MLC2 phosphorylation in GFP (control) or YFP- 
DMPK C, E or E kd-expressing myoblasts. MLC2 staining of a representative experiment is 
shown. 0: non-phosphorylated MlC2; -1: 1P-MLC2; -2: 2P-MLC2. The graph summarizes 
results of four experiments. Asterisks refer to both non-phosphorylated MLC2 and 2P-MLC2.
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Remarkably, three other well-known actin-binding proteins, vinculin (30), a-actinin 
(31) and cofilin (32) showed no obvious colocalization with the protein-dense core 
of the stellar structures (Figure 3). As expected, vinculin and a-actinin (although 
less prominent) did localize along normal stress fibers and concentrated at focal 
adhesions, where these stress fibers associate with the cell membrane. Only 
occasionally a-actinin accumulated around the core of stellar structures in a fraction 
of cells (Figure 3). Cofilin localized throughout the cell, with no obvious association 
to stress fibers at all. We noted that in some cells YFP-DMPK E protein appeared 
concentrated along stress fibers, but YFP signal was never seen in the stellar core. 
Perhaps this particular staining is often obscured by the strong overall cytosolic 
staining, as most of our other experimental evidence indicates that the E isoform is 
truly located free in the cytosol (Figure 1-3). No obvious relationship of the location 
of stellar stress fibers with the tubulin cytoskeleton was observed (Figure 3).
F-actin DM PK E marker merge
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Figure 3. Subcellular localization of cytoarchitectural proteins in relation to stellar 
actin structures. DMPK KO myoblasts expressing YFP-DMPK E (green) were processed 
for immunofluorescence. To investigate a potential relationship with stellar stress fibers, 
subcellular localization of a-actinin, P-/cofilin, vinculin, and a/ 6-tubulin was investigated 
using specific antibodies. F-actin was stained with Texas Red-conjugated phalloidin. Bars, 
10 nm.
Myosin II activity is regulated by phosphorylation of its regulatory light chain 
(MLC2), mainly at positions Thr18 and Ser19 (30, 33). We investigated whether 
DMPK E expression would modify the extent of MLC2 phosphorylation. Urea-glycerol 
polyacrylamide gelelectrophoresis in combination with Western blot analysis was 
used to discriminate between non-phosphorylated MLC2, monophosphorylation 
at position Ser19 (1P-MLC2) and diphosphorylation at positions Thr18 and Ser19 
(2P-MLC2) (24). Figure 2B shows that the degree of diphosphorylation was 
strongly increased in cells expressing DMPK E, but that MLC2 phosphorylation was 
unaltered in cells expressing DMPK C, the E kd variant or GFP control protein. The 
diphosphorylated state of MLC2 has been correlated with stress fiber formation 
before (27) and we therefore assume that also in our DMPK KO myoblasts the high 
amount of 2P-MLC2 reflects abundant formation of stellar fibers.
DMPK E expression affects myoblast polarity and motility
Stress fibers constitute a distinct category of actomyosin structures and are 
contractile bundles essential for cell morphology, specifically for the retraction of 
the trailing edge during migration. To examine whether DMPK E-induced changes in 
actomyosin-based structures also affect cell morphodynamic behavior we followed 
proliferating KO myoblasts complemented with DMPK C, E or E kd for a period 
of twenty-four hours by time-lapse imaging (see stills in Figure 4A and videos in 
supporting information). Only DMPK E, not DMPK C or the inactive variant E kd, 
led to a morphodynamic change. An altered cell form, with a shift in the major/ 
minor axis length ratio, was observed when cells before and after onset of DMPK 
E expression were compared (Figure 4B). The same recordings were also used to 
calculate motility - defined as the total migrated distance during the 24-hours-period
- which revealed that myoblasts expressing DMPK E migrated over a significantly 
shorter distance than cells containing DMPK C or E kd (Figure 4C). Taken together, 
our data indicate that DMPK activity affects cell morphodynamics via effects on the 
remodeling behavior of the actomyosin cytoskeleton.
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Figure 4. Myoblasts expressing DMPK E display altered cell morphology and motility. (A)
DMPK KO myoblasts were transduced with adenoviruses which express single YFP-DMPK 
isoforms and subsequently imaged for 24 hours. Phase contrast recordings of DMPK C, E or E 
kd-expressing myoblasts at start (T=0) and end (T=24) of the experiment. Bar, 50 um. Images 
were used to determine the cell morphodynamic change (B; defined as the major/minor 
cell diameter ratio at the end (T=24) divided by the major/minor cell diameter ratio at the 
beginning of the measurement (T=0)) and (C) total migrated distance during the recording 
period. For each DMPK isoform, ten individual myoblasts of two to four independent 
experiments were analyzed.
High cytosolic DMPK expression perturbs and delays myogenesis
Specific changes in cell morphology and the actin cytoskeleton are required during 
myoblast alignment and fusion in the process of skeletal myogenesis (14, 15). We 
wondered whether complementation of DMPK KO myoblasts with individual DMPK 
isoforms would have differential effects on myotube formation in vitro. We adopted 
a protocol whereby fully confluent DMPK KO myoblast cultures were transduced 
with adenoviruses encoding YFP-DMPK proteins and subsequently placed in low 
serum medium to induce myogenic differentiation. Next, the fusion process was 
monitored by phase-contrast microscopy. Myoblasts expressing DMPK C or E kd 
differentiated into long, thin, well-aligned myotubes (Figure 5A; data not shown). 
In contrast, myotubes expressing DMPK E were shorter, thicker, often branched 
and poorly aligned. Ultrastructural analysis demonstrated that DMPK E expression 
resulted in immature, disorganized sarcomeres, whereas DMPK C-expressing 
myotubes contained properly organized sarcomeres with an alternating pattern 
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of thick and thin bands (Figure 5B). Western blot analysis showed that expression 
levels of both isoforms were similar in seven-day-old transduced myotubes (Figure 
6A and S2). Furthermore, direct comparison to the level of endogenous DMPK 
expression (mainly long isoforms (8)) in seven-day-old WT myotubes showed that 
DMPK proteins were only moderately, i.e. three-to-five-fold, overexpressed in 
transduced KO myotubes (Figure S2). In our view, this is strong evidence that effects 
observed are truly isoform specific and not simply attributable to secondary effects 
of differences in relative overexpression of DMPK E versus C.
A  day 1 day 3 day 5 day 7
Figure 5. DMPK E expression deregulates myogenic differentiation. (A) Confluent cultures of 
DMPK KO myoblasts were transduced with adenoviruses which express DMPK C or E (or E kd, 
data not shown). Myoblast differentiation was initiated four hours after start of transduction 
and imaged every twelve hours for seven days. Representative phase contrast images of one 
of three experiments are shown. In each experiment, cells in two marked areas per dish were 
followed in time. Bar, 100 um. (B) Ultrastructural analysis revealed that sarcomere assembly 
was incomplete in DMPK E-expressing myotubes after seven days of differentiation. By that 
time, proper contractile units were present in DMPK C-expressing myotubes. Bar, 1 um (C) 
Quantification of myoblast fusion after one and two days of differentiation by counting the 
number of nuclei per cell (50 cells counted per DMPK isoform).
Abnormal myotube formation in the presence of DMPK E was already 
apparent during the first days of differentiation. The myogenic fusion index (defined 
here as the number of nuclei residing in myotubes containing at least three nuclei 
divided by the total number of nuclei counted in 50 cells) for cells with 24h DMPK 
E-expression was somewhat lower than that of cells with DMPK C (0.85 vs 0.91).
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After 48 hours, myogenic fusion indices were equal: 0.97 vs 0.98. More importantly, 
the pattern of number of nuclei per myotube was significantly different (Figure 5C; 
P<0.001) and the average number of nuclei per myotube (containing at least three 
nuclei) was lower in DMPK E cultures than in DMPK C cultures (4.4±0.6 vs 5.7±0.7 
nuclei/myotube after 24 hours (P=0.07) and 7.8±1.1 vs 13.4±1.6 nuclei/myotube 
after 48 hours (P<0.05).
Structural changes in myotube morphology were also reflected in expression 
of myogenic marker proteins. Expression of a differentiation-specific MLC2 isoform 
was delayed and reduced from the start of differentiation in DMPK E-expressing cells, 
compared to cells expressing DMPK C or mock-transduced cells (Figure 6A). This 
corroborates that DMPK E affects early steps in myogenesis. Expression of creatine 
kinase (CK), a protein that appears after developing myotubes switch CK-isoenzyme 
expression from brain-type CK (BCK) to muscle-type CK (MCK) (34) started earlier in 
DMPK C transduced myotubes than in DMPK E-transduced myotubes (Figure 6B). 
MyoD, a protein expressed during early differentiation but absent in proliferating 
myoblasts (35, 36), remained virtually absent in myotubes, even in seven-day-old 
DMPK E cultures, whereas the first MyoD signal in DMPK C-expressing myotubes was 
detected already after three days of differentiation (Figure 6C). Finally, sarcomeric 
MHC isoforms (25, 37, 38) were more prominently expressed in DMPK C-expressing 
cultures than in DMPK E-expressing cells (Figure 6C). Next to that, the composition 
of the isoform population differed between DMPK C- and DMPK E-expressing 
cultures.
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Figure 6. DMPK E expression perturbs early steps in myogenesis. Confluent cultures of 
DMPK KO myoblasts were transduced to express DMPK C or E. Myoblast differentiation was 
initiated four hours after start of transduction. Lysates were prepared one to seven days 
after start of differentiation, as indicated, and analyzed by Western blotting. (A) Expression 
of a myotube-specific MLC2-variant. Mock-transfected samples were used as reference 
and DMPK isoform expression was confirmed. (B) Differential expression of CK variants. To 
be able to discriminate between signals from MCK and BCK, we included lysates of whole 
WT brain (Br; = BCK control); whole BCK-KO brain (-/- Br; = BCK-negative control) (34); 
gastrocnemius (G; = MCK control) and DMPK KO myoblast (Mb; = mock control). Note the
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comparable smiling effect across both CK and PKpanels. BCK is equally expressed at various 
time points of myogenesis in both cultures, but induction of MCK expression is delayed in 
DMPK E-expressing myotubes. (C) Impaired expression of MyoD and altered expression and 
composition of the sarcomeric MHC population during myogenesis in presence of DMPK E. 
MHC isoforms were separated by a special form of SDS-PAGE and visualized by CBB staining 
(arrow heads) (25). Anti-pyruvate kinase staining (PK) was used as loading control in all 
panels.
DMPK E induces formation of myosacs with large actin aggregates
We often observed enlarged, deformed, multinucleated cells in myogenic cultures 
that expressed DMPK E (Figure 7). These so-called myosacs have previously been 
associated with impaired sarcomere formation (39). We stained differentiating 
myotube cultures for F-actin and NM-MHC IIA to investigate whether myosac 
formation would relate to DMPK E effects on the actin cytoskeleton. At day one 
of differentiation, myosacs with still normal stress fiber-like structures started to 
appear (Figure 7A).
A  DAPI DM PK E F-actin N M -M H C -IIA  merge
day 1 day 2 day 3
Figure 7. DMPK E induces formation of myosacs containing large F-actin aggregates. (A) To
visualize the actomyosin cytoskeleton during differentiation, DMPK C- or DMPK E-expressing 
KO myotube cultures were stained with phalloidin-Texas Red. Large F-actin aggregates (red) in 
myosacs, reminiscent of stellar stress fibers, were first observed on day two of differentiation 
in cultures expressing DMPK E. NM-MHC IIA (orange) colocalized in these F-actin structures. 
Nuclei were counterstained with DAPI (blue). Bar, 50 um. (B) Quantification of myosacs 
including presence/absence of F-actin aggregates in cultures expressing DMPK C or E.
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When differentiation proceeded, myosacs of increased size became visible. These 
cells contained large actin aggregates, which co-stained for NM-MHC IIA and were 
reminiscent of the dense stellar stress fibers seen in non-differentiated myoblasts 
(Figure 7A). Quantification showed that the number of myosacs with large 
actomyosin aggregates increased over time in DMPK E-expressing cultures only 
(Figure 7B).
DISCUSSION
Using DMPK-deficient myoblasts as host for single DMPK protein isoforms, we 
identified a cytoskeleton-modifying activity for DMPK E, with clear effects on cellular 
F-actin structures and MLC2 phosphorylation. Given the prominent sequence 
homology in the kinase domain and the size of the protein, cytosolic DMPK E (~60 
kDa) may be considered a C-terminally truncated version of ROCK, MRCK, or citron 
kinase (40, 41). The latter proteins are large (>160 kDa), multi-domain relatives, 
each with a known role in actomyosin remodeling (9-11). DMPK proteins are among 
the least-studied members of the ROCK subgroup in the large family of serine/ 
threonine protein kinases.
What distinguishes DMPK E's effects on the actin cytoskeleton and what 
could be the biological significance of this activity? Unlike MRCK, ROCK or citron 
kinase, the DMPK gene is an evolutionary "young" gene and only present in the 
mammalian genome (Wansink et al., data not shown). The DMPK gene is expressed 
early in muscle development (17), but alternative splicing down-regulates DMPK 
E expression during differentiation of myoblasts to myotubes (8). In contrast, 
membrane-anchored DMPK splice isoforms remain equally abundant in myoblasts 
and myotubes, indicating that their function does not require developmental 
regulation. Other ROCK relatives also appear as anchored proteins, localized to 
defined areas of the cellular infrastructure. Given these considerations, it is tempting 
to speculate that cytosolic DMPK E participates in aspects of cell morphodynamics 
that cannot be carried out by other ROCK family members and/or are carried out by 
other non-related cytosolic kinases in non-mammalian species. Alternatively, DMPK 
E could have an as yet unknown, highly specialized task in actomyosin remodeling 
and muscle cell maturation, a task that is unique for mammalian development.
DMPK E kinase activity - and not the structural presence of the protein per 
se - appeared to be a crucial determinant of stellar stress fiber formation, as DMPK 
E kd expression did not induce these actin-rich structures. Furthermore, subcellular 
membrane anchoring seems to restrain stellar stress fiber formation as DMPK A 
and C expression did not promote their production. Free diffusion of cytosolic 
DMPK E protein enables phosphorylation of specific substrates, which cannot be 
reached otherwise. Structure of the kinase may also be a determining factor, as 
biochemical experiments using purified compounds revealed that some proteins 
are preferentially phosphorylated by the truncated DMPK variants, like DMPK E, but 
are unfavorable substrates for isoforms with a long C-terminal membrane domain
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(6). All points considered, we conclude that the delay in myogenic differentiation, 
accompanied by the formation of actin deposits and myosac structures, is probably 
caused by DMPK enzymatic activity at the wrong place and the wrong time in the 
myoblast cell.
Isoform DMPK E is highly expressed and virtually the sole DMPK variant 
in terminally differentiated smooth muscle cells in stomach and bladder (8, 42). 
The question why these cells require this high expression of DMPK E, or whether 
the activity of DMPK E is regulated otherwise, cannot be easily answered in the 
absence of clear functional clues. All we know is that smooth muscle cells do not 
fuse during differentiation and that the architecture of the actomyosin cytoskeleton 
in these cells differs strongly from the highly organized and highly ordered, protein- 
dense, sarcomeric arrangement in skeletal muscle myotubes (43). To dig deeper 
into the relationship between DMPK protein structure variation and function and 
the cell-type dependent needs for morphodynamic change during development 
and maintenance of physiological capacity, we need better access to differentiating 
smooth muscle model systems, which are currently not easily available.
Stellar stress fiber formation in myoblasts induced by DMPK E activity was paralleled 
by enhanced MLC2 phosphorylation, specifically Thr18 Ser19 diphosphorylation. 
At least a dozen other kinases, among which the above-mentioned ROCK, MRCK 
and MLCK have been shown to phosphorylate MLC2 on Thr18, Ser19 or both 
residues (30, 33). Besides, MLC2's phosphorylation status is strongly dependent 
on the activity of myosin phosphatase (PP1), which counteracts kinase activity 
by removing phosphate groups from phosphorylated Thr18 and Ser19 residues. 
Myosin phosphatase is inactivated by phosphorylation of its targeting subunit 
MYPT1, which is also a known substrate of DMPK (6 and data not shown, 44) and 
ROCK (45). As a result, the net phosphorylation level of MLC2 is determined in a 
delicate balance between kinase and phosphatase activities, involving concerted 
activities of enzymes like ROCK and MRCK (46), and - as suggested from our 
findings reported here - also DMPK. Cytosolic DMPK may thus influence MLC2 
phosphorylation directly by phosphorylating the MLC2 protein itself, or indirectly 
by activating another kinase or by inactivating MYPT1 (6), or both. Clearly, further 
work in distinguishing between these possible mechanisms is necessary.
Stress fibers are contractile, thick actin filament bundles which can be found 
in motile and non-motile cells (28, 29). In cultured mammalian cells, they may be 
classified as ventral or dorsal stress fibers or transverse arcs, depending on the 
subcellular location, spatial orientation and direction of cell locomotion (28, 29). 
How the stellar stress fibers observed in this study fit in this classification is not 
entirely clear. In fact, not much is known about the formation and structure of 
stellar stress fibers and their physiological relevance has not been studied in detail. 
What we do know is that stellar stress fibers contain actin and myosin II and are 
abnormal structures typical for cultured cells (28, 29, 47). Stellar stress fibers have 
been observed by others upon expression of truncated ROCK mutants or inhibition
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of MYPT1 (27, 48-51) but, interestingly, not upon expression of a truncated form of 
citron kinase (52). As this citron kinase mutant does not phosphorylate MYPT1 and 
is therefore unable to inactivate myosin phosphatase, formation of stellar stress 
fibers may be related to a robust increase in diphosphorylation of MLC2. Persistent 
activation of MLC2 may thus lead to massive actomyosin contraction, resulting in 
the large electron-dense aggregate-like structures observed by electron microscopy. 
However, we cannot exclude the possibility that ectopic phosphorylation of actin- 
associated proteins, e.g. ADF/cofilin (28, 29), tropomyosin (53) or other as yet 
unidentified proteins, have a facilitating or dominant role in the process of stellar 
stress fiber formation.
Living in a situation where the appearance and role of stellar stress fibers 
is still rather poorly understood, how can we explain the apparent associated 
effects on myogenesis? Or should we interpret the inhibitory effect of DMPK E 
on myoblast-myotube differentiation in a different context? Skeletal myogenesis 
follows a tightly regulated developmental program that directs myoblasts to 
differentiate into muscle fibers (54). In particular, the structure and cytoskeletal 
organization of myoblasts are important determinants in myotube differentiation, 
myofibrillogenesis and costamerogenesis (55, 56). We report here that DMPK E 
expression in myoblasts not only resulted in reorganization of actin filaments, but 
also caused a change in cell shape and cell motility. DMPK E, by fixing the cell in 
a state with a too high content of diphosphorylated MLC2, may thus produce an 
abnormally rigid cytoskeletal organization, unable to reorganize rapidly as myoblast 
move, or as needed to re-orient their position with respect to fusion partners.
In order to fuse, myoblasts must be able to align, a process involving the 
activities of non-muscle myosins IIA and IIB (15). As DMPK E-mediated induction 
of stellar stress fibers also engaged non-muscle myosin IIA and IIB and probably 
other still unidentified proteins, it is possible that recruitment of one or more of 
these proteins from their normal location at the cortical actin wall at the plasma 
membrane in aligned cells (57) does no longer proceed normal. As a consequence, 
cell orientation for fusion may have become abnormal, resulting in the occurrence 
of myosacs at later stages in myogenesis in our cell culture system. Previous 
studies showed that formation of these enlarged, abnormal, multinucleated cells 
is generally related to a compromised cytoarchitecture, coupled to impaired 
sarcomere assembly and retraction of the growth tip of myotubes (reviewed in 39).
In summary, our data support the idea that the cytosolic DMPK E isoform is a 
potent modulator of actomyosin cytoskeleton dynamics. We presented evidence 
that unscheduled cytosolic DMPK activity is directly linked to excessive MLC2 
phosphorylation and to abnormal regulation of morphodynamic events that control 
myogenesis via myoblast-myotube fusion. Our findings, together with DMPK isoform 
profiling data, suggest that DMPK E's activity should be tightly controlled during early 
steps of skeletal muscle differentiation to promote normal development. Future 
study of DMPK's function in the cytosol of other cell types in which the protein is
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abundantly expressed, like smooth muscle cells (e.g., in bladder, stomach, intestine) 
and cells of the heart (8) is now warranted. Swapping strategies, by replacing the 
entire complement of DMPK isoforms by one single isoform, as used here, may be 
beneficial in such studies.
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SUPPORTING INFORMATION 
SI Figures
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Figure S1. DMPK protein is expressed in myoblasts and differentiating myotubes. Western 
blot analysis demonstrates DMPK protein expression in wild type (WT) myoblasts and four- 
day-old differentiating myotubes. DMPK-deficient (KO) myoblasts and myotubes were 
included as negative controls. A curly bracket encloses the DMPK isoform repertoire in WT 
differentiating myotubes. Asterisks indicate signals of cross-reacting proteins (which partly 
obscure expression of short DMPK proteins in myoblasts (8)). Coomassie Brilliant Blue (CBB) 
staining was used to control protein loading.
YFP
DMPK
C E
WT
KO myotubes myotubes
DMPK
PK
*
Figure S2. DMPK protein expression in WT myotubes and transduced DMPK KO myotubes.
Cell lysates of seven-day-old WT myotubes and DMPK KO myotubes which transiently 
expressed YFP-DMPK C or E were resolved by SDS-PAGE and analyzed by Western blotting. 
A DMPK antibody detected endogenous DMPK proteins (~70-80 kDa) in WT myotubes and 
YFP-DMPK fusion proteins (~100-110 kDa) in transduced KO myotubes. Lysate from non­
transduced DMPK KO myotubes was included as negative control. Pyruvate kinase staining 
(PK) revealed protein loading. Asterisks indicate reactivity towards an unrelated cross­
reacting protein.
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Videos S1-S3. DMPK E alters myoblast morphology and movement.
See doi: 10.1016/j.bbamcr.2011.01.024
Morphology and migration assays were performed with DMPK KO myoblasts expressing 
YFP-DMPK E (Video S1), C (Video S2) or E kd (Video S3). DMPK E expression strongly altered 
myoblast morphology and initiated some cell death. DMPK E-expressing myoblasts migrated 
over a smaller distance in time compared to cells expressing DMPK C or E kd. Time-lapse 
phase contrast microscopy was performed by taking an image every ten min. Display rate is 
ten frames/s.
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ABSTRACT
Myotonic dystrophy type 1 (DM1) is caused by toxicity of an expanded, noncoding 
(CUG)n tract in DM protein kinase (DMPK) transcripts. According to current evidence 
the long (CUG)n segment is involved in entrapment of muscleblind (Mbnl) proteins in 
ribonuclear aggregates and stabilized expression of CUG binding protein 1 (CUGBP1), 
causing aberrant pre-mRNA splicing and associated pathogenesis in DM1 patients. 
Here, we report on the use of antisense oligonucleotides (AONs) in a therapeutic 
strategy for reversal of RNA-gain-of-function toxicity. Using a novel mouse DM1 
myoblast-myotube cell model and DM1 patient cells as screening tools, we have 
identified a fully 2'-O-methyl-phosphorothioate-modified (CAG)7 AON that silences 
mutant DMPK RNA expression and reduces the number of ribonuclear aggregates 
in a selective and (CUG)n-length dependent manner. Direct administration of this 
AON in muscle of DM1 mouse models in vivo caused a significant reduction in the 
level of toxic (CUG)n RNA and a normalizing effect on aberrant pre-mRNA splicing. 
Our data demonstrate proof of principle for therapeutic use of simple sequence 
AONs in DM1 and potentially other unstable microsatellite diseases.
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INTRODUCTION
Myotonic dystrophy type 1 (DM1) is the most common neuromuscular dystrophy 
in adults and the first triplet repeat RNA-mediated disorder described (1, 2). Its 
complex, multisystemic pathology involves the production of toxic (CUG)n transcripts 
after expansion of a mutant (CTG)n tract in the DMPK gene. In DM1 patients with 
expansions ranging from 50 to >2000 triplets in their blood DNA severity of disease 
correlates to (CTG)n tract length.
Currently, the weight of evidence argues in favor of a model in which the 
harmful effect of a mutation in the DMPK gene occurs at the gene product level and 
involves protein binding to the long (CUG)n segment. Other cell stress effects of 
expression of the mutant DMPK gene cannot be excluded, however (1, 2). Members 
of the Mbnl and CELF families of RNA-binding proteins are most likely implicated 
in DM1 pathogenesis (3, 4). Mbnl1 is sequestered together with expanded (CUG)n 
transcripts in ribonucleoprotein (RNP) aggregates, resulting in reduced free Mbnl1 
levels in the cell. Conversely, steady-state levels of CUGBP1 are increased in cells or 
tissues with a high (CUG)n dose. The ensuing imbalance in splicing factors causes 
missplicing of several transcripts, usually resulting in expression of fetal proteins 
inappropriate for adult tissue (2).
Use of DM1 mouse models has pointed out that harmful effects of toxic 
(CUG)n RNA are largely reversible. For the HSALR model (5), characterized by 
high expression of skeletal a-actin transcripts bearing a (CUG)250 tract, it was 
demonstrated that viral overexpression of Mbnl1 reverses splicing defects and 
alleviates myotonia (6). In 5-313 mice, which inducibly overexpress the human DMPK 
(hDMPK) 3' UTR including a (CUG)5 repeat tract as part of a GFP transcript, typical 
DM1 myotonia and cardiac defects disappeared when the transgene was silenced
(7). These observations underscore the idea that reducing (CUG)n RNA dosage is 
beneficial to patients and forms an attractive therapeutic goal for improvement of 
DM1 features.
Here, we investigated the feasibility of antisense oligonucleotide (AON) 
technology, which has shown a range of promising applications (8-11). Among a 
series of chemically modified AONs designed to induce post-transcriptional gene 
silencing of mutant hDMPK transcripts a (CAG)7 AON was identified that causes 
specific reduction of expanded (CUG)n transcripts and reverses DM1 features in cell 
and mouse models. We demonstrate that an effective, therapeutic strategy based 
on an AON consisting of simple repeats may become feasible, which may also have 
bearing for other microsatellite disorders.
MATERIALS AND METHODS
For details see SI Materials and Methods.
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Animals
DM500 mice - derived from the DM300-328 line (12) - and HSALR20b mice have been 
described (5). All animal experiments were approved by the Institutional Animal 
Care and Use Committees of the Radboud University Nijmegen and the University 
of Rochester Medical Center.
Cell culture
An immortal mouse myoblast cell culture expressing hDMPK (CUG)500 transcripts 
was derived from GPS tissue isolated from DM500 mice additionally expressing one 
copy of the H-2Kb-tsA58 allele. The generation of human DM1 myoblast lines has 
been described (15).
Oligos
All AONs used in this study are listed in Figure 2A and Table S1. PS58 is a synthetic 
RNA oligonucleotide with sequence 5'-CAGCAGCAGCAGCAGCAGCAG-3' which 
carries full-length 2'-OMe-substituted ribose molecules and PT internucleotide 
linkages.
Oligo transfection
Cells were transfected with AONs complexed with polyethyleneimine (PEI; ExGen500, 
Fermentas, Glen Burnie, MD) according to the manufacturer's instructions.
RNA isolation
RNA from cultured cells was isolated using the Aurum Total RNA Mini Kit (Bio-Rad, 
Hercules, CA) according to the manufacturer's protocol. RNA from muscle tissue 
was isolated using TRIzol reagent (Invitrogen). Alternative methods are described in 
SI Materials and Methods.
Northern blotting and RT-PCR
Northern blotting and semi-quantitative RT-PCR analysis were done following 
standard procedures. For analysis of alternative splicing, embryonic (E):adult (A) 
splice ratio was defined as embryonic form signal divided by adult form signal 
in each sample. Splice ratio correction illustrates the effect of PS58 treatment 
on alternative splicing. Splice ratio correction is defined as the mock-treated 
embryonic:adult splice ratio divided by the PS58-treated embryonic:adult splice 
ratio for a given transcript per mock/PS58-treated muscle pair (i.e., per mouse). 
Hence, a splice ratio correction of 1.0 means no change in alternative splicing, while 
a correction >1.0 implies an increase in adult splice forms.
Western blotting
Western blotting was done by standard methods described in SI Materials and 
Methods.
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In vivo treatment
The GPS complex of DM500 mice was pretreated with PEI-5% glucose injections 
on days one and two. This pretreatment was followed by two injections with 2 
nmoles PS58 in a PEI-5% glucose solution on days three and four. Mock-treated 
mice received the same treatment except that oligo PS58 was left out. Mice were 
sacrificed and muscles were isolated on day fifteen.
Diverse treatment protocols were tested in HSALR mice. In each case, one 
leg of a HSALR mouse was treated with 1 or 2 nmoles PS58, while the contralateral 
leg served as mock control. (i) HSALR mice were injected twice in the GPS complex as 
described above, without PEI pretreatment. Injections took place at days one and 
eight, and tissues were isolated on day twenty-two. Non-injected TA muscle served 
as negative control. (ii) TA muscle was injected once as described above, without 
PEI pretreatment, and muscle tissue was isolated seven days later. (iii) TA muscle 
was injected with or without PEI, followed by electroporation (11) and analyzed on 
day eight or fifteen.
Immunofluorescence and FISH
Immunofluorescence and FISH were performed by standard methods. Images were 
collected on a Zeiss Axioplan fluorescence microscope (Carl Zeiss, Sliedrecht, NL). 
Pictures were captured by a Zeiss AxioCam MR camera with Axiovision 3.1 software.
Intratissue imaging
The distribution of FAM-labeled PS58 was imaged in the GPS complex of DM500 
mice with the Olympus OV110 whole mouse imaging system (Olympus Corp., 
Tokyo, Japan).
Statistical analysis
See details in SI Materials and Methods.
RESULTS 
A novel myogenic cell model for DM1
As model for testing DM1-specific AONs in vitro, we derived conditionally 
immortalized myoblast-myotubes from skeletal muscle of the DM300 lineage (Figure 
1A) (12). DM300 mice were originally generated as carriers of a hDMPK (CTG)300 
transgene, but ongoing expansion was observed in this lineage. The DM1 repeat 
locus in our cell model at the time of derivation comprised around 500 triplets. 
Hence, we will refer to these cells as DM500 myoblasts/myotubes.
DM500 myoblasts expressed hDMPK (CUG)500 mRNA at levels comparable 
to that of endogenous mouse DMPK (mDMPK) mRNA (Figure 1B). Ribonuclear foci, 
a hallmark of DM1 pathogenesis (13), were observed in proliferating myoblasts 
and in differentiated myotubes (Figure 1C). FISH using a (CAG)7 probe confirmed 
presence of five to ten foci per nucleus, not seen with a (CUG)7 control. Altogether,
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our DM500 cells displayed molecular characteristics of DM1, which makes them a 
useful test system for AON effects on cell stress caused by mutant hDMPK transcripts.
Figure 1. Novel cell model for testing DM1 therapy. (A) Conditionally immortalized myoblasts 
derived from DM500 mice differentiate to myotubes under low serum conditions. Bars, 
30 um. (B) Northern blot analysis of RNA isolated by two different methods from DM500 
myoblasts demonstrated expression of transgenic hDMPK mRNA bearing a (CUG)500 tract 
next to endogenous mDMpK mRNA. (C) FISH using a (CAG)7 probe revealed ribonuclear 
(CUG)n foci, mainly in cell nuclei. A (CUG)7 probe was used as negative control. Insets show  
nuclei at higher magnification. Bars, 10 um.
Silencing of hDMPK (CUG)500 RNA by PS58, a chemically modified (CAG)7 oligo
A series of modified RNA- and DNA-based AONs was designed with a target 
sequence for a particular region within the hDMPK primary transcript (Figure 2A 
and supporting information (SI) Table S1). Thirteen AONs were tested for their 
ability to suppress hDMPK (CUG)500 RNA expression in DM500 myotubes. Northern 
blotting revealed that silencing capacity varied between AONs (Figure 2B). PS58, 
a 2'-O-methyl (2'-OMe) phosphorothioate (PT) modified (CAG)7 oligo designed to 
target the (CUG)n segment was most effective, causing a ~90% reduction in hDMPK 
(CUG)500 mRNA (Figure 2C). Not surprisingly, endogenous mDMPK mRNA bearing 
a (CUG)2(CAG)2(CUG) sequence instead of an uninterrupted (CUG)n segment was 
left intact. To ensure that our appraisal of PS58's silencing capacity was correct and 
that the disappearance of hDMPK (CUG)500 mRNA signal was not due to events 
that occurred during the RNA isolation procedure, we tested various methods 
(Figure S1) and also carried out RT-PCR analysis across the hDMPK transcript 
(Figure 2D). Data obtained are consistent with a breakdown of hDMPK (CUG)500 
transcripts by PS58. For reasons unknown, the 5' region (exons 1-7) of the mRNA 
appeared relatively resistant to degradation compared to 3' regions (Figure 2D). In 
this respect, it is important to note that no short DMPK mRNA products of discrete 
size were detected on Northern blot or by RT-PCR.
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Figure 2. PS58-mediated silencing of expanded hDMPK transcripts in DM500 cells. (A)
Location of target sites of AONs (black bars) along the hDMPK pre-mRNA. (B) Northern blot 
analysis to detect ability of AONs to silence hDMPK mRNA in DM500 myotubes. Gapdh was 
used as loading control. Oligos were tested at least twice; a representative blot is shown.
(C) PS58, directed at the (CUG)n segment, was the most successful AON (P<0.001, n=19).
(D) PS58 activity was corroborated by semi-quantitative RT-PCR analysis of individual 
segments of the hDMPK transcript (primers indicated with black arrows). Numerals in lanes 
indicate relative abundance to mock samples (set at 100), using 6-Actin for normalization. A 
representative result from two experiments is shown. (E) A reduction in the number of nuclei 
containing (CUG)n foci was observed after PS58 treatment of DM500 myoblasts (P<0.001, 
n=4).
Examination of time and concentration effects revealed that maximal 
efficacy of PS58 in our DM500 cell model was already reached within two hours 
after transfection (Figure 3A). Human DMPK (CUG)500 mRNA levels remained 
virtually undetectable for up to ten days after a single oligo dose (Figure 3B and 
C). From concentration response analyses, we deduced an IC50 of 0.40 ± 0.15 nM 
(Figure 3D). Combined, our studies demonstrated that PS58 silenced expanded 
hDMPK transcripts quickly and with high affinity.
Since PS58 is a (CAG)7 triplet repeat oligonucleotide, (CUG)n-bearing 
transcripts other than DMPK could potentially serve as targets too. We searched 
databases for (CUG)n tracts in the mouse transcriptome and identified nine candidate 
transcripts that contain at least six CUG triplets (Table S2). RT-PCR-mediated 
quantification of four candidates revealed that PS58 treatment only marginally 
affected expression; for Mapkap1 (CUG)26 transcripts a more pronounced effect 
was noted at high PS58 concentration (Figure S2).
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Figure 3. PS58-induced silencing is rapid, persistent and occurs with high efficacy. (A)
DM500 myotubes were mock-treated or treated with PS58. RNA was isolated 2-48 hours 
after start of transfection. Northern blot analysis indicated that expanded hDMPK was 
degraded within two hours. A representative blot is shown. The means of three experiments 
are summarized in the bottom panel (P<0.05). (B, C) DM500 myoblasts and myotubes in 
different stages of myogenesis were treated with a single 200 nM PS58 dose or mock-treated 
and then cultured for up to ten days. Northern blot analysis demonstrated that hDMPK RNA 
remained undetectable for up to ten days. (D) Concentration-response curve in DM500 
myotubes. Data points are the mean of at least three measurements.
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In human cells, PS58 preferentially silences DMPK transcripts with an expanded 
(CUG)n repeat
Symptoms in DM1 strongly correlate with the length of the (CTG)n segment in the 
mutated DMPK allele (1). To be functional in patients, PS58 should ideally silence 
transcripts from the expanded allele and not be active towards transcripts from the 
normal-sized allele - which may carry up to 37 triplets (14). To test this requirement, 
we analyzed PS58 efficacy in four patient myoblast cultures (15). These myoblasts 
expressed transcripts from expanded alleles that contained 200, 800, 1400 or 
2000 CTG triplets, representing different severities of disease, and normal-sized 
alleles bearing 5, 13 or 21 triplets. Northern blot analysis demonstrated that PS58 
silenced expanded DMPK transcripts in these human cells to the same degree as in 
DM500 mouse myotubes (Figure 4A and B). PS58 efficacy clearly correlated with 
the number of CUG triplets in the hDMPK transcript since normal-sized transcripts 
were only mildly reduced (Figure 4A-C). Effects on non-mutant transcripts appeared 
variable, as (CUG)13 transcripts were reduced in 13/800 cells, but unchanged in 
13/2000 cells. Western blot analysis confirmed that undesired silencing of normal­
sized transcripts did not result in great loss of DMPK protein, as 71% of control level 
was still present at 72 h after PS58 treatment in 21/200 myoblasts (Figure 4D and E).
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Figure 4. PS58 silences preferentially expanded DMPK transcripts in patient cells. (A)
DM1 myoblasts expressing different expanded and normal-sized DMPK alleles were treated 
with PS58 or mock-treated. Northern blot analysis indicated that expanded mRNA was 
strongly reduced whereas normal-sized DMPK transcripts were less sensitive to breakdown. 
A representative blot is shown. (B) Quantification of three experiments as described in a 
(P<0.05). (C) A clear correlation was demonstrated between the number of CTG triplets 
and Ps 58 efficacy (P<0.05, Spearman correlation, r=-0.79). (D, E) 21/200 myoblasts were 
analyzed by Western blotting 72 hours after mock or PS58 treatment. A muscle sample 
from a DMPK KO mouse (-/-) served as negative control. A 29% reduction in DMPK protein 
(arrowhead) was observed (P<0.01, n=3).
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Secondary effects of PS58 activity in DM500 cells
Next, we used our DM500 cell model to examine whether PS58 treatment had 
beneficial effects on the DM1-typical formation of nuclear RNA foci or occurrence 
of embryonic modes of pre-mRNA splicing. Muscleblind proteins and CUGBP1 are 
prominently involved in these events (2). FISH analysis demonstrated that PS58 
treatment caused a fourfold reduction in the percentage of cells that contained 
ribonuclear foci (Figure 2E). Presence of PS58 had no effect on CUGBP1 level, but 
it should be noted that the CUGBP1 level in DM500 myotubes was not increased 
compared to controls (similar to DM500 mice). Also the pattern of alternative 
splicing of a representative subset of DM1-specific transcripts was not altered in 
presence of PS58 in DM500 myotubes nor wt myotubes (Figure S3). This excludes 
anomalous effects of PS58 on RNA processing. Effects of PS58 activity on splicing 
required study in vivo, as the terminal end stage of myogenic differentiation and 
adult programming of RNA processing cannot be achieved in cells in culture (Figure 
S3)
PS58 is active in DM1 mouse models in vivo
As a prelude to in vivo experiments, we investigated the distribution of fluorescently- 
labeled PS58 after injection into the GPS (gastrocnemius-plantaris-soleus) complex 
of DM500 mice. A non-homogeneous staining was observed throughout the tissue 
(Figure S4A). Virtually no signal was found in the tibialis anterior (TA) demonstrating 
that intertissue spreading was minimal. Analysis of muscle sections showed that 
PS58 molecules concentrated in cell nuclei (Figure S4B).
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Next, we assessed efficacy of PS58 in two different mouse models. In 
DM500 mice, injection in the GPS complex followed by RT-PCR analysis of RNA 
content confirmed silencing of hDMPK (CUG)500 mRNA in the gastrocnemius 
and plantaris, but not the TA control (Figure 5A). Again, the 5' end of the hDMPK 
transcript appeared relatively resistant to degradation (Figure S5). PS58 injection in 
the GPS complex of HSALR mice (5) resulted in significant silencing of toxic (CUG)250 
transcripts, predominantly in soleus and to a lesser extent in gastrocnemius (Figure 
5B).
The very high expression of transgenic transcripts in the HSALR mouse 
culminates in formation of large RNP foci in every cell nucleus in skeletal muscle, 
which makes it a particular attractive model for examining effects of PS58 treatment 
on this feature. We categorized appearance of RNP foci according to FISH signal 
intensity and pattern after PS58 treatment and observed a significant shift from 
nuclei packed with foci towards nuclei containing smaller, discrete foci (Figure 5C). 
No nuclei void of foci were detected. Simultaneous study of nuclear aggregation 
behavior of Mbnl1 in this model revealed a substantially more diffuse distribution 
of Mbnl1 (Figure S6) (6).
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Figure 5. PS58 reverses molecular features in DM1 mouse models in vivo. (A) PS58 was 
injected in the GPS complex of DM500 mice, followed by RNA isolation at day fifteen. 
Semi-quantitative RT-PCR analysis demonstrated hDMPK mRNA silencing in gastrocnemius 
(P<0.01, n=3) and plantaris (P<0.05, n=3) (see Figure S5). (B) A similar protocol was used 
in HSALR mice. TA muscle served as uninjected control. HSALR transcripts were quantified on
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Northern blot, using mouse a-actin (MSA) for normalization. The blot represents one of four 
independent experiments. The histogram shows average values: lower HSALR mRNA levels 
were observed in soleus (35 ± 8%; P<0.01) and gastrocnemius (61 ± 7%; P=0.01), but not 
in plantaris (81 ± 11%; P=0.19). (C) FISH analysis was performed on sections of PS58- or 
mock-injected HSALR gastrocnemius muscle. (CUG)n foci were found in every nucleus. Nuclei 
were categorized in three groups according to their (CUG)n foci appearance (top panels each 
show one representative nucleus). A significant shift towards smaller and fewer foci was 
observed after PS58 treatment (P<0.01, n=2). (D) TA muscle in HSALR mice was electroporated 
with PS58 or mock-treated. rN a was isolated after seven days. Northern blotting showed 
significantly lower HSALR mRNA levels after PS58 treatment (bottom panel; 51 ± 7%; P<0.01, 
n=4). Splice modes were investigated by RT-PCR. Numerals indicate embryonic (E):adult (A) 
splice ratio in each lane. Lower ratios in PS58-treated samples, compared to their mock- 
treated samples, demonstrate positive effects on alternative splicing (see also Figure 
S7). (E) Correlation between splicing correction and HSALR mRNA levels in PS58-treated 
muscles. Each symbol represents a TA muscle or one muscle from the GPS complex. Splice 
ratio correction illustrates the mean effect on alternative splicing of five transcripts (see D) 
(P<0.01; Spearman correlation, r=-0.64; n=27).
Many embryonic splice modes in DM1 skeletal muscle observed in DM1 
patients are replicated in HSALR mice (16) - in contrast to DM500 mice, which display 
hardly any DM1-typical splice modes in skeletal muscle and also RNP foci much 
less overtly (21). We measured splice modes of five different transcripts - Serca1, 
Mbnl1, Ttn, Clcn1 and Tnnt3 - upon PS58 treatment in TA and GPS muscles. In 
electroporated TA muscle, a reduction of ~50% of HSALR mRNA was achieved after 
seven days, which was paralleled by a significant shift in splicing pattern from an 
embryonic-like (E) to normal-adult (A) mode for four out of five transcripts tested 
(Figure 5D and Figure S7).
Finally, we combined all data obtained with HSALR mice, irrespective of the 
mode of PS58 administration, muscle type, or timing of muscle isolation. Collective 
evaluation of the results revealed a clear correlation between PS58-induced 
reduction of HSALR (CUG)250 mRNA levels and the accompanying effects on splicing 
(i.e., splice-ratio correction, defined as the mock-treated embryonic:adult splice 
ratio divided by the PS58-treated embryonic:adult splice ratio; Figure 5E). This 
demonstrated that PS58-induced suppression of abnormally expanded (CUG)n RNA 
mitigates toxicity effects in vivo.
DISCUSSION
DM1 was the first RNA toxic-gain-of-function disorder described (2). Here, we 
explored a therapeutic approach that directly deals with its root cause - i.e., 
expression of expanded (CUG)n RNA. Only few experimental studies were dedicated 
in the past to the breakdown of normal or mutant hDMPK RNA, all restricted to use of 
cell models and mostly viral-based vectors for the delivery of the active component 
(17-20). To circumvent problems associated with viral-based therapy in humans, we 
chose AONs to degrade toxic (CUG)n RNA. The (CAG)7 AON PS58 identified in this 
paper was successfully delivered into cells with the help of transfection reagents
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or locally via injection-electroporation protocols in mouse muscle, to demonstrate 
proof of principle. The chemical nature of PS58 precludes efficient uptake in 
tissues. We will therefore need to concentrate on the design of more sophisticated 
delivery techniques to promote uptake in vivo, before we can proceed with a study 
of systemic treatment of DM1 animal models or patients. Clearly, this remains a 
challenge for future efforts.
PS58 silencing capacity for expanded (CUG)n RNA ranged from up to 90% in 
cells to between 30-80% in vivo, with differences between muscle types (soleus > 
gastrocnemius ~ tibialis anterior > plantaris). The HSALR and DM500 models clearly 
differ in the degree of muscle pathology, presumably because the level of expanded 
(CUG)n transcripts in muscle from the HSALR model is much higher than in DM500 
muscle. Still, a similar range of silencing was observed for muscles of both models. 
Based on these observations, we think that membrane integrity or physiological state 
of individual muscle types, rather than the initial cellular concentration of target 
RNA forms the most important parameter for AON uptake and breakdown capacity. 
Also size of the (CUG)n segment or differences in sequence context or subcellular 
localization of target RNAs are considered parameters of lesser importance.
Studies of Mbnl1 protein overexpression in HSALR mice (6), expression 
inhibition of a (CUG)5 RNA-encoding transgene in an inducible mouse model (7) 
or correction of Clcn1 splicing (11) have illustrated that particular DM1 features 
are reversible. Our findings demonstrate that also non-genetic modalities, e.g., 
treatment with a simple repeat AON, can reverse DM1 pathogenesis in vivo. Our 
findings on the PS58-induced reduction of nuclear RNP foci are in line with the 
notion that foci containing (CUG)n RNA, Mbnl1 protein and potentially other 
unknown factors, are dynamic structures (2). We therefore may assume that upon 
degradation of the (CUG)n RNA component, less Mbnl1 will be captured in the 
aggregated state and more Mbnl1 will be available for regulation of splicing. Our 
findings in the HSALR model confirm this idea. PS58 treatment significantly improved 
splicing of five different transcripts, in a manner clearly correlating to the degree of 
(CUG)n RNA reduction in this model.
Whether the (CUG)n repeat dose, splice abnormalities and phenotypic 
features in HSALR mice accurately reflect the situation in patients is a hotly debated 
question in the DM field. The disbalance introduced by transgene expression in 
the currently available models may be either considered too extreme (e.g., the 
HSALR model) or too mild (e.g., DM500 model). Further progress in knowledge on 
this topic is needed before we can productively proceed with studies towards the 
development of PS58-based therapy. Analysis on the reversal of phenotype in DM1 
mouse models and its value for prediction of possible effectiveness in clinical trials 
in DM1 patients therefore needs further work.
Our AONs were originally designed to bind and degrade expanded (CUG)n 
RNA or induce exon skipping (compare 22) or abortive splicing (23). The unique 
effectiveness of PS58 can best be explained by induction of selective breakdown,
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presumably starting at the 3' target segment with the (CUG)n tract, as we noticed 
relatively stable behavior of the 5' part of the hDMPK transcripts. Currently, we do 
not know much about the molecular mechanism involved in this breakdown, but 
do not expect that PS58, being an AON with a 2' O-methyl-based backbone, will 
work via recruitment of RNase H. Selective effects of PS58 on pre-mRNA processing 
events, like the use of premature polyadenylation sites or complete skipping of 
exon 15 or segments thereof, can also not be involved as no smaller DMPK mRNA 
products of discrete size were identified using RT-PCR or Northern blot analyses. 
PS58-induced breakdown of repeat expanded transcripts in DM500 myotubes was 
fast and went nearly to completion. So we assume that both the cytoplasmic mature 
mRNA pool (constituting probably only a minor fraction) as well as the nuclear pool 
of primary and mature expanded (CUG)n transcripts served as targets. Moreover, in 
patient cells we observed effects on non-mutant DMPK transcripts residing in the 
cytoplasm. Thus, an exclusive effect of PS58 in the nucleus seems unlikely.
It is known that 2'-OMe PT modifications, like in PS58, protect against 
enzymatic breakdown in the cell, resulting in higher AON efficacy (9). The PT moiety 
is probably also responsible for the dominant nuclear localization that we observed 
for PS58 (24). A fully modified 2'-OMe PT AON has to our knowledge not been used 
successfully before in antisense silencing strategies (9, 25, 26). Our data suggest 
that the structural composition of PS58 determines entry in novel RNA degradation 
mechanisms, but this will require further testing.
Regardless of the mechanism operating, we have observed that PS58 
provides selectivity between expanded and normal-sized hDMPK transcripts. 
Patients carrying a normal-sized allele in the (CTG)18-37 range are only present 
in ~10% of the DM1 population (14) and also other transcripts with a (CUG)310 
segment are scarce in the human transcriptome (Table S2). From a kinetic point of 
view, it is important to note that PS58 has multiple binding sites on a long (CUG) 
n segment but only one or a few on a normal (CUG)n segment. Assuming that 
binding of one oligo to a (CUG)n transcript is sufficient for degradation, a lower 
dose may thus increase selectivity and reduce chance of undesired side effects. 
Changing the number of CAG triplets in the AON could also positively influence 
selectivity. Although at this point, unfamiliar with the working mechanism of PS58, 
it is impossible to predict whether a shorter or longer (CAG)n AON will be equally 
effective. Experiments with (CAG)n AONs of different lengths in cells expressing 
DMPK transcripts with diverse (CUG)n segments should provide answers.
Successful development of RNA-directed therapy for DM1 will also create 
new opportunities for treatment of other microsatellite diseases caused by RNA 
toxicity, like DM2, SCA8, SCA10, FRAXA and HDL2, but maybe also disorders like 
Huntington's or oculopharyngeal muscular dystrophy. Each of these diseases 
progressively affects muscle, heart and brain and functioning of various body 
systems. For none of these disorders is a cure or therapy available.
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SUPPORTING INFORMATION  
SI Materials and Methods 
Animals
Hemizygous DM500 mice - derived from the DM300-328 line (1) - express a 
transgenic human DM1 locus, which bears a repeat segment that has expanded to 
approximately 500 CTG triplets, due to intergenerational triplet repeat instability. For 
the isolation of immortal DM500 myoblasts, DM500 mice were crossed with H-2Kb- 
tsA58 transgenic mice (2). Homozygous HSALR20b mice express a (CUG)250 segment 
in the context of a human skeletal actin transcript (3). All animal experiments were 
approved by the Institutional Animal Care and Use Committees of the Radboud 
University Nijmegen and the University of Rochester Medical Center.
Cell culture
An immortal mouse myoblast cell culture expressing hDMPK (CUG)500 transcripts 
was derived from GPS tissue isolated from DM500 mice additionally expressing 
one copy of the H-2Kb-tsA58 allele (4). Independent myoblast lines were obtained 
by ring cloning. The DM500 myoblast culture used in this study consisted of an 
equal mixture of six independent clones. Likewise, a wild type myoblast culture was 
derived from wild type littermates from the DM500 mouse line and expressed only 
the H-2Kb-tsA58 allele.
Conditionally immortalized myoblasts were grown on gelatin-coated dishes 
in DMEM (Gibco, Gaithersburg, MD) supplemented with 20% (v/v) FCS, 50 ^g/ml 
gentamycin, 20 units y-IFN/ml (BD Biosciences, San Jose, CA) and 2% (v/v) chicken 
embryo extract (Sera Laboratories International, Bolney, UK) at 5% CO2 and 33°C. 
Differentiation to myotubes was induced by placing DM500 myoblasts, grown to 
confluency on Matrigel (BD Biosciences), in DMEM supplemented with 5% (v/v) 
horse serum (HS) and 50 ^g/ml gentamycin at 37°C. These low serum conditions 
were continued for a maximum of ten days. Spontaneous contractions appeared 
around five days of differentiation.
For the generation of human DM1 myoblast lines biopsies from quadriceps 
muscles were obtained during autopsies, in accordance with French legislation on 
ethical rules. Satellite cells were isolated from DM1 fetal muscle as described (5). 
Myoblasts were maintained in Ham's F10 medium supplemented with 20% FCS and 
25 ^g/ml gentamycin, at 5% CO2 and 37°C.
Analysis of (CTG)n repeat lengths
Sizes of the expanded (CTG)n segments in the human cell lines were estimated via 
Southern blotting of genomic DNA (5). The number of CTG triplets in the normal­
sized alleles was determined by PCR and DNA sequencing.
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AONs
The design of AONs was primarily based on open secondary structures in hDMPK 
mRNA as predicted by Mfold software (6). PS58 is a synthetic, modified RNA 
molecule with sequence 5'-CAGCAGCAGCAGCAGCAGCAG-3' which carries full- 
length 2'-OMe-substituted ribose molecules and PT internucleotide linkages. All 
AONs used in this study, their chemistry, sequence and position along the hDMPK 
transcript are listed (Figure 2A, and Table S1). All AONs were provided by Prosensa 
B.V.
Oligo transfection
Unless specified otherwise, cells were transfected with AONs complexed with 
polyethyleneimine (PEI; ExGen500, Fermentas, Glen Burnie, MD), according to 
the manufacturer's instructions. Typically, 5 l^ PEI per g^ AON was added in 
differentiation medium to myotubes on day five of myogenesis or in Opti-MEM 
(Invitrogen, Carlsbad, CA) to myoblasts, in both cases at a final oligo concentration 
of 200 nM. Fresh medium was supplemented after four hours. After 24 hours 
medium was changed. RNA was isolated 48 hours after transfection.
RNA isolation
Typically, RNA from cultured cells was isolated using the Aurum Total RNA Mini Kit 
(guanidine-HCl/mercaptoethanol-based lysis, silica membrane binding; Bio-Rad, 
Hercules, CA), according to the manufacturer's protocol. RNA from muscle tissue 
was isolated using TRIzol reagent (Invitrogen). Alternative methods to isolate 
RNA from cultured cells involved: (i) use of the TRIzol reagent, according to the 
manufacturer's protocol; (ii) an oligo(dT) affinity column (NucleoTrap mRNA Mini 
Kit; Macherey-Nagel, Düren, Germany) for the isolation of poly(A) RNA; or (iii) a 
TRIzol procedure preceded by a proteinase K digestion of the whole cell lysate (7): 
in short, cells were lysed in 500 mM NaCl, 10 mM Tris-HCl, pH 7.2, 1.5 mM MgCl2, 
10 mM EDTA, 2% SDS, and 0.5 mg/ml proteinase K for 45 minutes at 45°C. Nucleic 
acids were precipitated with 2.5 volumes ethanol and collected by centrifugation. 
Precipitates were then processed following the standard TRIzol procedure.
Northern blotting
RNA was electrophoresed in a 1.2% agarose-formaldehyde denaturing gel. 
Depending on the source and the isolation procedure, one to fifteen g^ RNA per 
lane was loaded. RNA was transferred to Hybond-XL nylon membrane (Amersham 
Pharmacia Biotech, Little Chalfont, UK) and hybridized with random-primed 
32P-labeled probes (2.6 kb hDMPK cDNA (covering the entire ORF and 3' UTR; i.e., 
the 3' part of exon 1 and all exons 2-15), 1.1 kb rat Gapdh cDNA or 1.1 kb mouse 
Mapkap1 cDNA) or 32P-end-labeled (CAG)9 or mouse skeletal actin-specific (MSA) 
oligos (3). Blots were exposed to X-ray film (Kodak, X-OMAT AR). Quantification of 
signals was done by phospho-imager analysis (GS-505 or Molecular Imager FX, Bio­
Rad) and analyzed with Quantity One (Bio-Rad) or ImageJ software. Gapdh/GAPDH
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or MSA levels were used for normalization. RNA levels for control samples were set 
at 100.
Semi-quantitative RT-PCR analysis
Approximately 0.5 g^ RNA was subjected to cDNA synthesis with random hexamers 
using the SuperScript first-strand synthesis system (Invitrogen) in a total volume of 
20 l^. One l^ of cDNA preparation was subsequently used in a semi-quantitative 
PCR analysis according to standard procedures. In RT control experiments, reverse 
transcriptase was omitted. A repeat-primed RT-PCR assay was developed for the 
hDMPK (CUG)n segment as described (8, 9). PCR primers were designed based on 
NCBI database sequence information (see list of primers below). Product identity 
was confirmed by DNA sequencing. The signal for P-actin was used for normalization. 
Cycle number was 18 for P-actin and 23-31 for other primer sets. The repeat-primed 
RT-PCR in exon 15 was analyzed after 36 cycles. PCR products were analyzed on
1.5-2.5% agarose gels, stained by ethidium bromide. Quantification of signals was 
done using the Labworks 4.0 software (UVP BioImaging systems, Cambridge, United 
Kingdom). Values for control samples were set at 100. Human DMPK mRNA levels in 
DM500 cells and mice were quantified with five independent primer sets covering 
almost the entire transcript.
For analysis of alternative splicing, embryonic (E):adult (A) splice ratio was 
defined as embryonic form signal divided by adult form signal in each sample. Splice 
ratio correction illustrates the effect of PS58 treatment on alternative splicing. Splice 
ratio correction is defined as the mock-treated embryonic:adult splice ratio divided 
by the PS58-treated embryonic:adult splice ratio for a given transcript per mock/ 
PS58-treated muscle pair (i.e., per mouse). Hence, a splice ratio correction of 1.0 
means no change in alternative splicing, while a correction >1.0 implies an increase 
in adult splice forms. In the analysis of HSALR mRNA levels versus splicing correction, 
splice ratio corrections of five transcripts (i.e., Serca1, Mbnl1, Ttn, Clcn1 and Tnnt3) 
were averaged per muscle pair. A total of 27 different muscle samples, originating 
from 20 mice, were included.
The following primers were used: 
hDMPK exon 15-F; 5'- GGGGGATCACAGACCATT-3'; 
hDMPK exon 15-R; 5'-TCAATGCATCCAAAACGTGGA-3'; 
hDMPK exon 12 - exon 15-F; 5'- AAAGAATTCGGGACCTAGAGGCACACGT-3'; 
hDMPK exon 12 - exon 15-R; 5'- AAACTCGAGCGAACAGGAGCAGGGAAA-3'; 
hDMPK exon 7 - exon 9-F; 5'- ACGGCGGAGACCTATGGCAA-3'; 
hDMPK exon 7 - exon 9-R; 5'- TCCCGAAT GT CCGACAGT GT-3'; 
hDMPK exon 1 - exon 7-F; 5'- CGAACTGGCCCAGGACAAGTA-3'; 
hDMPK exon 1 - exon 7-R; 5'- TACACCCAGCGCCCACCAGT-3'; 
hDMPK exon 15 repeat-F; 5'-GGTCCTTGTAGCCGGGAAT-3'; 
hDMPK exon 15 repeat-R; 5'-GCGT CAT GCACAAGAAAGCTTT-3'; 
hDMPK exon 15 repeat-anchored; 
5'-GGTCCTTGTAGCCGGGAATGCTGCTGCTGCTGCTGCT-3';
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P-Actin-F; 5'- GCTAYGAGCTGCCTGACGG-3';
P-Actin-R; 5'- GAGGCCAGGATGGAGCC-3';
Serca1-F; 5'- GCTCATGGTCCTCAAGATCTCAC-3' (10);
Serca1-R; 5'- GGGTCAGTGCCTCAGCTTTG-3' (10);
Mbnl1-F; 5'- GCTGCCCAATACCAGGTCAAC-3' (10);
Mbnl1-R; 5'- TGGTGGGAGAAATGCTGTATGC-3' (10);
Ttn-F; 5'- GTGTGAGTCGCTCCAGAAACG-3' (10);
Ttn-R; 5'- CCACCACAGGACCATGTTATTTC-3' (10);
Clcn1-F; 5'- GGAATACCTCACACTCAAGGCC-3' (11);
Clcn1-R; 5'- CACGGAACACAAAGGCACTGAATGT-3' (11);
Tnnt3-F; 5'- TCTGACGAGGAAACTGAACAAG-3' (11);
Tnnt3-R; 5'- TGTCAATGAGGGCTTGGAG-3' (11);
Ptbp1-F; 5'- TCTGTCCCTAATGTCCATGG-3';
Ptbp1-R; 5'- GCCATCTGCACAAGTGCGT-3';
Sdc3-F; 5'- GCTGTTGCTGCCACCGCT-3';
Sdc3-R; 5'- GGCGCCTCGGGAGTGCTA-3';
Txlnb-F; 5'- CTCAGCCCTGCTGCCTGT-3';
Txlnb-R; 5'- CAGACCCATACGTGCTTATG-3';
Mapkap1-F; 5'- GTCCGACGCAGCCACAGT-3';
Mapkap1-R; 5'- CCTTCTCCCTGATTCAGTATA-3'.
Western blotting
DM1 patient 21/200 myoblasts were transfected with PS58 (200 nM) or mock- 
transfected and 72 hours later lysed in lysis buffer (1x TBS, 1% NP-40, 1 mM PMSF 
and 1x Protease Inhibitory Cocktail (Roche, Almere, The Netherlands) on ice. Cleared 
lysates were separated on an 8% SDS-PAGE gel and transferred to PVDF (Amersham 
Pharmacia Biotech). Blots were incubated with DMPK-specific antibody B79 (12) 
and P-tubulin monoclonal antibody E7 (Developmental Studies Hybridoma Bank, 
University of Iowa, USA), followed by ECL detection. Quantification of signals was 
done using a GS-690 Imaging Densitometer (Bio-Rad) and ImageJ software. Values 
for mock-treated samples were set at 100.
In vivo treatment and muscle isolation
One-year-old DM500 mice were anesthetized using isoflurane. The GPS complex 
was pretreated with PEI-5% glucose injections (0.3 ml insulin syringe with a 30-gauge 
needle) on days one and two to improve uptake of PS58. This pretreatment was 
followed by two injections with 2 nmoles PS58 in a PEI-5% glucose solution at the 
same central position in the GPS muscle on days three and four. In all cases, injection 
volume was 40 l^. Mock-treated mice received exactly the same treatment except 
that oligo PS58 was left out. Mice were sacrificed on day fifteen and individual 
muscles were isolated, snap frozen in liquid nitrogen and stored at -80 °C.
Diverse treatment protocols were tested in HSALR mice. In each case, one 
leg of a HSALR mouse was treated with 1 or 2 nmoles PS58, while the contralateral
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leg served as mock control. (i) HSA]LR mice were injected twice in the GPS complex as 
described above, without PEI pretreatment. Injections took place at days one and 
eight, and tissues were isolated on day twenty-two. Non-injected TA muscle served 
as negative control. (ii) TA muscle was injected once as described above, without 
PEI pretreatment, and muscle tissue was isolated seven days later. (iii) TA muscle 
was injected with or without PEI, followed by electroporation (13) and analyzed on 
day eight or fifteen.
Fluorescent in situ hybridization
DM500 myoblasts or myotubes grown on gelatin- or Matrigel-coated glass cover 
slips were fixed in 4% (w/v) formaldehyde in PBS for 30 minutes at room temperature 
and washed with PBS including 5 mM MgCl2. Cells were prehybridized in 40% (v/v) 
formamide/2x SSC for 30 minutes at room temperature. FAM-labeled and Cy3- 
labeled 2'-OMe PT (CAG)7 probes were used to detect (CUG)n RNA. A fluorescent 
(CUG)7 probe was used as negative control. Samples were incubated o/n in 125 l^ 
probe hybridization buffer (40% (v/v) formamide, 2x SSC, 0.2 mg/ml BSA, 10 mg/ 
ml dextran sulphate, 2 mM vanadyl sulphate, 1 mg/ml herring sperm DNA, 30 ng 
fluorescent oligo) in a humidified chamber at 37°C. Cells were washed three times 
with 40% formamide/2x SSC for 30 minutes at 37°C, followed by a wash with PBS 
at room temperature. Cells were mounted in Mowiol (Sigma-Aldrich, Zwijndrecht, 
NL).
FISH on eight micron HSALR gastrocnemius sections was performed as 
described, except that 0.2 ng/^l Cy3-(CAG)7 probe was present during hybridization 
and sections were mounted in DAPI-containing Mowiol.
For quantification of nuclear foci, sections were stained, imaged at 1600x 
magnification under identical exposure settings and analyzed using uniform threshold 
settings. Images were collected on a Zeiss Axioplan fluorescence microscope (Carl 
Zeiss, Sliedrecht, NL). Pictures were captured by a Zeiss AxioCam MR camera with 
Axiovision 3.1 software. In the case of DM500 myoblasts, around 50 nuclei were 
scored for presence of foci; size and intensity of foci were not considered during 
analysis. In HSALR sections, around 120 nuclei per treatment were classified in three 
groups by two or three examiners blinded to sample identity. To be able to compare 
signal intensities microscope settings were maintained constant.
Immunofluorescence
Frozen eight micron HSALR gastrocnemius sections were air dried and fixed in 3% 
(w/v) formaldehyde in PBS including 5 mM MgCl2, both for 30 minutes at room 
temperature. After washing with PBS for two minutes, sections were permeabilized 
in 2% pre-chilled (-20°C) acetone in PBS for five minutes, washed five times with 
PBS for two minutes, and then incubated in anti-Mbnl1 antibody A2764 (10) at 4°C 
overnight. After washing with PBS, sections were stained with ALEXA 488-coupled 
secondary antibody at room temperature for 30 minutes. Sections were washed 
with PBS and mounted in DAPI-containing Mowiol. Quantification of nuclear Mbnl1
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foci was done as described above for (CUG)n foci.
Intratissue imaging
The distribution of FAM-labeled PS58 was imaged at different time points after 
injection in the GPS complex of DM500 mice. At different time points, mice were 
sacrificed, muscles were dissected and analyzed individually. Intravital images were 
recorded with the Olympus 0V110 whole mouse imaging system (Olympus Corp., 
Tokyo, Japan).
Bioinformatics
BLAST analysis of EST and genome databases was done to identify mouse transcripts 
bearing one or more uninterrupted (CUG)n-tracts (n>6). Nucleotide query sequences 
of 6-50 CTG triplets were used. A list of transcripts bearing long (CUG)n segments in 
the mouse genome is given (Table S2). HomoloGene was used to identify annotated 
genes, design primers for PCR and detect homologs among genes in mouse and 
human genomes. Expression was predicted based on UniGene information.
Statistical analysis
DMPK and HSALR (CUG)250 mRNA signals (Northern blots and RT-PCR) of the 
experimental group and control group were compared using an unpaired Student's 
t-test. Analysis of (CUG)n-positive nuclei in DM500 myoblasts was done with an 
unpaired t-test. Ribonuclear foci in muscle sections were scored independently by 
two or three examiners blinded to sample identities and were compared using a 
Chi-Square test. Alternative splicing of HSALR muscle in vivo were analyzed using a 
paired t-test. Spearman's correlation was applied to evaluate if a correlation exists 
between DMPK mRNA level and number of CUG triplets in PS58-treated human 
myoblasts (Figure 4C), and between splice ratio correction and HSALR (CUG)250 
mRNA levels in PS58-treated muscle (Figure 5E). DMPK protein levels in human 
myoblasts were analyzed using a unpaired t-test. All values are presented as the 
mean ± s.e.m., unless specified otherwise in the legend. Differences between 
groups were considered significant when P<0.05. * P<0.05, ** P<0.01, ***  P<0.001. 
Statistical analyses were performed with GraphPad Prism 4 software.
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Figure S1. Three additional techniques to isolate expanded (CUG)n RNA after silencing by 
PS58. DM500 myotubes were cultured for five days and then mock-treated, treated with 200 
nM  PS58 or with control oligo PS57. RNA was isolated 48 hours after start of transfection 
using (i) TRIzol, (ii) a proteinase K-TRIzol method or (iii) the NucleoTrap mRNA Mini Kit, which 
employs an oligo(dT) affinity column. RNA detection and quantification using Northern 
blotting was done as described in Materials and Methods. For (i) and (ii) a representative 
blot of one of two independent experiments is shown.
53 61 100
72 100
Ptbpl (CUG)6 
Sdc3 (CUG)6 
Txlnb (CUG)9 
Mapkapl (CUG)26 
p-Actin
40 31 48 49 78 100
M apkapl (CUG)26 
p-Actin
lllllll
? ? ? # f  f  i  O O QD ¡V O O ^  H  (Vi rs
hDMPK
m DM PK
hDM PK
A
54
26
B
C
123
Chapter 5
Figure S2. Mouse transcripts bearing short (CUG)n segments are only mildly affected by 
PS58. (A) DM500 myotubes were cultured for five days and transfected with 200 nM PS58, 
control oligo PS113 or mock-treated. Forty-eight hours post-transfection, RNA was isolated 
and semi-quantitative RT-PCR was performed to measure levels of (CUG)n-containing 
transcripts (Table S2). In all RT-PCR analyses, the (CUG)n tract was present in the amplicon 
(tract size verified by sequencing). Numerals indicate relative abundance to mock samples, 
using 6-Actin levels for normalization (mock values set at 100). A representative result 
of two independent experiments is shown. (B) DM500 myotubes were transfected with a 
concentration series of PS58 (0.01-200 nM) or mock-treated. Mapkapl (CUG)26 RNA levels 
were measured via semi-quantitative RT-PCR using 6-Actin levels for normalization (mock 
values set at 100). (C) Independently, Northern blotting using total RNA, a Mapkapl cDNA 
probe and a Gapdh probe for normalization essentially confirmed these findings.
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Figure S3. No effect of PS58 on alternative splicing in wt myotubes. Wt myotubes were 
cultured for five days and transfected with 200 nM  PS58 or mock-treated. Forty-eight hours 
post-transfection, RNA was isolated and RT-PCR was performed to examine alternative splice 
modes of five different transcripts. Quantification of adult (A) and embryonic (E) splice forms 
was done as described in Materials and Methods. Numerals indicate the embryonic (E):adult 
(A) splice ratio in each lane. No significant differences in alternative splicing were observed 
between mock-treated and PS58-treated myotubes (n=4; p=0.76; the results shown here 
illustrate data from one of four experiments). Besides, these data also demonstrate that 
alternative splice modes displayed in fully differentiated skeletal muscle in vivo (10 ) cannot 
be obtained in this in vitro myogenesis cell model.
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Figure S4. Localization and spreading of PS58 oligo after injection in mouse GPS muscle.
(A) On two consecutive days, fluorescently labeled PS58 was injected in the GPS complex of 
DM500 mice. One or 14 days after the second injection, presence of fluorescence in muscle 
tissue was examined using a small-animal imaging system. Oligo was detected in a non- 
homogeneous fashion throughout the gastrocnemius, plantaris andsoleus muscle. In general, 
signal after 14 days was weaker than after one day, suggesting breakdown or clearance of 
the oligo. PS58 could also be detected in the tibialis anterior, but signal was extremely weak. 
Bars are 5 mm (A-H and J-O) and 50 um (I). (B) Fluorescently labeled PS58 was injected on 
two consecutive days in the left GPS complex of DM500 mice. The right complex was mock 
injected. Sixteen days after the second oligo injection, tissue sections of the g Ps  complex and 
tibialis were stained with DAPI and analyzed by fluorescence microscopy. PS58 was found 
concentrated in cell nuclei in the GPS sections. Focal areas of fluorescence in mock-treated 
muscle represent collections of autofluorescent pigment (lipofuscin), as demonstrated by 
fluorescence emission across a broad spectrum of wavelengths. In tibialis sections only 
autofluorescence was detected (not shown). Bars are 30 um. A representative result from  
three independent experiments is shown.
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Figure S5. RT-PCR analysis of silencing of individual hDMPK mRNA segments in DM500 mice 
following PS58 administration. DM500 mice were injected with PS58 or mock injected in the 
GPS complex. Fifteen days after injection, muscles were isolated and processed for RT-PCR 
analysis using primer pairs (arrows) covering five distinct segments of the hDMPK transcript. 
Representative results for gastrocnemius and plantaris are shown on the left. Silencing was 
quantified per segment (arrowheads), using the 6-Actin signal for normalization, setting 
mock levels at 100. Per segment, levels from three injected mice (including three different 
types of muscle: gastrocnemius, plantaris and soleus) were averaged (right column). (See 
also Figure 5A).
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Mock PS58
Figure S6. Localization of Mbnll protein in cell nuclei after PS58 treatment. GPS muscle of 
HSALR mice was injected with PS58 or mock-injected. Gastrocnemius muscle was isolated and 
sections were processed for immunofluorescence using an antibody against Mbnll. Mbnll 
staining was observed in every cell nucleus. Three categories of M bnll localization were 
scored (top panels). PS58-treated muscle showed markedly less nuclei with large foci and 
more nuclei with diffuse M bnll staining, although this distribution did not reach statistical 
significance (n=2, P=0.09, Chi-Square test).
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Figure S7. Correction of aberrant splicing upon silencing of (CUG)250 mRNA by PS58 in 
HSALR mice. TA muscles of four mice were electroporated with PS58 in one leg and mock- 
treated in the contralateral one. After eight days, TA muscles were dissected and RNA was 
isolated. Northern blotting showed that HSA (CUG)250 mRNA levels in PS58-treated muscles 
were 51±7% compared to mock-treated muscles. Quantification of aberrant splicing was 
performed via RT-PCR for five transcripts known to be aberrantly spliced in DM1 (see Figure 
5D). Embryonic splice form levels were significantly lowered for four out of five transcripts 
(n=4).
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SI Tables
Table SI
Oligo Chemistry Sequence ( 5 * - >  3’) Position mRN A/pre-mRN A
PS40 RNA 2‘OMe PT GAGGGGCGUCCAGGGAUCCG Intron 14-exon 15 Prc-mRNA
PS41 RNA 2 'O M c PT CiCGUCCACiGCiAUCCGGACCG Intron 14-exon 15 Pre-mRNA
PS42 RNA 2'OM e PT CAGGGAUCCGGACCGGAUAG Exon 15 Pre-mRNA
PS56 DNA CAÛCAGC AGC AGC AGC AGC AG Repeat in exon 15 mRN A/pre-mRN A
PS57 RNA 2 ’OMe PT CUGCUGCUGCUGCUGCUGCUG n.a. n.a.
PS58 RNA 2’OMe PT CAGCAGC AGC AGC AGC AGC' AG Repeat in exon 15 mRN A/pre-mRN A
PS59 RNA 2 ’OMe PT UG AGUIJGGCCGGC GUGGGCC ESE exon 15 mRN A/pre-mRN A
PS60 RNA 2 ’OMe PT UUCUAGGGUUCAGGGAGCGCGG ESE exon 15 mRN A/pre-mRN A
PS61 RNA 2 ’OMe PT ACUGGAGCUGGGCGGAGACCC ESE exon 15 mRN A/pre-mRN A
PS62 RNA 2 ’OMe PT CUCCCCGGCCGCUAGGGGGC ESE exon 15 mRN A/pre-mRN A
PS113 DNA PT GAGCCGCCTCAGCCGCACCTC Exon 1 mRN A/pre-mRN A
PSI14 DNA PT CiAAGTCGGCCACGTACTTGTC Exon 1 mRN A/pre-mRN A
PS115 DNA PT GGAGTCGAAGACAGTTCTAGG Exon 15 mRN A/pre-mRN A
PS 116 DNA PT GGTAC AC AGG ACTGGAGCTGG Exon 15 mRN A/pre-mRN A
Table S I. Sequences and characteristics of AONs used in this study. All are specific for 
the hDMPK transcript (see Figure 2A for locations). Except PS56, all AONs are modified 
throughout as indicated: 2'OMe = 2'-O-methyl sugar modification; PT = phosphorothioate 
backbone modification. ESE = putative exonic splicing enhancer. n.a. = not applicable.
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Table S2A: Human transcripts containing (CUG)n segments (n>10)
G en e n am e  
(ab b rev ia ted )
G en e n a m e  (fu ll)
C U G
trip let
n o .
R e fs C o m m en ts
C U G  
trip le t n o . 
in  m o u se
T C F4 Transcription Factor 4 2 5 -2 8 14 in intron 2
R PL 14 Ribosomal Protein L I 4 4-22 1 5 ,1 6 ,1 7 - 4
NOTCH4 NO TCH 4 5-13 1 5 ,1 6 ,1 7 - 5
LR P8 L ow  Density Lipoprotein Receptor-related Protein 8 11-12 1 5 ,1 6 - 4
PDCD1 Programmed Cell Death 1 10-11 15, 16 - 3
M A P3K 4 M itogen-Activated Protein Kinase Kinase Kinase 4 10-11 1 5 ,1 8 - 5
PAPSS2 3'-Phosphoadenosine 5-Phosphosulfate Synthase2 8-11 15, 16, 17 - 2
CHRNA3 Cholinergic Receptor, N icotinic, Alpha 3 6-11 15, 16, 17 - 2
BPG M 2,3-Bisphosphoglycerate Mutase 7 -10 15, 16, 17 - 2
BR I3B P Bri3 Binding Protein 9-1 0 17 - 4
L T B P3
Latent Transforming Growth Factor B eta Binding  
Protein 3
10 16 - 3
DM PK M yotonic Dystrophy Protein Kinase 5 -37 16, 17 expanded in DM1 2
SCA8 Spinocerebellar A taxia 8 16-37 16, 19
composite CU A /CU G  
repeat; expanded in 
SCA8
n.d.
JPH3 Junctophilin-3 6 -28 20
expanded in 
Huntington's disease­
like 2  (H D L2)
n.d.
Table S2B: Mouse transcripts containing (CUG)n segments (n>6)
G en e n am e  
(ab b rev ia ted )
G en e n a m e  (fu ll)
C U G
trip let
no.
E x p re ss io n  
in  sk eletal 
m u scle  
(U n ig e n e )
T ested  in R T -P C R  (co m m e n ts )
Mapkapl M itogen-Activated Protein Kinase Associated Protein 1 2 6 -2 9 yes yes
Fgd4 F Y V E , R hoG EF and PH  Domain Containing 4 21 no
no (repeat only in transcript variant 
gam m a)
Hsd3b6
Hydroxy-Delta-5-Steroid Dehydrogenase, 3 B eta- and 
Steroid Delta-Isomerase 6
15-16 +  6 no no
Grebl Gene Regulated by Estrogen in Breast Cancer Protein 9 -17 no no
Pcolce Procollagen C-Endopeptidase Enhancer Protein 1 2 (8  +  5) yes no (repeat starts at fourth nucleotide)
Mllt3 M ixed Lineage-Leukem ia Translocation to 3 Homolog 8-9 yes
no (repeat only in transcript variant 1); 
also large (U A G )i.3(C A G )6-7 repeat
Txlnb Taxilin Beta 9 yes yes
T acci Transforming, A cidic Coiled-Coil Containing Protein 1 8 no no
A rm cx6 Armadillo Repeat Containing, X-linked 6 7 no no
Sdc3 Syndecan 3 6 yes yes
Ptbpl Polypyrimidine Tract Binding Protein 1 6 yes yes
Table S2. (CUG)n-containing transcripts in human and mouse. (A) Summary of human 
transcripts containing long (CUG)n segments (n>10) previously described (14-20). Database 
analysis showed that none of these (CUG)n tracts were actually conserved in mouse (column 
far right). n.d. = not determined. (B) A bioinformatic approach was used to identify mouse 
transcripts with uninterrupted (CUG)n segments. A representative, but not necessarily 
complete, list of long (CUG)n tracts (n>6) in the mouse genome is shown here. Repeat 
polymorphisms are listed. Four transcripts were tested in RT-PCR (far right column).
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ABSTRACT
Myotonic dystrophy type 1 (DM1) is caused by dynamic expansion of a (CTG) 
n repeat in the 3' untranslated region of the DM protein kinase (DMPK) gene. In 
a previous study, we identified PS58, a 2'-O-methyl phosphorothioate-modified 
(CAG)7 antisense oligonucleotide, which has therapeutic potential because it is able 
to reduce toxic effects of RNA transcripts from the expanded gene. This protective 
activity has been observed upon injection of oligo-polyethyleneimine complexes or 
injection-electroporation of naked oligo in skeletal muscle of DM1 mouse models. 
For body-wide muscle delivery, however, these methods of administration are not 
useful. Here, we studied effects of systemic administration by intraperitoneal or 
subcutaneous injection of naked PS58 oligo in a DM1 mouse model that expresses 
expanded transcripts from a mutant human DMPK transgene. We observed that 
after injection PS58 was rapidly cleared from blood and accumulated mainly in liver 
and kidney and to only low level in muscle. Using the current protocols, systemic 
delivery of PS58 did not eliminate expanded DMPK transcripts from muscle tissue, 
presumably because the intracellular threshold concentration for targeting-silencing 
was not reached.
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INTRODUCTION
Myotonic dystrophy type 1 (DM1) is a dominantly inherited neuromuscular disorder 
with a complex, multisystemic pathology (1). DM1 belongs to the group of triplet 
repeat expansion diseases, which also includes fragile X syndrome, Huntington's 
disease and a number of spinocerebellar ataxias (2). The DM1 disease phenotype 
is caused by production of toxic transcripts from the mutant DM protein kinase 
(DMPK) allele, which carries an expanded (CTG)n segment in its final exon (3).
Current treatment for DM1 is limited to supportive care and symptom 
management; no cure is available yet (4). The main focus in the development of 
molecular therapy for DM1 is presently aimed at elimination of the toxic expanded 
(CUG)n RNAs. We recently provided proof of concept of neutralizing these RNAs 
by antisense oligonucleotides (AONs) (5). A fully 2'-O-methyl phosphorothioate- 
modified (CAG)7 oligonucleotide, PS58, complementary to the expansion mutation 
was identified, which was able to specifically reduce expanded DMPK mRNAs in 
DM1 cell and mouse models. With this AON, two hallmarks of DM1-related RNA 
toxicity were alleviated in mice in vivo: nuclear (CUG)n RNA aggregation was reduced 
and DM1-typical aberrant splicing was improved. However, the level of correction 
of aberrant chloride channel 1 splicing that was achieved was only modest and 
inadequate to reverse muscle myotonia. Based on theoretical considerations, this 
limited efficacy could be attributed to insufficient duration of PS58 treatment and/ 
or insignificant oligo concentration inside the muscle myofibers.
For AONs to be clinically effective in DM1, they need to reach a wide variety 
of tissues, and cell types therein, and be successfully delivered into the nuclei of 
these cells. Systemic delivery of related 2'-O-methyl phosphorothioate-modified 
AONs has proven effectiveness in restoring body wide expression of dystrophin in 
a Duchenne muscular dystrophy (DMD) mouse model (6, 7). AON penetration into 
cells with defective dystrophin may differ from the normal situation, however, since 
the membranes of these cells have a leaky character, making uptake more effective. 
Efficient delivery of AONs into tissues of patients or animal models with other types 
of genetic defects, including DM1, may thus pose a bigger challenge for molecular 
therapy. Here, we report on the outcome of a first set of pilot experiments exploring 
systemic delivery of our lead AON PS58 in a mouse model for DM1. Opportunities 
for follow-up studies are being discussed.
MATERIALS AND METHODS 
Antisense oligonucleotide PS58
PS58 was synthesized by Prosensa B.V. PS58 is a synthetic 
5'-CAGCAGCAGCAGCAGCAGCAG-3' oligonucleotide with full-length 2'-O-methyl- 
modified ribose moieties and phosphorothioate internucleotide linkages. 
Purification of PS58 was performed using an anion exchange GE Source 30Q column 
and high salt (NaCl) buffer for elution. The full length product was collected and
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desalted via ultrafiltration. The purity was 85% as measured by HPLC. The main 
impurities are full length oligo minus one and plus one nucleotide.
DM500 mice
Hemizygous DM500 mice, derived from the DM300-328 line (8), express a transgenic 
human DM1 locus which bears a repeat segment that has expanded to 500-600 
triplets. All animal experiments were approved by the Animal Ethics Committee of 
the Radboud University.
Administration of PS58 in mice and tissue isolation
In the first protocol, four female 14-months-old DM500 mice (average weight 43 g) 
were used. PS58 in PBS was administered at a dose of 100 mg/kg by i.p. injection 
(total volume 300 ^l). Control mice received vehicle only. Injections were given daily 
during a period of three days. Mice were killed 24 hours after the third injection.
In the second protocol, eight female or male 8-months-old DM500 mice 
(average weight 38 g) were used. PS58 in 0.9% (w/v) NaCl was administered at a 
dose of 250 mg/kg by s.c. injection (two males, two females). Control mice received 
vehicle only (two males, two females). Injections were given every other day for 
a total of five times. Mice were killed at either 1, 8, 15 or 22 days after the fifth 
injection.
Mice were killed by cervical dislocation and tissue samples (neck muscle, 
gastrocnemius, plantaris, soleus, tibialis, heart, stomach, tongue, liver, kidney and 
brain) were collected and snap frozen in liquid nitrogen and stored at -80°C. In the 
s.c. protocol, plasma samples were taken at the following time points: (i) 24 hours 
before the first injection (calibration sample); (ii) 15 minutes, (iii) 1 hour, (iv) and 
24 hours after the first injection; (vi) just before the final injection; and (vii) during 
tissue isolation.
AON hybridization-ligation assay
PS58 concentration in plasma and tissue samples was determined based on 
a hybridization-ligation assay as published by Yu et al. (9) with the following 
modifications: A template DNA probe (5'-GAATAGACGCTGCTGCTGCTGCTGCTGCTG- 
biotin-3') and a ligation DNA probe (5'-P-CGTCTATTC-DIG-3') were used. Samples 
were incubated with template probe (50 nM) at 37°C for 1 hour, and the hybridized 
samples were transferred to streptavidin-coated plates. Subsequently, the DIG- 
labeled probe (2 nM) was added. Detection was performed with anti-DIG-POD 
(1:4000, Roche Diagnostics). Absorption of 450 nm was measured in a BioTek Synergy 
HT plate reader (Beun de Ronde, Abcoude, the Netherlands). Plasma samples were 
diluted at least 100 times with PBS (Invitrogen) and subsequent dilutions were done 
in control mouse plasma. Tissue samples were homogenized to a concentration of 
60 mg/ml in prot K buffer (100 mM Tris-HCl, pH 8.5, 200 mM NaCl, 5 mM EDTA, 0.2% 
(w/v) SDS) containing 2 mg/ml of proteinase K (Invitrogen), followed by incubation 
for 2-4 hours rotating at 55°C. Samples were centrifuged and the supernatant was
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used in the assay. The absorption of plasma and tissue samples was read against a 
calibration curve of control plasma and tissue in PBS (correction for background).
RNA isolation and RT-PCR analysis
RNA from tissue was isolated following the standard TRIzol procedure (Invitrogen). 
In brief, tissue samples were homogenized in TRIzol (100 mg tissue/ml TRIzol) using a 
power homogenizer (ULTA-TURRAX T-8, IKA labortechnik). Chloroform (Merck) was 
added (0.2 ml per ml TRIzol), mixed, incubated for 3 minutes at room temperature 
and centrifuged at 13,000 rpm for 15 minutes. The upper aqueous phase was 
collected and 0.5 ml isopropanol (Merck) was added per 1 ml TRIzol, followed by a 
10 min incubation period at room temperature and centrifugation (13,000 rpm, 10 
min). The RNA precipitate was washed with 75% (v/v) ethanol (Merck), air dried and 
dissolved in MilliQ.
Semi-quantitative RT-PCR analysis was done following standard procedures 
as described (5). Cycle number was 22 for P-actin and 26-36 for other primer sets.
RESULTS AND DISCUSSION 
Systemic delivery via intraperitoneal injections
We used the DM500 mouse model for examining PS58 activity in a systemic 
treatment approach. DM500 mice belong to the transgenic DM300-328 lineage (8), 
from which descendants carrying a human DMPK (hDMPK) gene with a (CTG)500 
repeat were derived by successive rounds of breeding. The level of expression of 
hDMPK transcripts with a (CUG)500 repeat in DM500 mice is globally rather low, 
with a tissue distribution that is overtly similar to that of endogenous mouse DMPK 
(mDMPK) transcripts (data not shown; G. Gourdon, personal communication).
Two DM500 mice received an intraperitoneal (i.p.) dose of 100 mg PS58/kg 
and two other DM500 mice were treated with vehicle only, on three consecutive 
days (Figure 1A). Tissues were collected one day after the final injection. The choice 
of tissues used for oligo effect analyses was based on the DM1 phenotype (10), 
the DMPK expression profile (11, 12) and previous observations with intramuscular 
PS58 injections (5). Brain tissue was included to reveal if PS58 is able to cross the 
blood-brain barrier (13). RT-PCR analysis using RNA from these collected tissues 
revealed no change in hDMPK (CUG)500 transcript expression (Figure 1B and C).
Figure 1. Intraperitoneal treatment of DM500 mice with PS58. (A) Two DM500 mice 
were treated three times with an i.p. 100 mg/kg PS58 dose and sacrificed the next day as 
indicated in the scheme. Control DM500 mice were treated with vehicle only, following the 
same injection scheme. (B, C) Semiquantitative RT-PCR analysis of five separate segments 
of the hDMPK transcript (primers indicated with black arrows) demonstrated no change 
in expanded RNA level in any of the tissues examined. Numerals in lanes indicate relative 
abundance to the mock sample of the same tissue (set at 100) using 6-actin for normalization 
(bottom panel). The results of the individual segments are summed and averaged in C. >>
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Systemic delivery via subcutaneous treatment
In a second approach, four DM500 mice were injected subcutaneously (s.c.) in the 
neck region with 250 mg PS58/kg and four others were treated with vehicle every 
other day for a total of five times (Figure 2A). In this protocol, also blood samples 
were taken at different time points during the treatment to be able to examine 
AON levels in plasma. Whole tissues were isolated at different time points after 
the final injection. RT-PCR analysis revealed no silencing of hDMPK mRNA for any 
of the tissues, including stomach, tongue, heart and GPS, analyzed for the day-10 
time point (Figure 2B). Similarly, during the entire 31-day period of monitoring also 
no reduction of hDMPK mRNA was seen for soleus, one of the muscle types that 
appeared most sensitive to intramuscular PS58 treatment, (5) and data not shown) 
or the neck muscle, the tissue closest to the site of injection (Figure 2C-E). We have 
no clear explanation for the increase in hDMPK (CUG)500 RNA level in soleus at day 
10.
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Figure 2. Subcutaneous treatment of DM500 mice with PS58. (A) Four DM500 mice were 
treated five times with a s.c. 250 mg/kg PS58 dose injected in the neck region. Vehicle- 
treated mice were used as control group. Mice were sacrificed at days 10, 17, 24, or 31 
as indicated in the scheme. Plasma samples were taken to measure oligo levels in blood 
(asterisks). (B) Semiquantitative RT-PCR analysis of five separate segments of the hDMPK 
transcript (see E) demonstrated no change in expanded RNA levels in stomach, tongue, heart 
and gastrocnemius at the day-10 time point. Similarly, no reduction of hDMPK mRNA was 
found during the entire 31-day period in (C) soleus and (D) neck muscle. (E) RT-PCR results of 
individual DMPK RNA segments in neck muscle (primers indicated with black arrows; data 
averaged in D). Numerals in lanes indicate relative abundance to the mock sample of the 
same tissue (set at 100), using 6-actin for normalization (bottom panel).
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To study the biodistribution of the injected AON a quantitative hybridization 
assay was applied, which allowed quantification of AON levels in plasma and in 
tissue, albeit without discrimination between intracellular and circulating molecules. 
PS58 levels in plasma remained very high up to at least one hour after s.c. injection, 
but had dropped already dramatically twenty-four hours later (Figure 3).
Figure 3. PS58 concentration 
in blood after subcutaneous 
treatment. Plasma samples were 
taken 15 and 60 minutes after the 
first PS58 injection (day 1; n=4), 1 day 
after the first injection (day 2; n=4), 
just before the final injection (day 9; 
n=4) and during tissue isolation (day
10, 17, 24 and 31; each n=1). PS58 
level in blood was high immediately 
after the s.c. injection, but dropped 
dramatically to a low level at 24 
hours and gradually decreased 
further.
day 1
From that point on, PS58 concentration gradually decreased until becoming 
virtually undetectable at three to four weeks after injection. In tissues other than 
blood, the highest levels of PS58 were observed in kidney and liver (~200 ^g/g), 
which were 10-50-fold higher than in the GPS (gastrocnemius-plantaris-soleus) 
complex or tibialis anterior (TA) muscle (~10 ^g/g) (Figure 4). In all tissues PS58 
levels decreased only very slowly over the 31-days period, demonstrating a slow 
clearance rate of the oligo. In any case, for GPS and TA the PS58 concentration was 
clearly insufficient to induce silencing of hDMPK (CUG)500 transcripts.
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Figure 4. PS58 concentration in 
various tissues after subcutaneous 
treatment. Tissues were isolated 
at days 10, 17, 24 and 31 from  
DM500 mice treated according to 
the s.c. protocol (see Figure 2A) and 
PS58 concentrations determined. 
Note that the highest level of PS58 
occurred in kidney and liver and 
that levels in the GPS complex and 
tibialis anterior were approximately 
10-50-fold lower.
1
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Concluding remarks
We explored the potential of naked PS58 oligo to induce silencing of toxic (CUG)500 
transcripts upon systemic delivery. Oligonucleotides containing a phosphorothioate 
backbone, like PS58, are known to bind highly effectively to plasma proteins and 
transfer rapidly from blood to tissue with the highest accumulation observed in 
kidney, liver and spleen (14). We determined AON concentration after s.c. injection 
and found that also PS58 accumulated mainly in kidney and liver, after it was rapidly 
cleared from the blood.
It should be noted that the ELISA method used for quantification of oligo 
concentration could not discriminate between PS58 inside the cell and oligo 
present in blood or extracellular fluid. Whether the AON biodistribution pattern 
differs between i.p. and s.c. injections remains to be investigated, but no change 
in hDMPK (CUG)500 mRNA level was observed after either administration method 
in any of the muscle types analyzed. In the GPS complex an average concentration 
of 10 g^ PS58/g tissue, corresponding to an oligo concentration of around 1.5 
^M, remained present over a prolonged period of several weeks (note that the 
local AON concentration can be even higher so this oligo concentration probably 
represents an underestimation). Such a PS58 concentration, when used in culture 
medium in the presence of polyethyleneimine as complexing reagent, causes robust 
uptake and silencing of hDMPK transcripts in cultured muscle cells in vitro (5). We 
must therefore conclude that introduction of naked PS58 in cells in tissues in vivo 
is a rather inefficient process and that adaptation of current protocols is urgently 
needed to achieve accumulation of PS58 to therapeutically relevant concentrations 
inside muscle cells.
Heemskerk et al. investigated pharmacokinetic and pharmacodynamic 
properties of a 2'-O-methyl phosphorothioate exon-skipping AON in m dx  mice 
(15). Although a different administration protocol was used in this study, a similar 
quantitative hybridization assay showed that AON accumulated up to ten times 
more in liver and kidney than in skeletal muscle, which is in accordance with our 
data in DM500 mice. However, compared to our 250 mg/kg s.c. injection protocol, 
their 250 mg/kg s.c. administration protocol (five injections during one week) 
resulted in three to five times higher AON levels in skeletal muscle of m dx mice. This 
difference in AON level probably reflects a difference in membrane permeability 
and oligo uptake, which may be higher in m dx  mice due to the increased myogenic 
regeneration process in these animals (16) or due to abnormal structural 
composition of the m dx cell membrane. Aberrant muscle physiology has also been 
described for DM500 mice (17), but whether this has any effect on or relationship 
with membrane permeability of muscle cells is currently not known.
PS58 will thus only become a successful therapeutic compound for DM when 
combined with sophisticated technology for targeted delivery to cells and tissues, like 
conjugation to cell-penetrating peptides, lipophilic conjugates or use of nanocarriers 
(18). Preliminary results obtained with a peptide-conjugated version of PS58 in 
DM1 cell and animal models without the use of transfection reagent suggest that
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peptide-PS58 is able to silence expanded hDMPK transcripts for ~90% in vitro and 
~50% in skeletal muscle in vivo using a local intramuscular injection protocol (data 
not shown). More extensive pharmacokinetic and pharmacodynamic studies with 
this type of AON modifications are required to improve our experimental design, 
with optimization of the actual AON dose, route of administration, promotion of 
muscle-specific uptake and better control of the half-life of potential DM1 AONs.
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ABSTRACT
Aberrant sequestration or upregulation of splice and transcription factors due to 
expression of mutant DMPK mRNA with an expanded (CUG)n repeat has been 
implicated in myotonic dystrophy type 1 (DM1). Antisense-oligonucleotide (AON) 
mediated suppression of toxic DMPK transcripts is therefore considered a potential 
therapeutic strategy for this frequent trinucleotide repeat disorder. The (CUG)n 
tract itself forms an obvious target, being the only known polymorphism between 
mutant and normal-sized transcripts. A 2'-O-methyl phosphorothioate-modified 
(CAG)7 antisense oligo, capable of silencing mutant transcripts in DM1 cell and 
animal models, was used as lead compound in a broad screen for novel effective 
AONs directed against the triplet repeat. Study of effects of newly identified AONs in 
a cell model that produces mutant DMPK-(CUG)500 transcripts revealed that oligo 
length and nucleotide chemistry are important determinants for high knockdown 
efficacy. A minimal length of five triplets was required and 2'-O,4'-C-ethylene- 
bridged-nucleic-acid-modified AONs appeared not effective. A subset of AONs was 
tested in patient myoblasts and demonstrated significant (CUG)n-length dependent 
activity, leaving normal-sized transcripts only mildly affected. Our collection of 
potent oligos forms an important resource basis and amplifies opportunities for 
development of safe antisense therapy for DM1, and potentially other triplet repeat 
diseases.
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INTRODUCTION
Myotonic dystrophy type 1 (DM1) is an autosomal dominant, trinucleotide repeat 
expansion disease and the most common form of adult-onset muscular dystrophy 
(1-3). The multisystemic symptoms are highly variable and involve different tissues 
and organs, including skeletal muscle, heart, brain, eyes, reproductive systems and 
the gastrointestinal tract. No cure to slow or stop the disease process is currently 
available.
The genetic cause of DM1 is an unstable (CTG)n expansion in the 3' 
untranslated region of the DM protein kinase (DMPK) gene. Length of this (CTG)n 
segment is correlated with age of onset and severity of disease (1, 4). In the healthy 
population, the CTG repeat number ranges from 5 to 37 (mostly below 15 (5, 6)), 
whereas disease alleles may contain between 50 and >2000 triplets (1, 4). The 
pathogenic mechanism of DM1 involves an RNA gain-of-function. Repeat-containing 
transcripts from the expanded allele accumulate in cell nuclei and alter the function 
of at least two RNA-binding proteins, muscleblind (MBNL) and CUG Binding Protein 
1 (CUGBP1) (2). In adult DM1 tissue, these antagonistic regulators of splicing cause 
misregulation of events in which embryonic patterns of splicing occur. For example, 
myotonia and insulin resistance, two key features of DM1, may be caused by altered 
splicing of muscle chloride channel and insulin receptor transcripts, respectively (2).
Recent results obtained with mouse models that inducibly express (CUG)n 
RNA show that features of RNA toxicity are reversible (7, 8), strongly suggesting that 
reducing the level of expanded DMPK transcripts will be beneficial to patients. In 
the past decade, antisense strategies have been developed to eliminate expanded 
DMPK transcripts via antisense RNA expression (9), ribozyme activity (10), oligo- 
mediated RNase-H activity (10) or application of RNA interference (RNAi) technology 
(11). Reduction of DMPK transcript levels was achieved by several of these methods, 
but selectivity between toxic and normal-sized transcripts was generally low. To be 
functional and safe for therapeutic use in DM1 patients, an antisense approach 
should ideally silence transcripts from the expanded allele but leave normal-sized 
DMPK transcripts or unrelated transcripts with a (CUG)n segment intact. Since 
length of the (CUG)n repeat segment is the only known polymorphic difference 
between mutant and normal transcripts, the repeat tract itself forms an attractive 
therapeutic target.
Use of PS58, an antisense oligonucleotide (AON) directed against the (CUG) 
n repeat, was recently published (12). PS58 is a (CAG)7 fully 2'-O-methyl (2'-OMe) 
phosphorothioate (PT) modified AON, which silences expanded (CUG)n transcripts 
in DM1 cell and animal models. Here, we report on identification of novel AONs and 
on analysis of specific biochemical properties that these AONs require for effective 
knockdown of expanded DMPK via (CUG)n triplet-repeat directed strategies. Triplet 
repeat AONs were tested in a broad, unbiased screen with use of a DM1 cell model. 
Effective AONs of different sequence, base-pairing abilities, length and chemistries 
were identified. We propose that this collection of triplet repeat AONs must be
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further studied in parallel, to fully exploit the potential of this antisense approach 
and bring DM1 therapy closer to reality.
MATERIALS AND METHODS 
Cell culture
Immortalized DM500 myoblasts were derived from DM300-328 mice (13) and 
cultured and differentiated to myotubes as described (12). Human DM1 myoblast 
lines were derived and cultured as described (14).
Oligonucleotides
AONs and siRNAs were complementary to the (CUG)n repeat. Their chemistry and 
sequence are listed in Table 1. PS304 was purchased from Gene Tools (Philomath, 
OR) (15). All other AONs and siRNAs were provided by Prosensa B.V. (Leiden, The 
Netherlands).
Transfection
AONs were transfected with polyethyleneimine (ExGen 500, Fermentas, Glen Burnie, 
MD), according to manufacturer's instructions. Typically, 5 l^ PEI per g^ AON was 
added in differentiation medium to myotubes on day five of myogenesis or in Opti- 
MEM (Invitrogen, Carlsbad, CA) to myoblasts, at a final AON concentration of 200 
nM. For concentration response experiments, oligo concentrations between 0.01 
nM and 500 nM were applied. Fresh medium was supplemented to a maximum 
volume of 2 ml after four hours. After 24 hours medium was changed. RNA was 
isolated 48 hours after transfection.
PS304 was tested following the protocol above with the exception that no 
transfection reagent was used.
SiRNAs were administered twice using a Lipofectamine 2000-based 
transfection protocol (Invitrogen, Carlsbad, CA), on day four and on day five of 
myogenesis, at a final concentration of 50 nM siRNA according to manufacturer's 
instructions. Four hours after each transfection and 24 hours after the second 
transfection medium was changed. RNA was isolated 48 hours after the second 
transfection.
RNA isolation
RNA was isolated using the Aurum Total RNA Mini Kit (Bio-Rad, Hercules, CA), 
according to manufacturer's protocol.
Northern blotting
Northern blotting was done as described (12). Random-primed 32P-labelled hDMPK 
(2.6 kb) and rat Gapdh (1.1 kb) probes were used. Signals were quantified by 
phospho-imager analysis (GS-505 or Molecular Imager FX, Bio-Rad) and analyzed 
with Quantity One (Bio-Rad) or ImageJ software. Gapdh levels were used for
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normalization; RNA levels of control samples were set at 100.
RT-PCR analysis
Approximately 0.5 g^ RNA was subjected to cDNA synthesis using the SuperScript 
first-strand synthesis system with random hexamer primers (Invitrogen) in a 
total volume of 20 l^. One l^ of cDNA preparation was subsequently used in a 
semi-quantitative PCR analysis according to standard procedures. In RT control 
experiments, reverse transcriptase was omitted. PCR primers were designed based 
on NCBI database sequence information. The repeat tract was always present 
in the amplicon. Product identity and repeat tract size were confirmed by DNA 
sequencing. The signal for P-actin was used for normalization. Cycle number was 
18 for P-actin and 22-31 for other primer sets. PCR products were analyzed on
1.5-2.5% agarose gels stained by ethidium bromide. Quantification of signals was 
done using Labworks 4.0 software (UVP BioImaging Systems, Cambridge, United 
Kingdom). Values for control samples were set at 100. Primers were as follows (5' 
-> 3'): Sec24b-F, CCCAGCACAGCTCTTACCT; Sec24b-R, TGGATACTACGGAGCTTGACT; 
Nr3c1-F, T GATTTTT CAAAAGGCTCAGCA; Nr3c1-R, AACT CACAT CTGGTCT CATT C; 
Hcn1-F, GTTGCTATTGACCGACTCGAT; Hcn1-R, GTGTGGAGCTACCAGGTGT or as 
described earlier (12).
Live cell imaging
DM500 myoblasts were cultured on gelatin-coated glass-bottomed Willco dishes 
(Willco Wells, Amsterdam, The Netherlands). Cells were transfected with FAM- 
PS58 or Cy3-PS138 as described above and analyzed directly after addition of the 
transfection mix in RPMI medium without phenol red (Invitrogen) containing 10 mM 
HEPES and 10% FCS. A Zeiss LSM510meta confocal laser-scanning microscope was 
used, equipped with a temperature controlled CO2 incubator (type S) and sample 
stage. For recording of oligo uptake, we used a PlanApochromatic 63x, 1.4 NA oil 
immersion DIC lens (Carl Zeiss GmbH, Jena, Germany).
Statistical analysis
Northern blot and RT-PCR signals were analyzed using an unpaired Student's t test 
or a one-sample t test (hypothetical value 100). All values in graphs are presented 
as the mean ± SEM. Pearson's correlation was applied to evaluate whether 
a correlation exists between silencing efficacy and number of CTG triplets in 
DMPK alleles in human myoblasts. Differences between groups were considered 
significant when P<0.05: *, P<0.05; ** , P<0.01; *** , P<0.001. Statistical analyses 
and sigmoidal concentration curve fitting were performed with GraphPad Prism 4 
software (GraphPad Software, Inc., La Jolla, USA).
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RESULTS
A series of triplet repeat AONs that differed in length, chemistry and nucleotide 
composition was designed and analyzed for their potency to silence expanded DMPK 
transcripts (Table 1). AONs were tested via transfection in the DM500 myoblast- 
myotube cell model (12). DM500 myoblasts and myotubes express transgenic 
human DMPK (hDMPK) transcripts bearing a (CUG)500 repeat at levels comparable 
to that of endogenous mouse DMPK (mDMPK) transcripts. It is important to note 
that mDMPK transcripts contain a CCG(CUG)2(CAG)2CUG sequence instead of the 
uninterrupted (CUG)n segment found in humans. Quantification of AON silencing 
efficacy was done by Northern blotting rather than Q-RT-PCR to reliably identify 
minor changes in RNA level (e.g., within the 1.5-3 fold range) and to be able to 
identify any stable breakdown products (Figure 1A).
Table 1. Antisense oligonucleotide sequences and characteristics
Name a Sequence Chemistrya Sequence with chemical modifications 5' ->  3 'a
PS56 (CAG)7 DNA CAGCAGCAGCAGCAGCAGCAG
PS 142 (CAG)7 DNA PT C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G
PS260 (CAG)7 RNA 2'-OMe PT/DNA PT C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G
PS139 b (CAG)3 ENA CAGCAGCAG
PS138 b (CAG)4 ENA CAGCAGCAGCAG
PS 137 (CAG)5 ENA/RNA 2'-OMe CAGCAGCAGCAGCAG
PS 136 (CAG)7 ENA/RNA 2'-OMe CAGCAGCAGCAGCAGCAGCAG
PS 135 (CAG)10 ENA/RNA 2'-OMe CAGCAGCAGCAGCAGCAGCAGCAGCAGCAG
PS304 c (CAG)8 PMO cagcagcagcagcagcagcagcag
PS251 (CAG)4 RNA 2'-OMe PT C*A*G*C*A*G*C*A*G*C*A*G
PS 147 (CAG)5 RNA 2'-OMe PT C*A*G*C*A*G*C*A*G*C*A*G*C*A*G
PS253 (CAG)6 RNA 2'-OMe PT C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G
PS58 (CAG)7 RNA 2'-OMe PT C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G
PS255 (CAG)8 RNA 2'-OMe PT C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G
PS256 (CAG)9 R N A 2-O M e PT C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G
PS 146 (CAG)10 RNA 2'-OMe PT C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G
PS258 (CAG)13 RNA 2'-OMe PT C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G
PS259 (AGC)7 RNA 2-O M e PT A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C*A*G*C
PS261 (CIG)7 RNA 2'-OMe PT C *I*G *C *I*G *C TG *C TG *C TG *C *I*G *C *I*G
PI-01 (CAG)7 DNA/RNA CAGCAGCAGCAGCAGCAGCAG
UCGUCGUCGUCGUCGUCGUCG
PI-02 (GCA)7 DNA/RNA GCAGCAGCAGCAGCAGCAGCA
G UCG UCG UCG UCG UCG UCG UC
Table 1. Antisense oligonucleotide sequences and characteristics. DNA (capital); RNA 
(capital, underlined); PT, phosphorothioate modification (*); 2'-OMe, 2'-O-methyl sugar 
modification (capital, underlined, bold); ENA, 2'-O,4'-C-ethylene-bridged nucleic acid (capital, 
italics); PMO, morpholino phosphorodiamidate (lower case); b, Cy3-labeled;c, coupled to 
octaguanidine dendrimer (Vivo-Porter).
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DNA (CAG)n AONs supporting RNase-H mediated cleavage
DNA oligonucleotides allow specific and efficient RNase-H mediated cleavage 
of RNA in a DNA-RNA heteroduplex. Several chemical modifications have been 
developed that improve metabolic AON stability, while maintaining hybridization to 
target RNA and ability to recruit RNase H (16). We tested three RNase-H dependent 
(CAG)7 AONs in DM500 myotubes (Table 1): (i) PS56, a pure DNA AON; (ii) PS142, 
a PT-modified DNA AON; and (iii) PS260, a PT-modified chimeric AON, so-called 
"gapmer", comprised of 2'-OMe 5' and 3' wings on either side of a DNA gap. DNA 
oligo PS56 did not show any silencing activity (Figure 1B). In contrast, PS142 and 
PS260, both stabilized against nuclease breakdown, were able to silence hDMPK 
(CUG)500 mRNA for ~53% and ~81%, respectively (Figure 1A-B). Endogenous 
mDMPK mRNA was left intact. A concentration response analysis yielded an IC50 of
0.3 ± 0.4 ^M for DNA/PT oligo PS142, which is about 1000-fold lower than that of 
lead compound PS58 (Figure 1C and supporting information Figure S1A).
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Figure 1. A collection of triplet repeat AONs tested for their ability to silence expanded 
hDMPK mRNA in DM500 myotubes. (A) Examples of typical signals from different Northern 
blots containing RNA isolated from DM500 myotubes probed with a DMPK and a Gapdh 
probe. Treatment with three AONs or mock-treatment is shown. (B) Summary of silencing 
efficiency. AONs are grouped according to their main chemical modification (see Table 
1). The means of at least three independent experiments for each AON are shown. (C) 
Concentration-response curves for a selection of AONs. DM500 myotubes were treated with 
a concentration series of 0.01-500 nM  (see supporting information Figure S1).
2'-O,4'-C-ethylene-bridged-nucleic-acid modified (CAG)n AONs
The bicyclic modification in 2'-O,4'-C-ethylene-bridged nucleic acid (ENA) confers a 
strong nuclease resistance, but above all a high binding affinity to complementary 
single stranded RNA (ATm/modification = 5.5oC versus 1.3oC for 2'-OMe) (17-19). 
We tested two fully ENA-modified AONs and three ENA/2'-OMe gapmers with a 
(CAG)n length of three, four, five, seven and ten, respectively (PS139-135, Table
1) in DM500 myotubes. Remarkably, none of the ENA AONs substantially reduced 
hDMPK mRNA levels (Figure 1A-B). PS136 gave a statistically significant reduction, 
but this effect was only minor (~30%).
The discrepancy in efficacy between ENA-modified and 2'-OMe/PT-modified 
(e.g., PS58) AONs might be caused by differences in subcellular targeting. To verify 
this possibility, we followed cellular uptake and routing of two fluorescently labelled 
AONs with these modifications in DM500 myoblasts. DM500 myoblasts have a 
rather flat morphology, which makes them perfectly suitable for live cell imaging 
(Figure S2). Forty minutes after transfection, fluorescent PS58 oligo concentrated in 
the cell nucleus and signal intensity further increased up to 60 minutes. In contrast, 
Cy3-PS138 was found in vesicle-like structures surrounding the cell nucleus, not in 
the nucleus itself (Figure S2). This pattern remained unchanged up to 48 hours after 
transfection (data not shown). We conclude that ENA modified (CAG)n AONs tested 
in this study probably never enter nuclei of muscle cells under the conditions used. 
Hence the location of the expanded RNA target is never reached.
Morpholino phosphorodiamidate (CAG)n AONs
Morpholino phosphorodiamidate oligos are uncharged AONs widely used as 
blocking oligos for selective inhibition of gene expression (20). A (CAG)8 morpholino 
(PS304, Table 1) was tested for its ability to silence expanded hDMPK RNA in DM500 
myotubes. The morpholino was coupled to an octaguanidine dendrimer (so-called 
Vivo-Porter) to facilitate cellular uptake (15). PS304 treatment caused a ~70% 
reduction of (CUG)500 transcripts and left mDMPK mRNA intact (Figure 1B).
Triplet repeat siRNAs
Krol et al. reported that (CXG)n triplet repeat hairpins are substrates for Dicer and 
produce short repeat RNAs that in turn may act as siRNAs against complementary 
repeats (21). We investigated whether we could silence expanded DMPK mRNA 
by the use of synthetic triplet repeat siRNAs. Two different siRNAs -  PI-01 (CAG)7
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and PI-02 (GCA)7 (Table 1) -  were transfected in DM500 myotubes. None of the 
two siRNAs silenced DMPK mRNA expression (Figure 2). Instead, we observed a 
moderate to strong increase in hDMPK (CUG)500 transcript level, suggestive of 
some unknown mRNA stabilization effect. Mouse DMPK transcripts remained 
unchanged or were also moderately increased.
N N
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mDMPK
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ct
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Figure 2. Targeting of hDMPK (CUG)500 
transcripts with triplet repeat siRNAs.
DM500 myotubes were transfected twice 
with siRNAs PI-01 (CAG)7 or PI-02 (GCA)7. 
Northern blot analysis revealed a significant 
increase of DMPK RNA, in particular expanded 
transcripts. PS58 served as a positive control. 
One representative blot of two independent 
experiments is shown. Data are summarized 
in the graph at the bottom.
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Oligo-length and base variations of 2'-O-methyl AONs
To investigate oligo length as a potential parameter in the performance of PS58- 
type oligos, we tested a series of 2'-OMe-modified (CAG)n AONs consisting of 
four to thirteen triplets (Table 1). All, except PS251 (CAG)4, silenced (CUG)500 
transcripts with great efficiency and selectivity in DM500 myotubes (Figure 1A-B). A 
(CUG)7 sense oligo or oligos directed against other target sequences in the hDMPK 
transcript did not have any effect (data not shown) (12). The lack of activity of the 
(CAG)4 AON is best explained by assuming that a minimum oligo length is necessary 
for effective hybridization to the (CUG)n target. We determined an IC50 of 5.5 ± 2.1 
nM for PS147 (CAG)5 and 5.9 ± 2.2 nM for PS146 (CAG)10 (Figure 1C and supporting 
information Figure S1B-C) Thus, both oligos have a tenfold lower efficacy than PS58 
(CAG)7.
We wondered whether the nature of nucleotide residues at the 5' and 3' 
ends of the AON is crucial for silencing and tested a repeat-shifted version, i.e., a 
2'-OMe-modified (AGC)7 AON (PS259, Table 1). Similar to PS58, PS259 treatment
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resulted in a significant reduction of ~90% of (CUG)500 transcripts without silencing 
mDMPK mRNA (Figure 1B).
Finally, a 2'-OMe-modified (CIG)7 AON was tested (PS261, Table 1). Thanks 
to the presence of inosine residues, PS261 should be able to hybridize to (CUG)n, 
(CAG)n, (CCG)n repeats and any combination of these triplets. Similar to PS58, PS261 
induced a ~90% reduction of expanded mRNA (Figure 1B). Notably, endogenous 
mDMPK mRNA was also significantly reduced, albeit with only ~37% efficiency. This 
effect may be best explained by binding of (CIG)7 to the (CHG)6 repeat in mDMPK 
mRNA.
Transcripts with a small (CUG)n or (CAG)n segment
(CUG)n-bearing transcripts, other than from the DMPK gene, potentially also serve 
as targets for (CAG)n AON silencing. In the mouse transcriptome, at least nine 
transcripts contain a (CUG)n segment of more than six triplets (12). We investigated 
whether 2'-OMe AONs of variable size (i.e., (CAG)5, (CAG)7 and (CAG)10) acted 
differently on a subset of these transcripts, which were chosen for their expression 
in skeletal muscle. RT-PCR quantification of three candidates -  Ptbp1 (CUG)6, 
Sdc3 (CUG)6 and Txlnb (CUG)9 -  showed no significant changes in expression 
after oligo treatment (Figure 3A). In contrast, Mapkap1 (CUG)26 transcripts were 
significantly silenced by all three AONs (~40-95% reduction); the longest (CAG)10 
AON demonstrating the most pronounced effect (Figure 3A).
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PS58 (CAG)7 
PS146 (CAG)10
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Figure 3. Effects on transcripts 
with small (CUG)n of (CAG)n 
repeats. DM500 myotubes were 
treated with (CAG)5, (CAG)7 or 
(CAG)10 2'-OMe/PT AONs. RT-PCR 
analysis was performed to measure 
concentrations of different gene 
transcripts with small (CUG)n- or 
(CAG)n-tracts. Beta-actin signal was 
used for normalization. (A) Four 
(CUG)n-containing transcripts were 
tested. A significant reduction of 
only Mapkap1 levels was observed 
(n=3), with the (CAG)10 AON 
having the strongest effect. (B) 
Three (CAG)n-containing transcripts 
were selected. None of them was 
targeted as a result of (CAG)n AON 
transfection (n=3).
0
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To exclude the possibility that oligo-mediated breakdown would generate 
short (CUG)n RNAs that might act as siRNAs on complementary (CAG)n transcripts 
(compare (21)), we measured levels of transcripts with a small (CAG)n segment,
i.e., Sec24b (CAG)15, Nr3c1 (CAG)17 and Hcnl (CAG)7 + (CAG)20. After treatment 
with PS147, PS58 and PS146 no significant change in expression of any of these 
transcripts was detectable (Figure 3B).
(CUG)n length selectivity in DM1 patient myoblasts
A safe, antisense strategy for DM1 needs to differentiate between expanded 
and normal-sized DMPK transcripts. To test this requirement, we used two DM1 
myoblast lines: one expressing DMPK transcripts with 21 (normal) and 200 (mutant) 
triplets (abbreviated 21/200), the other 5 and 1400 CUG-triplets (5/1400) (14). The 
activities of 2'-OMe AONs with five, seven or ten CAG triplets (PS147, PS58, PS146, 
respectively) and (CAG)7 gapmer PS260 were examined in myoblast cultures.
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Figure 4. (CUG)n length selectivity in 
DM1 myoblasts. (A) Human myoblast 
lines expressing 21/200 or 5/1400 DMPK 
transcripts were treated with PS147 
(CAG)5, PS58 (CAG)7 or PS146 (CAG)10 
2'-oMe/PT AONs, or with gapmer PS260 
(CAG)7. Northern blot analysis indicated 
that expanded DMPK transcripts ('exp', 
arrow heads) were efficiently silenced 
by all AONs. Also (CUG)21 transcripts 
('normal', double arrow head) were 
moderately silenced. Only RNase-H 
recruiting PS260 substantially degraded 
(CUG)5 transcripts ('normal', double 
arrow head). One representative blot of 
three independent experiments is shown 
for each cell line. All data are summarized 
in the graphs at the bottom. (B) A 
significant correlation was demonstrated 
between the number of CTG triplets and 
silencing activity of PS147, PS58 and 
PS146 (P<0.05, Pearson's correlation, r = 
-0,98), but not PS260.
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The three pure 2'-OMe AONs behaved more or less similar: levels of (CUG)1400 
and (CUG)200 mutant transcripts were strongly decreased, with efficiencies of 
90-95% and 65-80%, respectively; (CUG)21 transcripts appeared somewhat less 
susceptible to breakdown (45-55%); and, as expected, (CUG)5 DMPK mRNA was 
left intact (Figure 4A). Silencing efficacy significantly correlated with the number of 
CUG triplets in DMPK transcripts (Figure 4B). RNase-H recruiting AON PS260 did not 
show (CUG)n-length dependent activity (Figure 4A-B). It not only silenced expanded 
transcripts, but also had a noticeably strong effect on normal-sized DMPK RNA, 
especially (CUG)5 transcripts (60-65% reduction).
DISCUSSION
This study demonstrates that a wide range of triplet repeat AONs is capable of 
silencing RNA transcripts with long (CUG)n repeat segments. A long (CUG)n segment 
is a special RNA sequence, since it can form a relatively stable stem-loop structure 
(22) containing an antiparallel double-stranded helix (23), despite the periodic U^U 
mismatches. From our results, we conclude that this stable hairpin structure, which 
sequesters MBNL1 protein, does not hamper accessibility of most antisense triplet 
repeat AONs used in this study.
Chemical modifications of (deoxy)ribose ring and phosphate backbone of an 
oligonucleotide usually serve to confer resistance against cellular nucleases (16). This 
most likely explains silencing efficacy of modified AONs PS142 and PS260 compared 
to the lack of activity of PS56, a pure DNA AON. Derivatization of nucleotides can 
also alter oligo nucleocytoplasmic distribution. As target transcripts in DM1 are 
concentrated in the nucleus, any AON must be able to enter this compartment to 
become useful (2). Microscopic evidence is provided that ENA-modified AONs are 
retained in vesicular structures and never reach the nucleus, rendering them a poor 
choice for repeat-directed antisense DM1 strategy. We have no simple explanation 
for this finding, as similarly modified 2'-OMe RNA/ENA chimeras have shown 
activity in the nucleus during exon skipping for Duchenne muscular dystrophy (17). 
Certainly, effects of nucleotide sequence on oligo subcellular localization, but also 
choice of cell model or transfection method cannot be excluded at this point.
A combination of oligo sequence and chemistry may also be responsible for 
the failure to induce RNAi response by triplet repeat siRNAs. The poor performance 
of the two tested duplexes can be the result of unfavourable subcellular distribution, 
even though the RNAi machinery is active in cytoplasm and nucleus (24). An earlier 
report demonstrated that expanded DMPK transcripts were degraded by RNAi via 
lentivirus-delivered short hairpin RNA, but not by synthetic siRNAs (11). Combined 
with our observations here, this may point at improper processing of siRNAs in the 
nucleus or insufficient accessibility of (CUG)n-RNA containing inclusions to certain 
components of the RNAi pathway in our myogenic cell model. Likewise, we can 
only speculate about the unexpected increase of mDMPK and hDMPK (CUG)500 
transcripts after siRNA transfection. A high cellular siRNA concentration may inhibit
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regular DMPK RNA decay in cytoplasm and nucleus. Alternatively, we cannot exclude 
that CUG strands of the employed siRNAs interfered with expression of (CAG)n 
antisense transcripts originating from the DM1 locus (25), thereby perturbing the 
regulation of expression of (CUG)n sense transcripts from the DMPK gene (21, 25). 
More work needs to be done to examine these possibilities further.
An oligonucleotide series consisting of four to thirteen CAG triplets allowed us to 
test whether oligo length provided selectivity between RNAs from expanded and 
normal-sized DMPK alleles or other (CTG)n-carrying genes. The shortest variant, 
PS251 (CAG)4, was unable to knockdown expanded transcripts in DM500 myotubes. 
Most likely, its hybridization strength was insufficient for a stable interaction with a 
(CUG)n segment in the living cell, even though the theoretical Tm for this interaction 
is around 39oC (18).
AONs longer than four triplets all very efficiently silenced transgenic 
hDMPK (CUG)500 transcripts. In contrast, Mapkap1 (CUG)26 transcripts were much 
better preserved by PS147 (CAG)5 than by its (CAG)7 and (CAG)10 counterparts. 
Assuming that a certain part of the RNA target needs to be in an oligo duplex form 
for efficient knockdown, these observations can be best explained by a combination 
of differences in oligo hybridization strength (Tm(CUG)5 < Tm(CUG)7 < Tm(CUG)10) 
and number of potential oligo binding sites in a given target RNA. Hence, oligo 
concentration will be an important parameter in future applications and a lower 
dose might improve (CUG)n length selectivity.
Significant (CUG)n-length dependent activity in patient cells was displayed 
by (CAG)5, (CAG)7 and (CAG)10 2'-OMe/PT AONs. Between them, however, they 
showed no significant difference in activity towards normal-sized DMPK transcripts: 
(CUG)5 transcripts (carried by ~40% of the Caucasian population (5)) were left 
intact, but (CUG)21 transcripts were ~50% reduced. At present, we cannot predict 
whether partial reduction of normal-sized transcripts will have any adverse 
consequences. We know that DMPK KO mice have relatively mild phenotypes (26) 
and a low level of remaining DMPK protein might be sufficient to protect functional 
and structural integrity of cells in which it is expressed. Another still unresolved 
issue is the minimum efficacy needed for a beneficial effect: a partial suppression of 
toxic (CUG)n RNA may already be of clinical relevance in patients.
What do we know about the molecular mechanism underlying silencing activity 
of triplet repeat AONs examined here? Although the goal of this study was not to 
identify distinct pathways or describe novel interference principles, our findings 
in combination with specific literature knowledge do provide some new insight. 
For example, we expect DNA-based oligos PS142 and PS260 to recruit endogenous 
RNase H in cytoplasm and nucleus for a first endonucleolytic cleavage (16, 27). 
Unprotected 5' and 3' RNAs will be degraded according to the RNA quality control 
system by conventional exonucleases (28, 29). Nucleotide analogs like morpholinos 
(30) or modifications like 2'-OMe (data not shown), however, do not support RNase-H
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dependent degradation. These AONs must therefore use distinct pathways, which 
may be the reason why PS58, a 2'-OMe/PT (CAG)7 AON, but not PS260, a 2'-OMe/ 
DNA/PT (CAG)7 gapmer, displayed effective (CUG)n-length dependent silencing.
The RNAi pathway is unlikely to be involved in activity of fully 2'-OMe/PT 
AONs or (CAG)n morpholinos. Imperfect hybrids of 2'-OMe/PT or morpholino (CAG) 
n AONs, or perfect hybrids that these AONs may form with (CUG)n transcripts, are 
not known substrates for the RNAi machinery (31-34). Furthermore, the size of the 
shortest effective AON (15 nucleotides) and tolerable 5' covalent modifications 
like a fluorescent group (as in FAM-PS58) or a peptide (data not shown) render 
involvement of RNAi enzymes highly unlikely (35-37). Also, we did not find evidence 
for AON-induced processing of expanded DMPK transcripts into (CUG)n siRNAs that 
could trigger degradation of (CAG)n transcripts (compare (21)).
Fully 2'-OMe/PT-modified AONs and morpholinos are usually designed and 
employed as blocking oligos to modulate splicing or prevent translation (16, 20, 
38). A particularly elegant application was reported for a (AGC)8A morpholino that 
blocked Mbnl1 protein binding to transgenic (CUG)250 transcripts in a mouse model 
for DM1-related RNA toxicity (39). In this study, cytoplasmic levels of expanded 
transcripts raised upon treatment, but, surprisingly, the total amount of (CUG)250 
transcripts was ~50% reduced. A comparable reduction was recently reported for 
expanded Huntington (CAG)n RNA using a (GCT)6G locked nucleic acid (LNA) type 
blocking oligonucleotide (40). The authors of the first mentioned report, Wheeler 
et al., suggested that morpholino-driven displacement of expanded transcripts to 
the cytoplasm may have induced DMPK mRNA decay. A similar mechanism may be 
at play for the (CAG)8 morpholino and (CAG)n 2'-OMe/PT AONs examined here. 
Alternatively, these AONs may activate a yet to be identified RNase or RNA decay 
program in nucleus or cytoplasm. Further study into these possibilities is therefore 
needed.
In sum, we here provide further evidence that the expanded (CUG)n repeat 
segment in DMPK mRNA, being the product from the only known mutation in DM1, 
forms an attractive target for antisense oligonucleotide therapy. For development 
of such therapy, chemical structure and oligo length in combination with the 
rather special sequence content needed -  i.e., the complementary (CAG)n-repeat 
character -  have now been identified as important determinants. Our findings 
also open up interesting possibilities for other triplet repeat diseases. In particular, 
AON (CIG)7 is a promising new lead compound, able to bind to (CUG)n and (CAG) 
n transcripts. Potential application of these types of AONs for treatment of other 
trinucleotide repeat disorders than DM1, e.g., for Huntington's disease, many forms 
of spinocerebellar ataxias and several other polyQ diseases (41) is therefore now 
open for further study.
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SUPPORTING INFORMATION  
SI Figures
Log [PS142 (CAG)7]
Log [PS147 (CAG)5]
Log [PS146 (CAG)10]
Figure S1. Concentration-response curves of PS142, PS147 and PS146 (including raw data).
DM500 myotubes were treated with a concentration series of 0.01-500 nM  of (A) PS142, (B) 
PS147 or (C) PS146. RNA was isolated 48 hours post-transfection and analyzed by Northern 
blotting. Data points are the mean of at least three measurements.
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Figure S2. Differential uptake and localization of AONs in DM500 myoblasts. DM500 
myoblasts were transfected with FAM-PS58 (A-D) or Cy3-PS138 (E-H). Uptake was visualized 
using live cell imaging. Time points indicate minutes after addition of the oligo-transfection 
reagent complex to the culture medium. Dashed lines delineate cell boundaries. No nuclear 
localization was detected for ENA-modified PS138, whereas 2'-OMe/PT-modified PS58 
showed clear nuclear localization. Intense signals in panels A-D represent FAM-PS58- 
polyethyleneimine complexes in the medium. Representative images of two independent 
experiments are shown. Bars: 20 mm.
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Chapter 8
SUMMARY, CONLUDING REMARKS AND FUTURE PROSPECTS
A subset of nucleotide expansion disorders result from presence of long non-coding 
repeat segments in the human transcriptome, encoded by unstable microsatellite 
DNA (1). This PhD study is focused on molecular, cellular and therapeutic aspects 
of one archetypal disorder that belongs to this class of genetic diseases, myotonic 
dystrophy type 1 (DM1). DM1 is characterized by a (CTG)n expansion in the 3' 
untranslated region of the DMPK gene.
The currently best accepted theory to explain the complex DM1 phenotype 
involves a toxic RNA gain-of-function for expanded DMPK transcripts (2). DMPK 
transcripts carrying a long (CUG)n triplet repeat bind and sequester proteins which 
function in splicing and transcription and are retained in small ribonuclear protein 
complexes in cell nuclei. One part of this thesis is dedicated to the development 
of a molecular therapeutic strategy for an effective treatment for DM1. Based on 
reports on the successful application of antisense oligonucleotides (AONs) as a 
therapeutic tool in human disease (3) the idea was developed to use these artificial 
molecules in strategies aimed to eliminate the toxic-expanded RNA from cells and 
tissues of DM1 patients.
Although there is an overwhelming amount of support for the RNA gain- 
of-function model it is not yet proven that all aspects of disease in DM1 can be 
fully explained by toxic effects of expanded (CUG)n RNA on global cellular RNA 
production and processing alone. Therefore, the question remains whether there 
could also be a role for abnormal expression of protein products from the DMPK 
gene. Following this line of reasoning, it was decided to dedicate the other part 
of this thesis work to (i) the study of expression and function of DMPK proteins 
under normal conditions and (ii) to the potential involvement of an imbalance in 
the repertoire of DMPK splice isoforms in DM1's disease pathogenesis.
DMPK ISOFORM EXPRESSSION AND FUNCTION
DM1 is a multi-systemic, highly variable disorder with involvement of skeletal muscle, 
heart, gastrointestinal tract, endocrine system (diabetes), eyes, reproductive organs 
and brain (4). Although a significant correlation exists between (CTG)n repeat length 
and disease severity, a wide range of DM1 features may be associated with any given 
repeat length (5). The basis for this phenotypic variability is unclear and studies in 
mice still leave open the possibility that multiple, distinct molecular mechanisms 
together make up DM1's spectrum of symptoms.
None of the current DM1 mouse models displays all features observed 
in patients, but all transgenic models which express a non-coding (CTG)n repeat 
in the context of otherwise unrelated genomic insert manifest particular clinical 
symptoms of DM1 (6-8). Also Mbnl1 knock-out mice (9) and CUGBP1 overexpressor 
models (10-12) display DM1-typical features. A further complication finding was that 
even the DMPK knock-out mice without the pertinent gene region developed mild
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myopathy, impaired insulin signaling in skeletal muscle and some cardiac and brain 
abnormalities (13-18) but see also (19). Similarly, DMPK overexpressor mice showed 
a severe cardiac phenotype, skeletal muscle abnormalities and disrupted smooth 
muscle function (13, 20). Furthermore, Six5 knock-out mice developed premature 
cataracts and cardiac conduction defects (21-23). When considered together, these 
latter observations leave open the possibility for a disbalance in DMPK and SIX5 
gene product levels as a co-determining cause of disease pathogenesis in DM1 
patients.
One approach to see whether abnormal expression of products from the 
DM locus could add to the complex phenotypic expression of DM1, would be to 
cross DMPK knock-out or overexpressor mice with transgenic mice expressing 
expanded (CUG)n transcripts. Severity of the phenotype and age of onset of 
problems in the resulting offspring should then be compared with those of the 
parental mouse lines. Note that - since animal studies have mainly concentrated on 
genotype-phenotype relationships in skeletal muscle - basically nothing is known 
about the role of normal (and aberrant) DMPK gene products in other organs and 
tissues. Especially the biology of DMPK RNA and protein products in heart cells 
(cardiomyocytes), brain cells (e.g., astrocytes versus neurons (see Chapter 2)), and 
smooth muscle cells requires more detailed attention.
To be able to reveal a role for protein products from the DMPK gene (or aberrant 
expression thereof) in the development of DM1 pathology, it is therefore of major 
importance to first identify the tissues and cell types in which particular DMPK 
protein isoforms are normally expressed. Using western blotting approaches, we 
identified expression of long and short DMPK protein isoforms in cardiac, brain 
and muscle cells (24) (Chapter 2), cell types from tissues that are among the most 
severely affected in DM1. In both atrial and ventricle segments of the heart an 
equally high expression of long and short DMPK isoforms was found and a similar 
balance in abundance was seen in a cardiomyocyte cell line. To us this suggests 
that both long and short DMPK isoforms are required for proper cardiac function, 
leaving open the possibility that a distortion of isoform concentration (i.e. the rate 
or ratio of isoform expression) could contribute to cardiac failure seen in DM1. 
Having a panel of DMPK-isoform specific antibodies would help us to quantitatively 
and qualitatively discriminate between isoforms on western blot and in in situ  
studies on heart tissue from DM1 patients and healthy individuals. Unfortunately, 
all attempts to generate antibodies specific for individual DMPK C-termini in rabbits 
have failed until now (Wansink et al, unpublished data).
We noticed that during maturation, DMPK levels in brain increased (Chapter
2). This suggests a role for DMPK protein in CNS development. All brain regions 
examined expressed both long and short DMPK isoforms, but the long DMPK isoforms 
dominated in abundance. Strikingly, and unexpectedly based on findings of DMPK 
RNA expression in other studies, we noticed that DMPK protein expression was 
particularly prominent in astrocytes. Further studies, involving complementation
168
Chapter 8
of DMPK-knockout astrocytes with individual DMPK isoforms in in vitro culture, are 
now necessary to reveal more details about the biological significance of individual 
DMPK isoforms in this cell type. Then, later, studies in transgenic mice wherein 
DMPK isoform cDNAs can be conditionally and tissue-specifically expressed should 
be initiated to learn more about the role of DMPK-astrocyte coupling in functioning 
of the entire brain, especially in cognition, mood-determination and sleep control, 
or any of the other processes which are affected in brain of DM1 patients. Similarly, 
studies with neuron targeted expression of DMPK isoforms should help to provide 
additional insight because not much is currently known about the cellular basis of 
cognitive dysfunction in DM. One indication that distortion of DMPK expression 
may indeed affect memory function comes from Epstein and co-workers (17), who 
showed a change in synaptic plasticity in a behavioral study performed on the 
DMPK KO model. However, in a separate study, also performed on DMPK KO mice, 
no cognitive and behavioral abnormalities were reported (19). Additional in vivo 
work is thus necessary to bring more clarity on DMPK's role in the impairment of 
brain functions in DM.
High expression of mainly short DMPK isoforms (DMPK E and F) was found 
in bladder and stomach, both tissues rich in smooth muscle cells. A much weaker 
DMPK expression was seen in skeletal muscle (e.g., gastrocnemius, soleus and tibialis 
anterior), dominated by long DMPK isoforms A-D. This strong cell-type dependence 
of splice site choice in different muscle types confirms the idea of importance of 
tight regulation of DMPK protein isoform balance. The under-representation of 
short DMPK isoforms in skeletal muscle was confirmed in Chapter 3, where we 
report on the use of an in vitro myoblast-myotube cell model to profile DMPK mRNA 
expression during the course of myogenesis. In this chapter we also report on a 
ratio shift in expression of hDMPK transcripts with and without the exon 8 segment 
encoding the VSGGG sequence, during progression of myogenesis. As the VSGGG 
motif is implicated in the regulation of DMPK (auto)phosphorylation activity (25), 
use or avoidance of its inclusion by alternative splicing may serve a role in adapting 
DMPK's kinase to specific needs during different stages of the myoblast-fusion and/ 
or myotube-formation processes. More elaborate investigations are now necessary 
to establish whether the VSGGG motif and C-terminal tail could also play a role in 
the determination of substrate selectivity during muscle development (25).
Evidence for the importance of level and ratio of DMPK isoform presence 
during myogenesis came from the observation (Chapter 4) that aberrant (over) 
expression of the cytosolic DMPK E isoform in DMPK KO myoblasts resulted in the 
formation of stellar stress fibers, changes in cell shape and motility and delayed 
differentiation upon the induction of myogenesis. Whether these problems have 
any resemblance to the developmental abnormalities described in skeletal muscle 
in patients suffering from congenital DM or muscle wasting in adult patients is not 
known (26).
DMPK splice profile analysis, both at the RNA and protein product level, 
on muscle tissue from DM1 patients and healthy controls would be required to
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provide an answer to this question. These experiments would also shed light on 
the biological significance of the rare alternative DMPK splice isoforms identified in 
Chapter 3.
The significance of DMPK products for normal development and 
homeostasis, and that of aberrant DMPK protein expression for the DM1 disease 
process might differ between organs and tissues. Hence, also for tissues other 
than skeletal muscle it would be interesting to compare DMPK alternative splicing 
patterns, RNA and protein levels between healthy individuals and DM1 patients 
with variable degree of disease severity, due to different (CTG)n repeat lengths. 
Unfortunately, for obvious reasons, many anatomical regions and organs are 
unsuitable for biopsy and the number of biopsies that can be taken from one person 
during his or her lifetime is limited. Founding of a biobank of well-matched control 
and patient materials, composed of frozen tissue and stocks of cells that can be 
brought into culture (e.g. primary cells or induced pluripotent stem cells (iPCs)), will 
therefore become crucial for further progress, in both the areas of basic research 
and therapeutic development.
SILENCING EXPANDED (CUG)n RNA AS A BASIS FOR THERAPY FOR DM1
Studies that appeared in recent papers have demonstrated that certain features of 
DM1-associated RNA toxicity are reversible (27-30). In this thesis, we focused on 
the use of AONs as a molecular therapeutic tool to reduce RNA-mediated toxicity 
by eliminating expanded (CUG)n RNA directly. Many questions regarding use of 
AONs as a therapeutic tool in DM1 can still be asked. Among the most relevant 
are: (a) What is the best target sequence in expanded DMPK RNA? (b) How can 
AON specificity be optimized and off-target effects be minimized? (c) What is the 
preferred AON length and chemical modification that best suits the therapeutic 
purpose? (d) How are AONs efficiently delivered to those cells and tissues that are 
at the heart of problems in DM1 patients? (e) What is the underlying mechanism of 
AON-induced expanded (CUG)n RNA degradation?
In Chapter 5 we describe the design and testing of a series of AONs with the aim 
to degrade expanded DMPK transcripts, possibly by the recruitment of different 
molecular pathways for RNA breakdown, or induction of exon skipping (31). AONs 
designed to induce skipping of the toxic (CUG)n repeat by taking advantage of a 
cryptic splice site situated just behind the (CUG)n repeat (32), were ineffective. 
Splice switching induced by AONs with a steric blocking ability has been applied for 
many disease-relevant genes (33), like dystrophin in Duchenne muscular dystrophy 
(DMD) and chloride channel 1 (Clcn1) in DM1 (30). Failure to induce splice switching 
in DM1 models may be explained by (a) a false choice of target sequence(s) or AON 
design, or (b) intrinsic biological problems, coupled to very rare use of genuine/ 
cryptic splice sites that flank the repeat region in the last exon, exon 15, of the 
primary DMPK transcript. Furthermore, we realize that for splice switching to
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become useful in DM1, it will be essential that the spliced-out segment carrying 
the repeat expansion is degraded. Studies in DM2 have demonstrated that repeat 
regions in introns, a (CCTG)n expansion in this case, can remain after splicing and 
still have disease causing effects.
PS58, a 21 nt (CAG)7 fully 2'-O-methyl phosphorothioate (2'-OMe PT) 
modified oligo directed against the (CUG)n repeat itself, was identified as a lead 
compound for use in elimination of expanded (CUG)n transcripts and reversal of 
RNA toxicity in DM1 cell and animal models (Chapter 5). PS58 treatment of HSALR 
mice resulted in partial correction of aberrant Clcn1 splicing, but the myotonia 
directly correlated to Clcn1 missplicing (30) was not reduced. In remarkable 
contrast to our findings, Wheeler et al. reported that treatment with CAG25, a 
25 nt (AGC)8A morpholino which interferes with binding of Mbnl1 to the (CUG) 
n stem loop structure, did result in myotonia reversal in the HSALR model (34), 
and triggered partial breakdown of repeat containing transcripts. To explain these 
findings -  and the differences between the two studies -  we must assume that 
50% reduction of toxic HSALR transcripts p er se  as a result of PS58 treatment in our 
model is not sufficient to free enough Mbnl1 protein to restore Clcn1 splicing and 
correct Clcn1 channel activity. Alternatively or in addition, Mbnl1 protein may not 
become available because PS58 is -  unlike the morpholino -  not capable of freeing 
all aberrantly bound Mbnl1 protein, and a significant fraction of this factor remains 
sequestered to short (CUG)n tracts outside RNP foci (35). Whether indeed the dual 
dissociative and target-destructive properties of PS58 and CAG25 differ should be 
tested in experiments where both compounds can be compared (Wheeler et al., 
2009).
For PS58 we confirmed that undesired silencing of normal-sized transcripts 
after treatment of DM1 patients cells in vitro is not a serious problem, also because 
the anticipated corresponding decrease in steady-state DMPK protein level was 
not observed (see analysis by western blotting, Chapter 5). More work needs to 
be done to also confirm that the normal balance in DMPK protein expression is not 
harmed in vivo during different stages of muscle development after long term PS58 
treatment.
To better understand the effects of size and structure and for efficacy 
optimization a series of (CAG)n AONs of different lengths and chemistries were 
generated and tested (Chapter 7). Use of a series of 2'-OMe PT AONs with sequence 
lengths varying from 4-13 triplets revealed that all AONs, except the (CAG)4 AON, 
showed high (CUG)n silencing activity. The hybridization strength of the (CAG)4 
AON may be too low for an efficient response. AON length did not alter selectivity 
between normal (bearing 5 or 21 CUGs) or expanded DMPK transcripts (bearing 
200 or 1400 CUGs) in patient cells. However, in DM500 cells the (CAG)10 AON 
had a more pronounced effect on Mapkap1 (CUG)26 transcripts than its (CAG)5 
and (CAG)7 counterparts. To better understand these observations, experiments 
in which effects of cell-type (or species type) or effects of transcript context are 
being compared in a systematic manner, for different short (CUG)n repeat-targets
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and (CAG)5-10 AONs combinations, should now be initiated. Oligo chemistry is an 
important determining factor in AON efficacy. We showed this by demonstrating 
that all 2'-O,4'-C-ethylene-bridged nucleic acid (ENA) modified AONs failed to 
induce mutant hDMPK transcript silencing. Both DNA and morpholino oligos 
showed lower hDMPK transcript silencing activity than 2'-OMe PT modified 
oligos. We expect that these variations are caused by a combination of insufficient 
intracellular AON targeting (i.e. the cytosolic-nuclear distribution behavior is clearly 
different for differentially modified oligos) and perhaps hybridization strength. Also 
the molecular mechanism underlying silencing potency may differ between AONs 
with different chemistry.
Strikingly, both siRNAs (i.e., short RNAs with natural base composition) 
tested, failed to induce silencing of expanded DMPK mRNA transcripts. Instead, the 
level of mutant DMPK mRNA appeared increased in presence of the repeat directed 
siRNAs (Chapter 7). Formation of siRNA-hDMPK (CUG)500 RNA complexes and 
protection of these complexes against entry in normal siRNA breakdown pathways, 
could play a role. In addition, competition of the siRNAs with (CAG)n antisense 
transcripts produced from the DM1 locus (36) may be involved. Clearly, more work 
must be done to understand this unexpected stabilization effect.
To be successful in DM1 patients the effective AON has to penetrate a wide 
range of tissues and cells throughout the body and ultimately should reach the cell 
nucleus efficiently. Systemic delivery of unconjugated PS58 failed to induce silencing 
of hDMPK transcript in muscle of a DM1 mouse model (Chapter 6). This failure of 
toxic (CUG)n RNA silencing is best explained by the intracellular concentration in 
muscle being too low. Rapid clearance from the blood and accumulation in kidney 
and liver in combination with poor oligo uptake in all other tissues may explain the 
low level in muscle. It is for these reasons that exploration of the possibilities for a 
system-wide delivery should have high priority, forming a big challenge for future 
work.
Thus far, we have little insight in the molecular mechanism underlying the cellular 
activity of 2'-OMe PT triplet repeat AONs. We observed rapid effects for AONs that 
varied in length between 15 and 39 nucleotides. A 5' modification did not influence 
activity. An RNase-H-dependent mechanism can be excluded, because|2'-O-methyl 
modifications are not compatible with RNase-H-mediated degradation (31, data not 
shown, 37). Along the same line, an RNA interference mechanism is highly unlikely 
because all functional AONs used were fully 2'-OMe PT modified and are therefore 
not recognized by molecular players in the RNAi pathway (38-40).
RT-PCR experiments using primer pairs directed at segments across the 
entire hDMPK transcript suggest that the 5' part of the DMPK mRNA is more 
refractory to PS58-induced degradation than the 3' segment (Chapter 5). A possible 
explanation for this finding is that RNA degradation starts at the site of cleavage, at 
the transcript's 3' end where PS58 targets to the (CUG)n tract and then progresses 
towards the 5' cap. Attempts to identify a stabilizing 3' poly(A) tail at the 5' segment
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of DMPK transcripts failed, so there is no evidence for involvement of production 
of prematurely truncated transcripts by use of alternative polyadenylation (which 
would result in RNAs that can no longer serve as PS58 targets).
What other working mechanisms could be involved in the activity of PS58? 
Based on current knowledge we can only speculate. One possibility is that the 
duplex AON-(CUG)n repeat structure recruits endoribonucleases, which specifically 
cut the transcript in this area. Next, normal RNA quality control of unprotected 
RNAs may follow, in which 5' and 3' exonucleases could play a role (41).
Because PS58 activity was rapid, we examined if the AON itself perhaps 
exhibits intrinsic catalytic activity, like for example observed for so-called DNAzymes 
(42) or ribozymes (43). We performed test tube experiments whereby purified 
expanded (CUG)n RNA was incubated with PS58 under various buffer conditions, 
but RNase activity was not observed (data not shown). We cannot exclude the 
possibility, however, that our experimental conditions were still suboptimal, 
because DNAzymes and ribozymes need delicate combinations of metal ions or 
other cellular co-factors, necessary for their activity or to assist in proper folding of 
the RNA target (44). Further work is also necessary here.
(CAG)n 2'-OMe PT AONs may have mechanistic properties in common with 
(CAG)n morpholinos. Morpholinos were originally described as oligonucleotide­
like molecules that act via an occupancy-only mechanism by hybridizing to a 
complementary RNA sequence without activating cleavage of the target (45). As 
already discussed above, Wheeler et al. reported that morpholino CAG25 not 
only dissociated Mbnl1-(CUG)n RNA complexes, as expected, but also gave rise 
to a reduced level of expanded (CUG)n transcripts in vivo (34). Also the (CAG)8 
morpholino that we used in our study produced a reduction in the level of expanded 
DMPK transcripts in DM500 cells. To us this suggests that CAG25 and PS58 have 
more in common than first anticipated. We hypothesize that both types of (CAG) 
n AONs are able to dissociate expanded (CUG)n hairpins from RNP aggregates and 
thereby - directly or indirectly -  cause RNA breakdown.
Recent developments in the molecular therapeutics field clearly show that 
AON-based strategies have therapeutic potential (31, 46, 47). Probably the biggest 
hurdle now to overcome is efficient delivery of active compounds in vivo. DM1 
is a multisystemic disease affecting many different organs, including brain. Novel 
delivery strategies for AONs will therefore be required to direct PS58 to relevant 
tissues, and there promote local uptake. Pilot experiments using unconjugated 
PS58 in systemic delivery regimes were unsuccessful as discussed above. Unlike 
cells from DMD patients, DM1 cells do probably not show increased cell membrane 
permeability, which would enhance passage of low molecular weight material such 
as AONs - although this aspect has not been studied extensively. For further progress, 
use of PS58 as lead compound is promising, but new chemistry, combined with 
rational design of conjugation-modifications, use of non-covalently linked carrier 
compounds or sophisticated formulation technology will be needed. Only then, in
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combination with safety pharmacology and toxicity studies, a second generation 
of (CAG)n-AON drugs may be developed, withlpotential for clinical testing in trials 
in DM1 patients. Ideally, prolonged use of such new drugs should have minimal 
disturbing effects on the normal balance in DMPK protein expression in different 
cell types during growth and ageing.
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DNA mutaties kunnen functieverlies van cellen, weefsels en organen veroorzaken, 
waardoor uiteindelijk ziekte zal optreden. Voor de meeste ziekten bestaat er een 
duidelijk beeld tussen het defect op DNA-niveau (genotype) en de uiteindelijke 
symptomen (fenotype) waarmee een patiënt te maken krijgt. Bij de erfelijke ziekte 
myotone dystrofie is de relatie tussen genotype en fenotype minder duidelijk.
Myotone dystrofie, afgekort DM, is een dominant erfelijke multisystemische 
aandoening, die wereldwijd ongeveer 1:8.000 mensen treft. Het is één van de meest 
voorkomende spieraandoeningen bij volwassenen. Het ziektebeeld van DM is vaak 
complex. De meest kenmerkende verschijnselen zijn het vertraagd ontspannen van 
de skeletspieren (myotonie) en een langzaam toenemende spierzwakte (dystrofie). 
Naast de spierafwijkingen kan er ook sprake zijn van hartfalen, staar, diabetes, 
overmatige slaperigheid en kunnen er leer- en gedragsveranderingen optreden. Al 
deze symptomen komen in sterk variabele combinaties bij patiënten voor.
In 1992 werd de mutatie voor myotone dystrofie type 1 (DM1) ontdekt: 
een (CTG)n-triplet-expansie in het myotone-dystrofie-proteïne-kinase (DMPK) 
gen. Verschillende hypotheses zijn vervolgens gepostuleerd om het complexe 
fenotype van DM1 te verklaren, waarbij ook een mogelijke rol voor het DMPK- 
eiwit is gesuggereerd. Toen in 2001 de genetische basis van de sterk gerelateerde 
aandoening DM type 2 (DM2) werd ontdekt - een geëxpandeerde (CCTG) 
n-sequentie gelocaliseerd in het ZNF9-gen - richtte het wetenschappelijk onderzoek 
zich minder op een mogelijke rol voor de eiwitten in het complexe ziektebeeld (i.e., 
DMPK en ZNF9), maar meer op de invloed van het RNA met de (CUG)n- of (CCUG) 
n-sequenties.
De verlengde (CUG)n- en (CCUG)n-sequenties komen voor in delen van de 
primaire transcripten die niet coderen voor eiwitten. Deze herhaalde volgordes 
vormen abnormale RNA structuren die het eiwit muscleblind 1 (MBNL1) of 
andere factoren wegvangen in onoplosbare complexen in de celkern. Verder 
zorgen de repeat RNA's, via een nog onduidelijk mechanisme, voor een verhoogde 
aanwezigheid van het CUG bindingseiwit 1 (CUGBP1). Al met al ontstaat er zo 
een afwijkende werkzame concentratie van MBNL1 en CUGBP1 in de cel. MBNL1 
en CUGBP1 zijn elkaars tegenspelers in de regulatie van alternatieve splicing van 
bepaalde pre-mRNA transcripten en de disbalans tussen MBNL1 en CUGBP1 kan dus 
oorzaak worden van foutieve processing van deze transcripten. Zo is aangetoond 
dat abnormaal gereguleerde splicing van het chloridekanaal 1 (Clcn-1) leidt tot de 
voor DM kenmerkende myotonie.
Samengevat, het verlengde (CUG)n-segment in het mutante DMPK-RNA is 
waarschijnlijk de belangrijkste speler in het ontstaan van DM1. Toch kunnen op dit 
moment nog niet alle DM1 symptomen verklaard worden vanuit een hypothese 
enkel en alleen gebaseerd op de effecten van toxisch (CUG)n RNA. Een bijdrage van 
een afwijkende expressie van het DMPK-eiwit aan de totstandkoming van één of 
meerdere symptomen in het complexe ziektebeeld van DM1 kan dan ook nog niet
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worden uitgesloten.
Het eerste deel van dit proefschrift beschrijft een studie naar de expressie en functie 
van het DMPK-gen onder normale condities en de mogelijke betrokkenheid van een 
disbalans van DMPK-eiwitisovormen bij de totstandkoming van DM1 pathologie.
Om de mogelijke rol van eiwitproducten van het DMPK-gen in het ontstaan 
van DM1 te onderzoeken is het van belang om het DMPK-expressiepatroon in 
weefsels en cellen te onderzoeken. In Hoofdstuk 2 is de weefselexpressie op 
eiwitniveau van lange DMPK-isovormen (isovormen A, B, C en D) en korte isovormen 
(E en F) onderzocht in wildtype en transgene DMPK-muizen met meerdere kopieën 
van een normaal gereguleerd humaan DMPK-gen. De hoogste expressie van met 
name de korte DMPK-isovormen werd gevonden in de maag en de blaas, beide 
voor een groot deel bestaand uit glad spierweefsel. In het hart en het diafragma 
werden gelijke DMPK-expressieniveau's gevonden voor de lange en korte DMPK- 
isovormen. In verschillende soorten skeletspier komen relatief lage hoeveelheden 
van voornamelijk de lange DMPK-isovormen voor. De preferentiële expressie van de 
lange DMPK-isovormen in skeletspier werd bevestigd in een spiercelkweekmodel 
waarbij differentiatie van myoblasten tot myotubes leidde tot een afname in de 
expressie van korte DMPK-isovormen. Beide type isovormen, maar voornamelijk 
de lange, werden ook gevonden in verschillende breinregio's. Opmerkelijk was 
de vinding dat DMPK-RNA's en -eiwitten in relatief hoge concentratie voorkomen 
in primaire astrocyten uit de cortex en vrijwel niet detecteerbaar zijn in primaire 
neuronen afkomstig van de hippocampus. DMPK-eiwitten worden dus isovorm- 
specifiek geëxpresseerd in weefsels en cellen die mogelijk zijn aangedaan in 
patiënten met DM1.
Hoofdstuk 3 beschrijft een studie naar alternatieve splicing van endogene 
muize DMPK (mDMPK) en geëxpandeerde humane DMPK-transcripten (hDMPK) in 
twee spiercelkweekmodellen. De hoeveelheid korte DMPK-isovormen neemt op 
RNA niveau af tijdens het differentiatieproces. Verder vindt er tijdens myogenese 
een verschuiving plaats van hDMPK-transcripten zonder VSGGG-motief naar 
transcripten met een VSGGG-motief. Hieruit blijkt dat alternatieve splicing van 
DMPK-transcripten geen stochastisch proces is, maar gereguleerd wordt en zich 
aanpast aan het ontwikkelingsstadium van de cel. Tenslotte is duidelijk geworden 
dat coëxpressie van geëxpandeerde hDMPK-transcripten weinig tot geen effect 
heeft op de alternatieve splicing van endogene mDMPK-transcripten.
In Hoofdstuk 4 is aangetoond wat de mogelijke gevolgen kunnen zijn van 
een verschuiving in de DMPK-isovormbalans, in het bijzonder van een hoge DMPK 
E expressie. Expressie van de cytosolische, korte DMPK E isovorm in DMPK-KO- 
myoblasten resulteert in de vorming van grote stervormige actine-stress-fibers. 
Dit gaat gepaard met een verandering van celvorm, celbeweeglijkheid en een 
vertraagde differentiatie. Biochemische en microscopische studies wijzen op een 
betrokkenheid van myosine II bij het ontstaan van DMPK E-geïnduceerde stress- 
fibers. Antilichamen gericht tegen de zware myosine ketens (MHC) tonen aan
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dat myosin II colokaliseert met de stervormige actine-fibers. Daarnaast blijken de 
lichte myosineketens (MLC), die de activiteit van myosine II reguleren, een hogere 
fosforyleringsgraad te bezitten in aanwezigheid van DMPK E. Meer onderzoek is 
nodig om te achterhalen of een verschuiving in DMPK's isovormbalans in DM1, 
bijvoorbeeld in glad spierweefsel waarin deze isovorm van nature het meest 
voorkomt (Hoofdstuk 2), mogelijk betrokken is bij de totstandkoming van bepaalde 
symptomen van de ziekte.
Deel twee van dit proefschrift beschrijft de eerste stappen in de ontwikkeling 
van een moleculaire therapie voor DM1. Vanwege het (pre)klinische succes met 
antisense-oligonucleotiden (AON) in de behandeling van de ziekte van Duchenne en 
bij spinale musculaire atrofie is onderzocht of de antisense-oligo-technologie ook 
gebruikt kan worden voor het opruimen/afbreken van toxische (CUG)n-segmenten 
uit het mutante DMPK mRNA om zo de DM1-symptomen te verminderen en te 
voorkomen.
In Hoofdstuk 5 is aangetoond dat het inderdaad mogelijk is om met behulp 
van AON's selectief toxische RNA's met abnormaal lange (CUG)n-segmenten te 
elimineren. Uit een serie geteste AON's bleek één oligo, PS58 genaamd, in staat 
om afbraak te induceren van geëxpandeerde mutante hDMPK-transcripten in een 
DM1 celmodel. PS58 is een chemisch gemodificeerde oligo van 21 nucleotiden, 
bestaande uit zeven CAG tripletten, die complementair zijn met het toxische 
(CUG)n segment. De werking van PS58 ging tevens gepaard met een vermindering 
van de hoeveelheid van onoplosbare RNA-eiwit-complexen in de kern. In cellen 
afkomstig van DM1 patiënten zorgt PS58 voor een selectieve reductie van alleen 
de geëxpandeerde transcripten. Hiermee wordt duidelijk dat er een positieve 
correlatie bestaat tussen de effectiviteit van PS58 en het aantal (CUG)n tripletten 
dat aanwezig is in een transcript. Tenslotte kon, na injectie in twee verschillende 
transgene DM1 muizenmodellen, ook aangetoond worden dat de PS58 (CAG)7 oligo 
ook werkzaam is in vivo en een gedeeltelijke correctie van DM1-typische afwijkende 
splicing teweeg kan brengen.
Vanwege het multisystemische karakter van DM1 is het cruciaal dat PS58 
optimaal wordt opgenomen in alle weefsels en cellen die bij de ziekte betrokken 
zijn. In Hoofdstuk 6 is onderzocht of het mogelijk is om een reductie van mutante 
hDMPK-transcripten in vivo te bewerkstelligen door PS58 systemisch toe te dienen 
aan transgene DM1 muizen. Twee verschillende injectieprotocollen - gebaseerd op 
intraperitoneale of subcutane injecties - zijn getest, maar er werd in beide gevallen 
geen reductie van het geëxpandeerde hDMPK-mRNA gevonden in de onderzochte 
weefsels. PS58 bleek snel via lever en nieren uit het lichaam te worden geklaard en 
slechts moeilijk het celmembraan te passeren, waardoor klinisch relevante niveau's 
in weefsels niet konden worden bereikt. Onderzoek naar een efficiënte opname van 
AON's door lichaamscellen is één van de belangrijkste uitdagingen in het toekomstig 
onderzoek naar een oligotherapie voor DM1.
In Hoofdstuk 7 is een grote serie verwante (CAG)n AON's getest op hun
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werkzaamheid tegen geëxpandeerde DMPK transcripten in cellen uit DM1 muizen 
en in cellen van patiënten. Deze AON's verschillen van elkaar in lengte en chemische 
modificatie. Van een reeks geteste 2'-O-methyl fosforothioaat-gemodificeerde (CAG) 
n oligo's met een lengte variërend van 4-13 tripletten vertoonde alleen de (CAG)4 
oligo geen (CUG)n-RNA-reducerende activiteit. Onderzoek in patiëntencellen 
wees uit dat AON-lengte zelf geen bepalende factor is in de selectieve reductie 
van geëxpandeerde transcripten. Wel is oligochemie zeer belangrijk voor AON- 
effectiviteit en speelt het een rol bij de intracellulaire stabiliteit en lokalisatie.
Samenvattend, het hier beschreven onderzoek heeft nieuwe elementen toegevoegd 
aan onze kennis omtrent DMPK-transcripten en eiwitisovormen. De nieuwe 
resultaten bieden een goede basis voor vervolgonderzoek naar de functie van 
alternatieve splicing van DMPK-transcripten in het algemeen en effecten van de 
cytosolische isovorm DMPK E op het actinecytoskelet in het bijzonder. Of storing 
in deze delicate processen een rol kan spelen in de pathofysiologie van myotone 
dystrofie kan nu eveneens beter worden onderzocht. Tenslotte is een belangrijke 
basis gelegd voor een succesvolle toepassing van antisense oligonucleotiden in een 
moleculaire therapie voor myotone dystrofie type 1.
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Abbreviations
ABBREVIATIONS
AON antisense oligonucleotide
AAV adeno-associated virus
cDNA copy DNA
Clcn-1 chloride channel 1
Cy3 cyanine dye family member 3
CTG triplet cytosine-thymine-guanine triplet
cTnt cardiac troponin T
CUGBP1 CUG binding protein 1
CUG triplet cytosine-uracil-guanine triplet
DM dystrophia myotonica
DMD Duchenne muscular dystrophy
DMEM Dulbecco's modified Eagle's medium
DMPK myotonic dystrophy protein kinase
DMSXL transgenic mice from the DM300-328 line with a (CTG)>1200 repeat
DMWD myotonic dystrophy WD-repeat gene
DM1 myotonic dystrophy type 1
DM2 myotonic dystrophy type 2
DM500 transgenic mice from the DM300-328 line with a (CTG)500 repeat
DNA deoxyribonucleic acid
ELISA enzyme-linked immunosorbent assay
ENA 2'-O,4'-C-ethylene-bridged nucleic acid
ER endoplasmic reticulum
ESE exonic splicing enhancer
FAM carboxyfluorescein
FCS fetal calf serum
FISH fluorescence in situ hybridization
FXTAS fragile X tremor ataxia syndrome
Gapdh glyceraldehyde 3-phosphate dehydrogenase
GPS gastrocnemius-plantaris-soleus
Hcn1 hyperpolarization-activated cyclic nucleotide-gated channel 1
HDL2 huntington's disease-like 2
hDMPK human myotonic dystrophy protein kinase
hnRNP H heterogeneous nuclear ribonucleoprotein H
HSALR human skeletal actin large repeat
IC50 half maximal inhibitory concentration
I.p. intraperitoneal
IR insulin receptor
KO knockout
LNA locked nucleic acid
Mapkap1 mitogen-activated protein kinase associated protein 1
MBNL muscleblind
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mDMPK mouse myotonic dystrophy protein kinase
MHC myosin heavy chain
MLCK myosin light chain kinase
MLC2 myosin regulatory light chain of myosin II
MOM mitochondrial outer membrane
mRNA messenger RNA
MYPT1 myosin phosphatase targeting subunit 1
Nr3c1 nuclear receptor subfamily 3, group C, member 1
N2A mouse neuro-2A neuroblastoma cells
PBS phosphate-buffered saline
PCR polymerase chain reaction
PEI polyethyleneimine
PMO phosphorodiamidate morpholino
PNA peptide nucleic acid
PT phosphorothioate
Ptbp1 polypyrimidine tract binding protein 1
RNA ribonucleic acid
RNAi RNA interference
RNAse H ribonuclease H
RNP ribonucleoprotein
ROCK Rho-associated coiled coil-containing kinase
RT-PCR reverse transcription polymerase chain reaction
S.c. subcutaneous
SCA spinocerebellar ataxia
Sdc3 syndecan 3
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis
Sec24b Sec24-related gene family, member b
SERCA sarcoplasmic or endoplasmic reticulum Ca2+-ATPase
siRNA small interfering RNA
SIX5 sine oculis homeobox gene 5
TA tibialis anterior
TF transcription factor
TG transgenic
Tnnt3 troponin T type 3
Ttn titin
TRED trinucleotide repeat expansion disorder
Txlnb taxilin beta
UTR untranslated region
WPRE woodchuck post-transcriptional regulatory element
WT wildtype
YFP yellow fluorescent protein
ZNF9 zinc finger protein 9
2'-OMe 2'-O-methyl
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Susan Mulders werd geboren op 27 juli 1978 in Groesbeek. Na het slagen voor 
het eindexamen MAVO in 1995 te Nijmegen, startte ze met de studierichting 
Chemie aan de Middelbare Laboratorium Opleiding (MLO) van het Rijn IJssel 
College in Arnhem; het diploma werd behaald in 1999. In 2002 voltooide zij aan 
de Hogeschool van Arnhem en Nijmegen (HAN) het Hoger Laboratorium Onderwijs 
(HLO) in de studierichting Biologie en Medisch Laboratoriumonderzoek. Voor deze 
opleiding volgde zij haar afstudeerstage binnen de Genomic Interactions Group van 
de Research School of Biological Sciences in Canberra, Australië onder leiding van 
Dr. U. Mathesius en Prof. dr. B. G. Rolfe. Na het behalen van haar diploma was ze 
van 2002 tot 2005 werkzaam als research-analist op de Afdeling Celbiologie van de 
Radboud Universiteit Nijmegen, onder leiding van Dr. D. G. Wansink en Prof. dr. B. 
Wieringa.
In 2005 startte Susan Mulders als junior-onderzoeker met haar 
promotieonderzoek op bovengenoemde afdeling. Hier voerde zij onder leiding 
van Dr. D. G. Wansink en Prof. dr. B. Wieringa het in dit proefschrift beschreven 
onderzoek uit. Tijdens de 6th International Myotonic Dystrophy Consortium Meeting 
(Milaan, 2007) presenteerde zij de eerste resultaten van haar onderzoek naar het 
gebruik van antisense oligonucleotiden in een therapie voor myotone dystrofie. 
Voor deze presentatie ontving zij de Excellence in Research Award van de Myotonic 
Dystrophy Foundation. Voor de wetenschappelijke publicatie waarin dit onderzoek 
is beschreven ontving zij de Prinses Beatrix Fonds-jaarprijs neuromusculaire ziekten 
2009. Vanaf januari 2010 is Susan Mulders werkzaam als Scientific Study Manager 
bij Prosensa Therapeutics B.V. in Leiden binnen de afdeling Discovery, waar ze haar 
werkzaamheden voor een therapie voor myotone dystrofie gebaseerd op antisense- 
oligonucleotiden voortzet.
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En dan is het moment daar dat ik kan beginnen aan het laatste hoofdstuk van dit 
proefschrift, het dankwoord. Elk hoofdstuk in dit proefschrift is ontstaan na langdurig 
overleg, bediscussieerd tot in het kleinste detail en vele malen herschreven om het 
in een acceptabele staat van perfectie te krijgen. Maar bij dit hoofdstuk, dat dan 
ook nog het meest gelezen wordt, sta ik er alleen voor.
In 2002 stapte ik de afdeling Celbiologie binnen naar aanleiding van een vacature 
waarin gevraagd werd naar een analist op het project myotone dystrofie. Negen jaar 
later werk ik (gelukkig) nog steeds aan dit onderwerp en loop ik nog steeds rond op 
de afdeling Celbiologie. Er is alleen in die tussenliggende tijd veel veranderd. Dit 
traject is niet zonder slag of stoot gegaan en vele personen hebben hieraan een zeer 
belangrijke bijdrage geleverd of een niet te onderschatten rol gespeeld. Voor jullie 
is dit hoofdstuk.
Bé en Rick, mijn "Celbiologie leventje" begon door jullie. Bé, na drie jaar als analist 
gewerkt te hebben gaf je me de mogelijkheid en het vertrouwen om te starten met 
een promotieonderzoek. Je bent een zeer kundige wetenschapper en jouw neiging 
naar perfectie is noemenswaardig, al zonk daardoor ook af en toe de moed me in 
de schoenen, het heeft me wel gevormd tot waar ik nu sta. Rick, het boekje dat voor 
je ligt draagt jouw stempel en zou er nooit in deze vorm zijn gekomen zonder jouw 
onvoorwaardelijke steun, hulp, tijd, kritische blik, oprechtheid en altijd durende 
enthousiasme voor het DM onderzoek. Ik voel me bevoorrecht om bij jou AIO te 
zijn geweest. Bedankt voor alle leermomenten en hopelijk blijven we samenwerken 
aan een antisense oligonucleotide therapie voor DM1.
Alle experimentele hoofdstukken in het boekje zijn mede tot stand gekomen door 
de kwaliteiten van twee zeer bijzondere Celbiologie mannen. Walther, hoe verder 
we kwamen met het antisense oligonucleotide werk des te meer had ik jouw hulp 
nodig. We wilden in vivo en ik had het geluk dat jij het wel zag zitten om deze 
experimenten samen op te gaan zetten. Voor jouw kunde en precisie bij het 
injecteren en isoleren van de muizen heb ik grote bewondering. Je bent een kei in 
je vak en dit resulteerde in hele mooie data, bedankt hiervoor. Daarnaast zijn de 
uurtjes die we samen doorbrengen op het CDL altijd gezellig. Huipie, altijd tijd om 
microscoopprobleempjes op te lossen, altijd tijd om coupes te snijden, altijd tijd om 
samen fantastische plaatjes te maken en altijd tijd om gewoon even bij te kletsen. Jij 
doet dit vaak af als de normaalste zaak van de wereld, maar dat is het niet. Bedankt 
voor je hulp bij alle prachtige plaatjes die in dit proefschrift voorkomen. Ik ben er 
enorm trots op dat jullie beiden naast mij willen staan tijdens de promotie.
Bij mijn binnenkomst bij Celbiologie viel ik met mijn neus in de boter. Gönül, Marloes, 
Femke, Lieke en Yvet; wat hebben we samen een lol gehad. Avondjes stappen,
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weekendjes weg, dance-parade, lekker uit eten en vele feestjes en gesprekken later 
zijn we naast ex-collega's gelukkig vriendinnen gebleven. Nu ieder meer z'n eigen 
weg, maar nog steeds in contact met elkaar. Bedankt voor de fantastische tijd bij 
Celbiologie.
Alles tijdens dit promotietraject werd gerelativeerd tijdens de vrijdagmiddag 
borrel, de nodige feestjes, dagjes uit, filmavondjes en kerstdiners; Lieke G en 
Mirthe (succes met jullie eigen promoties), Jack (op vrijdag is vijf uur echt vijf uur), 
Marieke W (zonder jou zou het erg stil zijn op de afdeling), Huipie, Frank, Ralph, Ad, 
Bas, Jan S, Edwin, René, Jan K, Gönül, Marco, Helma, Renato, Lieke vdB, Marloes, 
Femke, Yvet, Remco, Frank deL, Rick, Walther, Wilmaf, Irene, Mietske, Rinske, 
Gerda, Mariska, Ineke, Magda, Linda, Michiel, Wiljan, Anchel (good luck with your 
own PhD), Monique, Marieke dV, Alwin, Godfried en Peter zonder jullie was het 
een stuk minder gezellig geweest. Studenten Suzanne, Jeroen en Josee bedankt 
voor al het werk dat jullie verricht hebben. De "Moldiertjes" als buren hebben 
was geen straf; Jos, Dorien, Rob, Karen, Eric (ieder jaar weer met de kerstboom in 
de Twingo), Nick, Karelf, Jeroen, Jessica, Martine, Rick, Marcel, François, Astrid en 
Gerard bedankt voor alle gezelligheid. René, we leerden elkaar kennen op het werk 
maar hopelijk zetten we onze etentjes samen met Mieke en Gerrit voort. Bedankt 
voor je fantastische ontwerp van de kaft. Het vormt voor mij een heel persoonlijk 
"kroontje" op dit proefschrift.
Een AIO traject wordt een stuk leuker als er in je privéomgeving ook interesse wordt 
getoond in je werk. Gelukkig waren er vragen als "hoe gaat het met de muizen?" 
en "moeten de cellen nog omgedraaid worden?". Janine, Simone, Maike, Marieke 
en Dorien; onze vriendschap gaat ver terug en in de loop van de jaren zijn onze 
levens behoorlijk veranderd, maar gelukkig nog steeds als een vriendinnengroep 
bij elkaar. Bedankt voor alle lol tijdens carnaval, kermis, 4-daagse, weekendjes weg,
etentjes........ etc die we samen gehad hebben en hopelijk gaan hebben. Op "da liegt
d'r nie um" zal ik maar zeggen, X. Meiden dames 1; Heidi, Sonja, Ingrid, Manon Nas, 
Ilse, Loekie, Ankie, Joyce, Manon van Sas, Miranda en Jolanda. Hoe had ik die 4 jaar 
kunnen overleven zonder me niet drie keer per week samen met "me teammies" 
uit te kunnen leven op een handbalveld? Hoewel ik soms denk dat we buiten het 
veld nog net iets scherper zijn. Op de één of andere manier wordt elke gelegenheid 
met jullie een feestje. Bedankt voor alle super momenten.
Dingeman en Riek, bedankt voor het altijd warme welkom als we bij jullie zijn. Het 
voelt fijn om daar deel van uit te mogen maken. Arie, Sandra, Rozemarijn, Floris, 
Lucas, Sander, Sterre, Mare, Olivier en René; ook al wonen we allemaal wat verder 
uit elkaar, als we elkaar zien is het altijd gezellig. Bedankt voor jullie interesse in het 
promotieonderzoek en hopelijk nu wat meer tijd om eens vaker jullie kant op te 
komen.
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Dankwoord
Pap en mam, de basis lag bij jullie. Jullie hebben me zoveel gegeven dat dit eigenlijk 
niet in woorden om te zetten is, elk woord doet tekort. Bedankt voor alle liefde, 
vertrouwen en voor het "thuis" dat ik altijd bij jullie vind. Annelies, grote zus maar 
ook zoveel meer, zus alleen zou je enorm te kort doen. Samen met Dolf, Lotte en 
Joep vormen jullie een fantastisch gezin waar je trots op mag zijn. Bert, jij hebt je 
geluk gevonden samen met Sandy en Sophie en ook jij mag daar terecht trots op 
zijn. Succes met je eigen studie en jullie toekomstplannen. Pap, mam, Annelies, 
Dolf, Bert en Sandy, het is fijn om te weten dat er mensen zijn die onvoorwaardelijk 
voor je gaan, bedankt hiervoor. Lotte, Joep en Sophie jullie zorgen altijd voor een 
welkome afleiding. Kijk later nog eens op pagina vijf van dit proefschrift.
Gerrit, de laatste woorden in dit boekje zijn meer dan terecht voor jou. Bedankt 
voor al je geduld, flexibiliteit, steun, hulp, vrolijkheid en liefde. Ik kan me geen leven 
meer voorstellen zonder jou, je hebt mijn leven verrijkt. Ik hou van je, X.
X, S u u s
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